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CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts 
and Leukoencephalopathy) is a hereditary dementia and stroke syndrome caused 
by mutations in the NOTCH3 gene.1 The disorder was first described as a separate 
disease entity in the 1990’s2-4 and is now acknowledged as the most prevalent 
hereditary cerebral small vessel disease worldwide. Currently, there is no therapy 
that can delay or prevent CADASIL disease progression.
This introductory chapter will give an overview of CADASIL clinical symptoms 
and pathophysiology, and will provide background to the various studies included 
in this thesis, which are focussed on pre-clinical therapeutic development for 
CADASIL.
SCOPe Of THIS THeSIS
The aim of this thesis was to obtain pre-clinical proof of concept for a rational 
therapeutic approach for CADASIL, called NOTCH3 cysteine correction. To this 
end, we performed a detailed characterization of the type of NOTCH3 mutations 
that cause CADASIL, and identified NOTCH3 mutations that do not cause the 
disease. Furthermore, we performed in vitro proof of concept studies for NOTCH3 
cysteine correction, and demonstrate the technical feasibility of this approach 
in CADASIL patient derived cell models. To enable future in vivo testing of this 
therapeutic approach, we generated a novel CADASIL mouse model and developed 
a biomarker in this model. Finally, we investigated the prevalence of CADASIL-
causing NOTCH3 mutations in a large public exome database and identified a 
novel genotype- phenotype correlation in CADASIL.
CADASIL: A HereDITAry CerebrAL SmALL VeSSeL DISeASe
Chapter 2 of this thesis provides a detailed description of clinical symptoms in 
CADASIL and the role of brain imaging in the diagnostic setting. Briefly, the main 
clinical symptoms in CADASIL are ischemic strokes and cognitive decline leading 
to dementia. Ischemic strokes typically occur in watershed areas of the brain, and 
are recurrent in most patients. Mean age at first stroke is 45-50 years, but onset 
is variable, ranging from the 3rd to the 8th decade.5-8 Mild cognitive decline is 
detectable prior to the onset of first stroke,9,10 and progresses rapidly as the number 
of lacunar infarcts accumulates, ultimately resulting in severe vascular dementia. 
Up to 50% of CADASIL patients have migraine, typically with aura.11 If present, this 
is often the first clinical symptom. Psychiatric disturbances are found in one third 
of CADASIL patients, and are most frequently mood disorders.5,8
Brain MRI abnormalities are present in all CADASIL patients, and can be 











hyperintensities with a recognisable distribution are detectable from the early 
adult, pre-symptomatic phase onwards and are found in nearly all CADASIL patients 
by the age of 35.12 Brain MRI abnormalities become more pronounced and more 
extensive as the disease progresses with age, with lacunar infarcts, microbleeds, 
dilated perivascular spaces and brain atrophy.13-17 
CADASIL: A mONOgeNIC DISOrDer wITH DISTINCTIVe 
NOTCH3 geNe muTATIONS
In 1996, NOTCH3, located on the short arm of chromosome 19, was identified as 
the causative gene in CADASIL.1 NOTCH3 contains 33 exons encoding the NOTCH3 
protein; a transmembrane protein which, in adults, is predominantly expressed in 
vascular smooth muscle cells and pericytes.18 NOTCH3 is synthesized as a 280 kDa 
precursor protein, is cleaved in the Golgi (S1 cleavage, mediated by Furin) after which 
it is transported to the cell surface as a heterodimer composed of an extracellular 
domain (NOTCH3ECD), which is non-covalently attached to an intracellular domain.19 
The NOTCH3ECD contains 34 tandemly arranged epidermal growth factor like 
repeat (EGFr) domains. An EGFr domain is a modular protein subunit composed of 
approximately 40 amino acids, including a fixed number of six cysteine residues. In 
pairs, these six cysteines form three disulphide bridges which are important for correct 
folding of the EGFr domain.20 NOTCH3 mutations in CADASIL are very distinctive, 
as they are almost exclusively missense mutations that lead to a cysteine amino acid 
change in an EGFr domain.21 There are some reports of rare small NOTCH3 deletions 
and insertions, which also lead to the typical numerical cysteine amino acid change 
in an EGFr domain. Some authors have reported non-cysteine altering NOTCH3 
mutations in purported CADASIL patients, but their pathogenicity is still subject 
of debate.22 Chapter 2 of this thesis provides an overview of NOTCH3 mutations in 
CADASIL, and discusses both indisputable CADASIL causing mutations and those 
of which the association with CADASIL is uncertain. 
CADASIL PATHOPHySIOLOgy: AN uNeVeN Number Of 
CySTeINeS AND NOTCH3 AggregATION
As a result of the cysteine altering NOTCH3 mutation, the mutated NOTCH3 EGFr 
domain contains an uneven number of five or seven cysteine residues. This disrupts 
normal disulphide bridge formation and leads to increased multimerization and 
aggregation of the NOTCH3ECD.20,23,24 
CADASIL is characterized by accumulation of the NOTCH3ECD in close vicinity 
of vascular smooth muscle cells (VSMCs) in the small- to medium sized arteries,18 











of extracellular matrix proteins.25 Electron microscopy of e.g. a skin biopsy, typically 
reveals electron- dense deposits of granular osmiophilic material (GOM) in the 
vessel wall, which is considered pathognomonic for CADASIL.26
The NOTCH3 aggregation and accumulation process is believed to play a central 
role in CADASIL pathophysiology, via incompletely understood mechanisms. 
Recent studies have shown that functionally important proteins are recruited 
into the aggregates,27-29 thereby contributing to the pathological process, which 
ultimately leads to a reduced cerebrovascular reactivity and disturbed cerebral 
blood flow.30-32 This is turns leads to recurrent stroke, vascular cognitive decline 
and ultimately pseudobulbar palsy, disability and vascular dementia (Figure 1).
NOTCH3 plays an important role in VSMC differentiation and maturation,33 and 
there is an on-going debate whether, next to toxic protein aggregation, loss of 
NOTCH3 signalling function also contributes to CADASIL pathogenesis. NOTCH3 
signalling is activated when a ligand, Delta or Jagged, binds to the NOTCH3 ligand 
binding site (EGFr 10-11). This initiates two sequential cleavage steps (S2 and 
S3, mediated by TNFα-converting enzyme and presenilin-dependent ɣ-secretase, 
respectively), which enables the intracellular domain to translocate to the nucleus 
and regulate the transcription of target genes.19 It has been shown that most 
CADASIL mutated NOTCH3 proteins retain normal NOTCH3 signalling function,34-39 
and knocking out the NOTCH3 gene in mice does not lead to the development of 
a CADASIL-like phenotype.33 Rather, CADASIL- causing NOTCH3 mutations lead 
to toxic NOTCH3 aggregation (gain of toxic function) and CADASIL can therefore 
be classified as a protein aggregation disorder. Chapter 3 of this thesis describes 
the identification of individuals with a loss-of-function NOTCH3 mutation who do 
not have CADASIL, providing a crucial additional piece of evidence that loss of 
NOTCH3 function is not the primary CADASIL disease instigator. 
NOTCH3 cysteine correction: a rational therapeutic approach for 
CADASIL
There is no therapy available which can slow CADASIL disease progression, and 
there are no clinical trials ongoing for CADASIL (clinicaltrials.gov). The distinctive 
nature of NOTCH3 mutations in CADASIL, and the central role of a numerical 
cysteine alteration in disease aetiology, inspired the hypothesis that correction of 
the number of cysteines within a mutated NOTCH3 EGFr domain may counteract 
toxic NOTCH3 aggregation. This hypothesis prompted the development of the 
NOTCH3 cysteine correction approach as a rational therapeutic strategy for 
CADASIL, as described in chapter 4 of this thesis. In NOTCH3 cysteine correction, 
a minimal amount of EGFr domains, including the mutated one, are removed and 











figure 1. CADASIL pathophysiology. CADASIL-causing NOTCH3 mutations alter the 
number of cysteines in one of the 34 EGFr domains of the NOTCH3ECD. This causes 
multimerization and vascular aggregation of mutant NOTCH3ECD, and recruitment of other 
proteins into the aggregates. This pathological process results in disturbed cerebrovascular 
reactivity  and impaired cerebral blood supply, ultimately leading to stroke and dementia.
NOTCH3 cysteine correction can be achieved by using antisense 
oligonucleotides (AONs). AONs are short strands of nucleic acids which can bind 
to a specific target (pre-)mRNA via Watson-Crick base pairing. In NOTCH3 cysteine 











skipping of pre-selected NOTCH3 exons. The AON chemistry used in this thesis 
is 2’O-methyl phosphorothioate (2OMePS). This is one of the most widely studied 
AON chemistries, which has been shown to be safe in humans.40 
Developing a mouse model for pre-clinical testing of NOTCH3 cysteine 
correction
Pre-clinical therapeutic development usually requires testing of the therapy in 
an animal model of the disease. None of the currently available CADASIL mouse 
models is suitable for testing therapeutic strategies that target human NOTCH3 
specifically at the genomic or (pre-) mRNA level (Table 1). An ideal model for this 
purpose would be a transgenic model which contains the genomic human NOTCH3 
gene. Chapter 5 of this thesis describes the generation of such a novel CADASIL 
mouse model. 
Year Approach Species N3 Mutation Reference
2003;2009 transgenic cDNA human p.Arg90Cys; p.Cys428Ser 41,42
2005 knock-in mouse p.Arg142Cys 43
2010 transgenic genomic rat p.Arg169Cys 44
2011 knock-in mouse p.Arg170Cys 45
2011 transgenic cDNA human p.Cys455Arg; p.Arg1031Cys 29
2015 transgenic genomic human p.Arg182Cys chapter 5, 46 
Table 1. CADASIL mouse models
CADASIL biomarker development 
Disease variability in CADASIL complicates the development of feasible clinical 
end-points for future clinical trials. For example, using stroke as the primary 
end-point in a clinical trial of 2 years, would require thousands of patients to be 
included.47 Therefore, there is a need for surrogate end-points and biomarkers that 
enable monitoring of disease progression in a sensitive manner within a limited 
time-frame. Chapter 5 of this thesis describes the development of a pre-clinical 
biomarker in the novel human NOTCH3 transgenic mouse model. 
Causes of disease variability in CADASIL 
The causes of disease variability in CADASIL are not well understood. To 
date, no convincing or strong genotype-phenotype correlations have been 
found,8 and GWAS studies have not identified any major genetic modifiers.6,48 











families and even between monozygotic twins.49 Smoking and hypertension have 
been found to aggravate disease severity,8, 50 but only exert a relatively minor 
effect.  Chapter 6 of this thesis concerns the discovery of a hitherto unrecognised 
genotype-phenotype correlation, which may contribute significantly to CADASIL 
disease variability. 
CADASIL prevalence
To date, more than 200 distinct NOTCH3 mutations have been described in 
CADASIL patients worldwide. CADASIL prevalence estimations have been 
performed only in relatively small populations in the United Kingdom, which has 
led to an estimated minimum prevalence of 2-5/100,000.51-53 This number is widely 
held to be an underestimation. Chapter 6 of this thesis describes the finding of 
an unexpectedly high frequency of CADASIL- causing NOTCH3 mutations in the 
public exome database ExAC, showing that these mutations are 100-fold more 
prevalent than what would be expected based on current CADASIL prevalence 












OVerVIew Of THe THeSIS CHAPTerS
Chapter 2 provides recommendations for CADASIL diagnostics, especially for the 
interpretation of the results of molecular genetic testing. Specifically, it aims to 
separate the indisputable CADASIL causing mutations from those of which the 
causative association with CADASIL is uncertain. 
Chapter 3 describes the identification of individuals with a NOTCH3 loss-of-
function mutation, who do not have a CADASIL phenotype, providing important 
additional evidence that CADASIL pathogenesis is not driven by a loss of NOTCH3 
function. 
Chapter 4 describes the in vitro proof-of-concept for NOTCH3 cysteine 
correction, a rational therapeutic approach for CADASIL using antisense 
oligonucleotides, aimed at reducing toxic NOTCH3 protein aggregation.  
Chapter 5 describes the generation of a genomic, human NOTCH3 transgenic 
mouse model and the development of the NOTCH3 score as a biomarker in this 
model.
Chapter 6 shows that CADASIL causing NOTCH3 mutations are much more 
prevalent than currently estimated, suggesting not only that CADASIL is hugely 
underdiagnosed, but also that NOTCH3 mutations more frequently cause a 
relatively mild phenotype, partially explained by a newly discovered genotype-
phenotype correlation
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CADASIL is an autosomal dominantly inherited disease, characterized by mid-adult 
onset of cerebrovascular disease and dementia. CADASIL is caused by mutations 
in the NOTCH3 gene which encodes the NOTCH3 protein. Pathogenic mutations 
in CADASIL are highly distinctive in the sense that they typically lead to the loss 
or gain of a cysteine residue  in one of the 34 epidermal growth factor-like repeat 
(EGFr) domains of  the NOTCH3 protein. The majority are missense mutations, but 
small deletions, insertions and splice-site mutations have been reported, which 
typically also lead to a numerical cysteine alteration. Whether numerical cysteine 
altering mutations are a rule in CADASIL remains subject of debate, as there are 
reports suggesting pathogenicity of other types of mutations. However, for most of 
these the association with CADASIL was later revoked or is questionable. Here, we 
discuss and  provide recommendations for the interpretation of NOTCH3 mutations 





































CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and 
Leukoencephalopathy) is a hereditary small vessel disease, caused by mutations in 
the NOTCH3 gene. CADASIL patients can present with a history of migraine with 
aura, young to mid adult onset of cerebrovascular disease, mood disturbance, 
apathy, cognitive decline progressing to dementia, and diffuse white matter lesions 
and subcortical infarcts on neuroimaging. 
Compared to other inherited brain disorders with a comparable impact, such 
as Huntington’s chorea or inherited early-onset Alzheimer’s dementia, CADASIL is 
still relatively unknown in the medical community. This is not so much due to the 
fact that it is a rare disease, but more to the fact that there is only a short history 
of recognition of the disease. CADASIL was first described as a clearly defined 
and separate disease entity in the early 1990’s,1-3 followed by the identification of 
mutations in the NOTCH3 gene in 1996.4 Since then, NOTCH3 mutation screening 
has allowed for the identification of CADASIL families all over the globe, with an 
ever increasing prevalence due to increased awareness of the disease, diagnosis 
in clinically less severe or atypical cases and improved diagnostic tools. The 
minimum prevalence of CADASIL has been estimated to be between 2 and 4 per 
100.000,5-7 but the actual prevalence will probably prove to be higher. In the 
Netherlands, for example, the number of diagnosed CADASIL families started out 
with seven in 1998 and has increased to more than 150 Dutch families in 2013, with 
new families still being identified at a steady rate. (Lesnik Oberstein and Boon, 
unpublished results) 
The clinical diagnosis CADASIL is made based on a combination of the 
following: otherwise unexplained cerebral ischemic events and/or cognitive decline 
at a relatively young age, distinctive brain MRI abnormalities and a family history 
with a dominant pattern of inheritance of stroke or dementia. The clinical diagnosis 
can be confirmed by the detection of a characteristic cysteine-altering mutation 
in NOTCH3. If the results of molecular testing are unclear or comprehensive 
NOTCH3 screening is not available, the diagnosis can be confirmed by taking 
a skin biopsy. This shows pathognomonic vessel wall abnormalities, including 
positive NOTCH3 immunostaining and the presence of electron dense deposits 
called granular osmiophilic material (GOM).8,9 The correct diagnostic interpretation 
of NOTCH3 variants other than the typical cysteine-altering missense mutations 
requires expertise in both the clinical features and the distinguishing molecular 
aspects of CADASIL. Incorrect interpretation of mutations can lead to an erroneous 
CADASIL diagnosis, with far-reaching implications for the patient and his or her 
family members. Here, we provide recommendations for the clinical diagnosis and 




































NOTCH3 geNe, NOTCH3 PrOTeIN AND CADASIL 
PATHOgeNeSIS
The NOTCH3 gene is one of the four mammalian NOTCH homologues. NOTCH3 
contains 33 exons encoding the NOTCH3 protein, a single pass transmembrane 
protein of 2321 amino acids predominantly expressed in vascular smooth muscle cells 
(VSMC).10 Here, it plays an important role in VSMC maturation and differentiation.11  
The NOTCH3 protein is composed of an extracellular domain (NOTCH3ECD), non-
covalently bound to an intracellular domain. (Figure 1) After binding of a ligand 
(Delta-like or Jagged) to the NOTCH3ECD , the protein undergoes two proteolytic 
cleavage steps, leading to translocation of the intracellular domain to the nucleus 
where it functions as a nuclear transcription factor.12 The NOTCH3ECD  consists of 
34 epidermal growth factor- like repeat (EGFr) domains. These are modular protein 
subunits of approximately 40 amino acids which, by definition, each contain a fixed 
figure 1. Schematic representation of the NOTCH3 protein. The NOTCH3 protein 
is a transmembrane protein, composed of an extracellular domain (NOTCH3ECD ), a 
transmembrane (TM) and an intracellular domain (IC). The NOTCH3ECD contains 34 EGFr 
and three NOTCH/Lin repeats(LNR). The EGFr, each composed of approximately 40 amino 
acids, all contain 6 cysteine amino acids which form 3 disulphide bridges. In this example 
of CADASIL mutated NOTCH3 (with the representative p.Arg153Cys mutation), the number 
of cysteine residues in EGFr 3 is changed from 6 to 7, leaving one cysteine unpaired and 




































number of 6 cysteine residues. In pairs, these cysteines form three disulphide 
bridges which are important for EGFr secondary structure. NOTCH3 mutations in 
CADASIL invariably lead to an uneven number of cysteines (typically 5 or 7) in the 
mutated EGFr.13 This results in an  unpaired cysteine, which is predicted to disrupt 
normal disulphide bridge formation, causing misfolding of EGFr and increased 
NOTCH3 multimerization.14,15 
In patients, NOTCH3ECD  is seen to accumulate in the vessel wall, in close 
proximity to VSMC.10 This NOTCH3ECD  accumulation has a direct or indirect toxic 
effect on VSMC, leading to VSMC degeneration.9,16,17 The arteriopathy in CADASIL is 
systemic,9 as is also illustrated by the presence of vascular pathology in for example 
skin arterioles,8,17 but the small penetrating cerebral and leptomeningeal arteries 
are most severely affected.18 Next to NOTCH3ECD accumulation and the presence 
of GOM, affected arteries show a thickened vessel wall with lumen stenosis, 
abundance of extracellular matrix proteins and destruction of vascular smooth 
muscle cells.19,20 The vessel wall changes result in an impaired cerebrovascular 
reactivity and decreased cerebral blood flow, believed to cause both chronic 
cerebral ischemia and acute ischemic events.21-23  
CLINICAL DIAgNOSIS bASeD ON SymPTOmS, brAIN mrI 
AND fAmILy HISTOry
The main symptoms in CADASIL, affecting the majority of patients, are recurrent 
ischemic events (transient ischemic attacks and strokes) and cognitive decline 
leading to vascular dementia. Migraine with aura, psychiatric disturbances and 
apathy are other frequent symptoms. Most patients experience their first stroke 
around 45-50 years of age,24-27 but the range of age at onset is broad, varying from as 
early as the third decade to as late as the eighth decade. In the majority of patients, 
ischemic events are recurrent,24,26,27 eventually resulting in severe disability.25 
Cognitive decline initially manifests as a decreased executive function,28-30 followed 
by a slowly progressive and/or stepwise deterioration in cognitive function which 
becomes apparent in daily activities around the age of 50, leading to vascular 
dementia in about 80% of patients.25 Migraine is diagnosed in approximately 
35% of CADASIL patients. The migraine attacks are often the presenting clinical 
symptom with a mean age at onset of around 26 years, and are remarkable by 
the high prevalence of auras (90% of patients).24,27 Often, the migraine attacks 
are atypical, with prolonged, brainstem or hemiplegic auras and confusion, fever, 
meningeal signs or even coma. Also, during gestation and shortly after childbirth 
there appears to be an increased risk of transient neurological symptoms,31 mostly 
resembling migraine auras. Approximately one third of CADASIL patients have 




































later stages.32 Less frequent symptoms include epileptic seizures (5-10%), usually 
secondary to stroke,3,24,26,33 and acute encephalopathy.3,27,34-36 
The suspicion of CADASIL often arises when brain MRI imaging reveals 
symmetrically distributed white matter hyperintensities (WMH), which are much 
too extensive for the patient’s age. (Figure 2) MRI abnormalities in CADASIL 
precede clinical symptoms of ischemic events and cognitive decline by as much 
as 10-15 years, increase with age and have a recognizable, but not pathognomonic, 
distribution. In the early stages the WMH,  best seen on T2- weighted images or 
fluid –attenuated inversion recovery (FLAIR) sequences, are small and punctuate 
and are often seen to initiate in the anterior temporal lobes, periventricular frontal 
white matter, and external capsules,37-39 eventually affecting all of the white matter. 
Lacunar infarcts, most readily detected on T1- weighted images, can be seen from 
the age of 30 onwards, and are found in the basal ganglia, thalamus, brainstem 
and subcortical white matter.37 Microbleeds, predominantly seen in the subcortical 
white matter and thalamus, and dilated perivascular spaces are frequently 
figure 2. brain mrI abnormalities in CADASIL patients. In the early stages of CADASIL, 
brain MRI abnormalities consist of small circumscript white matter hyperintensities (WMH) 
(indicated by arrows), as shown here in the anterior temporal lobes (A1), in the semioval 
center (A2) and periventricularly (A3). (FLAIR images) Brain MRI images of patients with 
advanced stages of CADASIL showing confluent WMH (B1-B3), microbleeds (three marked 
with an arrow) (B1), lacunar infarcts (three marked with an arrow) (B2) and dilated perivascular 




































encountered.40-42 The MRI lesion load and pattern can vary quite significantly, such 
that some patients hardly show any lacunar infarcts even at later stages, or lack 
WMH in the temporal lobes.43 A consistent factor is the presence of symmetrical 
WMH, often visible from the early twenties onward, but present in most if not all 
patients from 35 years of age. MRI abnormalities in CADASIL can resemble those 
seen in other diseases, such as other types of small vessel disease or multiple 
sclerosis. In fact, a significant number of CADASIL patients are first erroneously 
diagnosed as having multiple sclerosis.44 
The family history of a CADASIL patient typically shows an autosomal dominant 
inheritance pattern of stroke and dementia, and family members often have 
migraine with aura or mood disturbances. However, the severity of the disease is 
variable, also within families. It has been noted, that CADASIL patients frequently 
report a negative family history,45 which in many cases can be attributed to the 
fact that affected family members, especially in older generations, have received 
other diagnoses such as Alzheimer’s dementia or multiple sclerosis. Taking this 
into account, a thorough family history will usually reveal affected family members. 
However, a small number of CADASIL patients with de novo NOTCH3 mutations 
have been reported, so a negative family history does not rule out CADASIL.46,47 
CADASIL can be diagnosed in a plethora of clinical presentations or settings, 
where the early onset of stroke, white matter hyperintensities on brain MRI and 
a family history of stroke, dementia or migraine with aura, may each contribute 
more or less strongly in leading the clinician to consider CADASIL. However, 
CADASIL should always, be considered in an individual presenting with otherwise 
unexplained ischemic events or cognitive decline and symmetrical white matter 
hyperintensities on brain MRI. 
wHeN TO PerfOrm A SkIN bIOPSy IN CADASIL 
If NOTCH3 screening is unavailable or does not reveal a typical cysteine 
altering missense mutation in a patient otherwise presenting with a convincing 
CADASIL phenotype, then taking a skin biopsy for NOTCH3 immunostaining and 
electron microscopy (EM) is recommended. (figure 3) The sensitivity of NOTCH3 
immunostaining of a skin biopsy has been reported to be between 85-100%, 
and the specificity between 90-100%.8,48 The detection of GOM in the vessel 
wall using electron microscopy is considered pathognomonic for CADASIL. Most 
studies report the presence of GOM deposits in all CADASIL patients,49-52 with 
only two studies reporting low GOM detection rate.53,54 Skin biopsy analysis using 
both NOTCH3 immunostaining and EM should therefore allow for a conclusive 





































NOTCH3 muTATIONS IN CADASIL 
A typical CADASIL causing mutation is a heterozygous NOTCH3 missense mutation 
that leads to a numerical cysteine amino acid change in one of the 34 EGFr of the 
NOTCH3 protein.(see supplementary table 1 for a list of known CADASIL- causing 
missense mutations) Pathogenic mutations have been found throughout exons 2-24, 
which are the exons that encode the EGFr, but the majority of mutations are found 
in exon 4. The prevalence of mutations in other exons varies between countries; in 
the French, German and English CADASIL population exon 3 is the second most 
frequently mutated exon,13,53,55 whereas in Dutch CADASIL patients, exon 11 is the 
second most frequently mutated exon.56 These geographic differences probably 
are due to the presence of founder mutations. 
When a clinical diagnosis of CADASIL is suspected, sequencing of exons 2-24 
of the NOTCH3 gene, including flanking intronic sequences, is the most reliable 
method to confirm the diagnosis. In patients with a typical clinical and radiological 
presentation and family history, the mutation detection rate exceeds 95%. (Lesnik 
Oberstein, unpublished observations) Detection of the disease- causing mutation 
then allows for (predictive) DNA-testing of family members. However, sequencing 
exons 2-24 is costly and can be time-consuming, and is not available in all countries. 
Targeted sequencing strategies are used in centres that do not offer complete 
NOTCH3 sequencing analysis, usually sequencing analysis of only the most 
frequently mutated exons. In cases with a confirmed clinical diagnosis by skin 
biopsy but no mutation detected by sequencing analysis, additional molecular 
techniques can be performed to detect larger deletions or duplications, or to 
assess the potential effect of novel variants on splicing. 
figure 3. Vessel wall abnormalities in CADASIL. (A) Electron microscopy on brain 
tissue from a deceased CADASIL patient. Pathognomic deposits of granular osmiophillic 
material (GOM) are seen, surrounding the vascular smooth muscle cell (VSMC). (B) NOTCH3 
immunohistochemistry of a skin biopsy showing the typical granular positive NOTCH3 staining 




































Although it has been suggested that some mutations may be associated with 
a milder or more severe phenotype,25,57 so far no clear genotype- phenotype 
correlations have been found.24,25,58,59 As disease severity can vary not only between, 
but also within  families, and even between monozygotic twins,60 it is likely that 
modifying factors other than the NOTCH3 mutation play a role in determining the 
course of the disease. 
Homozygous and compound heterozygous NOTCH3 mutations
A small number of CADASIL patients with homozygous NOTCH3 mutations have 
been reported.36,61-64 (Table 1) In some of these patients, the phenotype was found 
to be more severe, whereas others reported clinical severity similar to heterozygous 
mutation carriers. Overall, patients with homozygous mutations described so far 
have a phenotype within the normal CADASIL spectrum, and variation in severity 








Age at first 
stroke
Tuominen et al.62 c.397C>T 4 p.Arg133Cys 52 28
Vinciguerra et al.64 c.547T>A 4 p.Cys183Ser 44 40
Ragno et al.36 c.1582G>T 10 p.Gly528Cys 54 No stroke at 
age 54
Liem et al.61 c.1732C>T 11 p.Arg578Cys 65 64










Table 1. Homozygous mutations in CADASIL patients. A small number of CADASIL- 
causing mutations in a homozygous state have been reported. The severity of symptoms 
in these patients seems to be within the CADASIL spectrum. Mutations are described 
according to HGVS nomenclature,93 and may therefore differ from the mutation description 
in the original research article.
One CADASIL patient has been reported who has a typical cysteine-altering 
missense mutation on one of his NOTCH3 alleles, but also a large intragenic 
NOTCH3 deletion, leading to a premature stop codon, on his other allele.65 In 
effect, this means he is functioning on only one NOTCH3 allele which, moreover, 
harbors a CADASIL-causing mutation. The phenotype of this patient was within the 
normal CADASIL spectrum. In patients with a NOTCH3 mutation on one allele and 
a large NOTCH3 deletion on the other allele, the mutation may be interpreted to 
be a homozygous mutation if only sequencing analysis is performed. Therefore, in 




































one of the alleles should be excluded, for example by performing MLPA analysis. 
Although this has no clinical consequences for the patient, because the disease 
severity in these patients is within the normal CADASIL spectrum, it is of importance 
for the counseling of family members.
Small NOTCH3 deletions, duplications, splice site mutations and 
a deletion/insertion
Although the vast majority of CADASIL causing mutations are missense mutations, 
a few other rare types of NOTCH3 mutations have been reported, which also lead 
to the typical CADASIL-associated uneven number of cysteine residues in EGFr. 
These include some small intragenic deletions, duplications, splice site mutations 
and a deletion/insertion.14,25,43,51,66-71 (Table 2) As these mutations lead to a typical 
numerical cysteine alteration in  NOTCH3 EGFr, they are likely to be pathogenic, 
although the clinical diagnosis was not confirmed by skin biopsy in all cases and 
molecular analysis was not always comprehensive. 
Deletions leading to altered spacing of cysteine residues
In one study, a 12 base pair deletion not involving a cysteine residue was reported 
to be associated with CADASIL.72 The diagnosis was confirmed by skin biopsy, 
segregated with the clinical phenotype and all EGFr encoding exons had been 
sequenced. Although not resulting in a numerical cysteine alteration, this deletion 
does result in altered spacing between two cysteines in an EGFr, thereby possibly 
disrupting normal disulphide bridge formation. As no RNA analysis was performed, 
it cannot be excluded that the deletion results in abnormal splicing and thereby 
potentially alters the number of cysteine residues.  
A second study describes a small intronic deletion leading to retention of 
intron 3.73 This results in an insertion of 25 amino acids between the 5th and 6th 
cysteine of EGFr 2, thereby likely disturbing disulphide bridge formation between 
these two cysteines. 
NOTCH3 VArIANTS NOT ALTerINg CySTeINe reSIDueS IN 
egfr
NOTCH3 mutations not leading to a numerical cysteine amino acid change in 
NOTCH3 EGFr have also been described to be associated with CADASIL. Upon 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































NOTCH3 missense mutations not involving a cysteine residue 
The first group of mutations with an uncertain association with CADASIL are 
missense mutations in NOTCH3 which do not involve a cysteine residue. Various 
studies have reported such variants to be causative of CADASIL.43,74-81 (Table 3) In 
the majority of these reports however, the association is not proven, because either 
NOTCH3 was incompletely screened and thus a typical cysteine altering mutation 
in another exon was not excluded, or the clinical diagnosis was not confirmed by 
skin biopsy.75,76,78-80 In four studies, describing the p.Ala1020Pro, p.Arg213Lys, 
p.Tyr1098Ser, and p.Arg75Pro variants respectively, sequencing of exons 2-24 was 
comprehensive and the diagnosis was confirmed by skin biopsy.43,74,77,81 However, 
the p.Ala1020Pro, and also the p.His170Arg  mutation have been reported to be 
polymorphisms by others.82 (Supplementary table 2) That polymorphisms are 
mistakenly interpreted as causative mutations is further suggested by the fact that 
these variants have been found to co-segregate with a typical cysteine altering 
missense mutation.83 (Lesnik Oberstein and Boon, unpublished findings) 
The p.Arg213Lys and p.Tyr1098Ser mutations were found in a Japanese and a 
Chinese patient, respectively, but segregation analysis was not performed. Also 
for these mutations it remains possible they are polymorphisms, as a coinciding 
cysteine altering mutation, such as a large deletion or intronic mutation, might 
have been missed due to technical reasons. This may also apply to the p.Arg61Trp 
mutation, of which the pathogenicity was described as uncertain.84 A possible 
exception may be the p.Arg75Pro mutation, which has been frequently reported 
in Japanese, Chinese and Korean patients.43,74,85,86 In two of these families, 
comprehensive sequencing of NOTCH3 was performed, the mutation segregated 
with affected family members and GOM were present in skin biopsy.74 However, 
MRI abnormalities were not typical for CADASIL and NOTCH3 immunostaining 
was not performed. Therefore, drawing definite conclusions regarding the relation 
between this mutation and CADASIL remains precarious, but it cannot be excluded 
that this mutation does cause CADASIL or a CADASIL-like phenotype. In summary, 
with one possible exception, there is no compelling evidence that missense 
mutations that do not involve the loss or gain of a cysteine residue are associated 
with CADASIL. Therefore, if such a non-cysteine altering mutation is detected, the 
clinical diagnosis should be critically re-evaluated and, if the clinical symptoms 
are persuasive, be confirmed by skin biopsy. If the skin biopsy shows the typical 
vessel wall abnormalities seen in CADASIL, molecular testing should be elaborated 
by analysis of larger deletions or duplications using for example MLPA, and the 
potential effect on splicing of variants with unknown pathogenicity should be 
ascertained. Finally, if possible, segregation of the mutation with affected family 








































all EGFr encoding 
exons
Diagnosis confirmed 
by skin biopsy or 
autopsy
Brass et al.84 c.259C>T 2 p.Arg61Trp yes yes
Mizuno et al.74 c.224G>C 3 p.Arg75Pro yes yes







Roy et al.76 c.605C>T 4 p.Ala202Val no‡ not reported
Kotorii et al.77 c.638G>A 4 p.Arg213Lys yes yes
Uchino et al.78 c.709G>A* 5 p.Val237Met not reported not reported
Ferreira et al.79 c.1729A>G 11 p.Thr577Ala not reported not reported
Ferreira et al.80 c.2932A>C 18 p.Ser978Arg not reported not reported
Scheid et al.81 c.3058G>C* 19 p.Ala1020Pro yes yes
Wang et al.43 c.3292A>T 20 p.Tyr1098Ser yes yes
Table 3. NOTCH3 missense variants not involving a cysteine residue which have 
been suggested to be causative of CADASIL. Missense variants not involving cysteine 
residues have been reported in association with CADASIL in several studies. Most of these 
were later described to be polymorphisms, or their pathogenicity is questionable due to 
incomplete molecular analysis or uncertain clinical diagnosis. One possible exception is 
the p.Arg75Pro mutation, which was found to segregate with the clinical phenotype in two 
thoroughly studies families.74 Mutations are described according to HGVS nomenclature,93 
and may therefore differ from the mutation description in the original research article. 
†exons 2-6,8,11,14,18-19, 22-23 screened; ‡ exons 2-4, 11, 18-19 screened. * Also 
described as a polymorphism 94,95 (Supplementary table 2) ** Also described as a variant 
with unknown pathogenicity 82
NOTCH3 mutations leading to loss-of-function
A second group of mutations about which there is debate as to their pathogenicity 
in CADASIL, are  those leading to loss of NOTCH3 function (out-of-frame deletions 
or stop mutations). These mutations have been only rarely reported and there is 
no convincing evidence that such loss-of-function mutations cause CADASIL. As in 
the case of the non- cysteine altering missense mutations, the reports mentioning 
an association between CADASIL phenotype and loss-of-function mutations either 
lack comprehensive NOTCH3 molecular analysis, or the clinical diagnosis has not 
been confirmed.87,88 The hypothesis that loss-of-function mutations may also cause 
CADASIL is further discredited by the fact that NOTCH3 loss-of-function mutations 
have been found in thoroughly studied individuals in whom CADASIL was clinically 
excluded,65 as well as by the fact that Notch3 knock-out mice do not develop a 
CADASIL phenotype.89 In summary, loss of NOTCH3 function mutations appear 





































NOTCH3 muTATIONS OuTSIDe Of THe egfr eNCODINg 
exONS
In the initial report on the identification of NOTCH3 mutations in CADASIL, one 
mutation in exon 25 was described.4 Later reports have shown that mutations 
located outside EGFr encoding exons 2-24 do not lead to a CADASIL phenotype.90-92 
exPerT COmmeNTAry
Upon the discovery of NOTCH3 as the causative gene for CADASIL in 1996, it was 
clear that mutations were highly distinctive, namely all were missense mutations 
leading to a cysteine alteration in one of the 34 EGFr of NOTCH3. In the past two 
decades, this has remained a consistent finding in CADASIL patients reported from 
all over the world. However, there have also been a substantial number of reports 
suggesting that other types of mutations, mostly missense mutations that do not 
involve a cysteine, can also cause CADASIL. To date there is no convincing evidence 
that these mutations indeed cause CADASIL and they should be considered  to be 
coincidental findings, until proven otherwise. Incorrect interpretation of mutations 
leads to erroneous diagnosis, with far reaching implications for both the patient 
and his or her family members. In order to be certain of the diagnosis and the 
pathogenicity of the mutation, the analysis of patients with mutations that do not 
alter cysteines should always include comprehensive molecular NOTCH3 screening 
to exclude a coinciding cysteine-altering mutation, as well as a thorough clinical 
(re-)evaluation, including skin biopsy. This should preferably be performed by an 
experienced team, including a clinical laboratory geneticist,  clinical geneticist, 
neurologist, neuroradiologist and neuropathologist. 
fIVe-yeAr VIew
Nearly two  decades after the identification of NOTCH3 as the causative gene for 
CADASIL, it has become clear that the disease is much more prevalent than initially 
assumed and it is now considered the most prevalent type of hereditary vascular 
dementia.  However, there is likely still a substantial number of undiagnosed 
patients, due to lack of awareness of the disease and the non-specificity of many 
of the signs and symptoms. However, once the diagnosis has been considered, 
it is readily confirmed by the presence of a cysteine altering missense mutation 
in NOTCH3. As molecular testing is becoming more widely available, we expect 
that in the coming 5 years patients will be even more frequently diagnosed and 
a clearer picture will emerge of both the prevalence and the clinical spectrum 
of the disease. Thus far, there is no therapy to delay the onset of the disease. 




































or capturing the toxic mutated protein. In order to determine the effect of such 
therapeutic strategies in the future, a thorough and complete knowledge of both 
the mutational spectrum and the natural history of CADASIL is of vital importance. 
key ISSueS
•	 CADASIL is caused by gain-of-function mutations in NOTCH3, leading to toxic 
NOTCH3 accumulation in the vessel wall. 
•	 Only NOTCH3 mutations that alter the number of cysteines in one of the 34 
epidermal growth factor repeat (EGFr) domains of the NOTCH3 protein have 
been proven to cause CADASIL:
 – The great majority are missense mutations 
 – Mutations are found only in EGFr-encoding exons (2-24)
 – Most mutations are located in exon 4
•	 Some CADASIL patients with homozygous and compound heterozygous 
mutations have been described. The symptoms of these patients seem to be 
within the normal CADASIL spectrum.
•	 Small NOTCH3 in-frame deletions, insertions or splice-site mutations can also 
cause CADASIL. These typically also alter the number of cysteines in one of 
the 34 EGFr of NOTCH3.
•	 Mutations in NOTCH3 leading to loss of NOTCH3 function do not cause 
CADASIL. These rare mutations include mutations leading to a frame-shift and 
stop mutations.
•	 Missense mutations in NOTCH3 not altering a cysteine residue are unlikely to 
be pathogenic, and should be considered coincidental findings until proven 
otherwise. If such a mutation is detected, the following should be considered:
 – A coinciding cysteine altering mutation may have been missed due to 
technical reasons or incomplete sequencing analysis.
 – The clinical diagnosis of CADASIL may be incorrect and should be confirmed 
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change Amino acid change Exon EGFR Reference
1 c.127T>G p.Cys43Gly 2 1 Peters et al.3, Opherk et al.4
2 c.128G>T p.Cys43Phe 2 1 Lesnik Oberstein 5 
3 c.145T>G p.Cys49Gly 2 1 Oki et al.6
4 c.145T>C p.Cys49Arg 2 1 Wang et al.7
5 c.146G>A p.Cys49Tyr 2 1 Joutel et al.8
6 c.146G>T p.Cys49Phe 2 1 Peters et al.3, Opherk et al.4
7 c.157G>T p.Gly53Cys 2 1 Wang et al.7
8 c.160C>T p.Arg54Cys 2 1 Escary et al.9
9 c.179C>G p.Ser60Cys 2 1 Peters et al.3, Opherk et al.4
10 c.193T>G p.Cys65Gly 2 1 Cleves et al.10, HGMD
11 c.194G>C p.Cys65Ser 2 1 Peters et al.3, Opherk et al.4
12 c.194G>A p.Cys65Tyr 2 1 Bianchi et al.11
13 c.199T>A p.Cys67Ser 3 1 Tikka et al.1
14 c.200G>A p.Cys67Tyr 3 1 Moon et al.12
15 c.213G>T p.Trp71Cys 3 1 Joutel et al.13
16 c.226T>C p.Cys76Arg 3 1 Markus et al.14
17 c.228T>G p.Cys76Trp 3 1 Peters et al.3, Opherk et al.4
18 c.259T>C p.Cys87Arg 3 2 Peters et al.3, Opherk et al.4
19 c.260G>A p.Cys87Tyr 3 2 Opherk et al.4
20 c.265G>T p.Gly89Cys 3 2 Pavlovic et al.15, Lackovic et al.16
21 c.268C>T p.Arg90Cys 3 2 Joutel et al.8
22 c.278G>A p.Cys93Tyr 3 2 Kalimo et al.17
23 c.278G>T p.Cys93Phe 3 2 Dichgans et al.18
24 c.316T>C p.Cys106Arg 3 2 Yamada et al.19
25 c.318C>G p.Cys106Trp 3 2 Opherk et al.4
26 c.322T>C p.Cys108Arg 3 2 Wang et al.20
27 c.323G>C p.Cys108Ser 3 2 Testi et al.21  
28 c.323G>A p.Cys108Tyr 3 2 Peters et al.3, Opherk et al.4
29 c.324C>G p.Cys108Trp 3 2 Rojas-Marcos et al.22
30 c.328C>T p.Arg110Cys 3 2 Joutel et al.8
31 c.349T>C p.Cys117Arg  4  2 Wang et al.7
32 c.350G>T p.Cys117Phe 4 2 Dichgans et al.23
33 c.350G>C p.Cys117Ser 4 2 Spinicci et al.24
34 c.350G>A p.Cys117Tyr 4 2 Ampuero et al.25
35 c.353C>G p.Ser118Cys 4 3 Lee et al.26
36 c.368G>A p.Cys123Tyr 4 3 Escary et al.9






































change Amino acid change Exon EGFR Reference
38 c.382T>G p.Cys128Gly 4 3 Coto et al.27
39 c.383G>A p.Cys128Tyr 4 3 Kalimo et al.17
40 c.383G>T p.Cys128Phe 4 3 LOVD 
41 c.391G>T p.Gly131Cys 4 3 Ungaro et al.28
42 c.397C>T p.Arg133Cys 4 3 Joutel et al.8
43 c.402C>G p.Cys134Trp 4 3 Joutel et al.29
44 c.421C>T p.Arg141Cys 4 3 Joutel et al.8
45 c.425T>G p.Phe142Cys 4 3 Kalimo et al.17
46 c.431G>A p.Cys144Tyr 4 3 Dichgans et al.18 
47 c.431G>C p.Cys144Ser 4 3 Dichgans et al.18
48 c.431G>T p.Cys144Phe 4 3 Grigg et al.30
49 c.434C>G p.Ser145Cys 4 3 Opherk et al.4
50 c.436T>C p.Cys146Arg 4 3 Joutel et al.8
51 c.437G>A p.Cys146Tyr 4 3 Malandrini et al.31
52 c.445G>T p.Gly149Cys 4 3 Peters et al.3, Opherk et al.4
53 c.449A>G p.Tyr150Cys 4 3 Dichgans et al.18
54 c.457C>T p.Arg153Cys 4 3 Joutel et al.8
55 c.463T>A p.Cys155Ser 4 3 Ampuero et al.25
56 c.464G>A p.Cys155Tyr 4 3 LOVD
57 c.464G>C p.Cys155Ser 4 3 Opherk et al.4
58 c.484T>A p.Cys162Ser 4 4 Escary et al.9
59 c.484T>C p.Cys162Arg 4 4 Andreadou et al.32
60 c.486C>G p.Cys162Trp 4 4 Lesnik Oberstein et al.33
61 c.493G>T p.Gly165Cys 4 4 Ampuero et al.25
62 c.505C>T p.Arg169Cys 4 4 Joutel et al.34
63 c.511G>T p.Gly171Cys 4 4 Joutel et al.8
64 c.520T>C p.Cys174Arg 4 4 Santa el al.35
65 c.520T>A p.Cys174Ser 4 4 Tikka et al.1
66 c.521G>A p.Cys174Tyr 4 4 Dichgans et al.23
67 c.521G>T p.Cys174Phe 4 4 Kotorii et al.36
68 c.539C>G p.Ser180Cys 4 4 Escary et al.9
69 c.542T>G p.Phe181Cys 4 4 Granild-Jensen et al.37
70 c.544C>T p.Arg182Cys 4 4 Joutel et al.34
71 c.547T>A p.Cys183Ser 4 4 Dichgans et al.18
72 c.547T>C p.Cys183Arg 4 4 Dichgans et al.23
73 c.548G>T p.Cys183Phe 4 4 Peters et al.3, Opherk et al.4






































change Amino acid change Exon EGFR Reference
75 c.553T>G p.Cys185Gly 4 4 Joutel et al.29
76 c.553T>A p.Cys185Ser 4 4 Adib-Samii et al.38, HGMD
77 c.566A>G p.Tyr189Cys 4 4 Lesnik Oberstein et al.5
78 c.580T>A p.Cys194Ser 4 4 Markus et al.14
79 c.580T>C p.Cys194Arg 4 4 Kalimo et al.17
80 c.581G>A p.Cys194Tyr 4 4 Escary et al.9
81 c.581G>T p.Cys194Phe 4 4 Dichgans et al.18
82 c.581G>C p.Cys194Ser 4 4 Adib-Samii et al.38, HGMD
83 c.601T>C p.Cys201Arg 4 5 Uyguner et al.39
84 c.602G>A p.Cys201Tyr 4 5 Opherk et al.4
85 c.616T>C p.Cys206Arg 4 5 Matsumoto et al.40
86 c.617G>A p.Cys206Tyr 4 5 Escary et al.9
87 c.619C>T p.Arg207Cys 4 5 Lesnik Oberstein et al.41
88 c.634T>A p.Cys212Ser 4 5 Joutel et al.8
89 c.635G>A p.Cys212Tyr 4 5 Bentley et al.42
90 c.636C>G p.Cys212Trp 4 5 Spinnici et al.24
91 c.659A>G p.Tyr220Cys 4 5 Rojas-Marcos et al.43
92 c.664T>G p.Cys222Gly 4 5 Joutel et al.8
93 c.665G>A p.Cys222Tyr 4 5 Kalimo et al.17
94 c.665G>C p.Cys222Ser 4 5 Wang et al.7
95 c.671G>A p.Cys224Tyr 4 5 Joutel et al.8
96 c.697T>A p.Cys233Ser 5 5 Joutel et al.29
97 c.697T>C p.Cys233Arg 5 5 Adib-Samii et al.38, HGMD
98 c.698G>A p.Cys233Tyr 5 5 Peters et al.3, Opherk et al.4
99 c.699T>G p.Cys233Trp 5 5 Lesnik Oberstein 5
100 c.719G>C p.Cys240Ser 5 6 Opherk et al.4
101 c.733T>C p.Cys245Arg 5 6 Peters et al.3, Opherk et al.4
102 c.733T>A p.Cys245Ser 5 6 Razvi et al.44
103 c.751T>C p.Cys251Arg 5 6 Markus et al.14
104 c.751T>A p.Cys251Ser 5 6 Lesnik Oberstein 5
105 c.751T>G p.Cys251Gly 5 6 Viskelis et al.45
106 c.752G>A p.Cys251Tyr 5 6 Tikka et al.1 
107 c.773A>G p.Tyr258Cys 5 6 Joutel et al.8
108 c.778T>G p.Cys260Gly 5 6 De Silva et al.46
109 c.779G>A p.Cys260Tyr 5 6 Peters et al.3, Opherk et al.4
110 c.812G>T p.Cys271Phe 6 6 Kam-Ming Au et al.47






































change Amino acid change Exon EGFR Reference
112 c.895A>T p.Ser299Cys 6 7 Golomb et al.49
113 c.994C>T p.Arg332Cys 6 8 Oliveri et al.50
114 c.1004C>G p.Ser335Cys 6 8 Peters et al.3, Opherk et al.4
115 c.1010A>G p.Tyr337Cys 6 8 Lesnik Oberstein 5
116 c.1012T>C p.Cys338Arg 6 8 Dotti et al.51
117 c.1078T>C p.Cys360Arg 7 9 Kim et al.52
118 c.1096T>C p.Cys366Arg 7 9 HGMD
119 c.1098T>G p.Cys366Trp 7 9 Pradotto et al.53
120 c.1135T>C p.Cys379Arg 7 9 Del Rio-Espínola et al.54
121 c.1136G>C p.Cys379Ser 7 9 Peters et al.3, Opherk et al.4
122 c.1144G>T p.Gly382Cys 7 9 Lesnik Oberstein 5 
123 c.1163G>A p.Cys388Tyr 7 9 Ishida et al.55
124 c.1183T>C p.Cys395Arg 7 10 Peters et al.3, Opherk et al.4
125 c.1187C>G p.Ser396Cys 7 10 Testi et al.21
126 c.1241C>G p.Ser414Cys 8 10 Kim et al.52
127 c.1258G>T p.Gly420Cys 8 10 Joutel et al.29
128 c.1261C>T p.Arg421Cys 8 10 Peters et al.3, Opherk et al.4
129 c.1279C>T p.Arg427Cys 8 10 HGMD
130 c.1282T>C p.Cys428Arg 8 10 Dotti et al.51
131 c.1283G>A p.Cys428Tyr 8 10 Peters et al.3, Opherk et al.4
132 c.1283G>C p.Cys428Ser 8 10 Joutel et al.29
133 c.1303T>C p.Cys435Arg 8 11 Lesnik Oberstein 5 
134 c.1318T>A p.Cys440Ser 8 11 Federico et al.56
135 c.1318T>G p.Cys440Gly 8 11 Markus et al.14
136 c.1318T>C p.Cys440Arg 8 11 Peters et al.3, Opherk et al.4
137 c.1337G>C p.Cys446Ser 8 11 Opherk et al.4
138 c.1337G>T p.Cys446Phe 8 11 Lesnik Oberstein et al.33
139 c.1345C>T p.Arg449Cys 8 11 Thomas et al.57
140 c.1363T>C p.Cys455Arg 8 11 Arboleda-Velasquez et al.58
141 c.1364G<A p.Cys455Tyr 8 11 Kim et al.52
142 c.1370G>C p.Cys457Ser 8 11 Adib-Samii et al.38, HGMD
143 c.1394A>G p.Tyr465Cys 9 11 Lesnik Oberstein 5
144 c.1450T>G p.Cys484Gly 9 12 LOVD
145 c.1451G>A p.Cys484Tyr 9 12 Opherk et al.4
146 c.1451G>T p.Cys484Phe 9 12 Peters et al.3
147 c.1484G>A p.Cys495Tyr 9 12 Peters et al.3, Opherk et al.4






































change Amino acid change Exon EGFR Reference
149 c.1531T>C p.Cys511Arg 10 13 Peters et al.3, Opherk et al.4
150 c.1532G>T p.Cys511Phe 10 13 Mosca et al.60
151 c.1532G>A p.Cys511Tyr 10 13 Bianchi et al.61
152 c.1582G>T p.Gly528Cys 10 13 Dotti et al.51
153 c.1592G>C p.Cys531Ser 10 13 Mazzei et al.62
154 c.1594C>T p.Arg532Cys 10 13 Bianchi et al.63 
155 c.1624T>C p.Cys542Arg 11 13 Kim et al.52
156 c.1625G>A p.Cys542Tyr 11 13 Joutel et al.8
157 c.1630C>T p.Arg544Cys 11 14 Lesnik Oberstein et al.41
158 c.1645T>C p.Cys549Arg 11 14 Lesnik Oberstein 5
159 c.1646G>A p.Cys549Tyr 11 14 Peters et al.3, Opherk et al.4
160 c.1672C>T p.Arg558Cys 11 14 Joutel et al.8
161 c.1703G>A p.Cys568Tyr 11 14 Ferreira et al.64
162 c.1721A>G p.Tyr574Cys 11 14 Mazzei et al.65
163 c.1732C>T p.Arg578Cys 11 14 Joutel et al.34
164 c.1735T>C p.Cys579Arg 11 14 Roy et al.66
165 c.1759C>T p.Arg587Cys 11 15 Kim et al.67
166 c.1771T>C p.Cys591Arg 11 15 LOVD
167 c.1774C>T p.Arg592Cys 11 15 Praline et al.68, HGMD
168 c.1790G>C p.Cys597Ser 11 15 Bohlega et al.69
169 c.1816T>C p.Cys606Arg 11 15 Testi et al.21
170 c.1819C>T p.Arg607Cys 11 15 Escary et al.9
171 c.1918C>T p.Arg640Cys 12 16 LOVD
172 c.1999G>T p.Gly667Cys 13 17 LOVD
173 c.2038C>T p.Arg680Cys 13 17 Pradotto et al.70
174 c.2129A>G p.Tyr710Cys 13 18 Rutten et al.71
175 c.2149C>T p.Arg717Cys 14 18 HGMD
176 c.2182C>T p.Arg728Cys 14 18 Joutel et al.8
177 c.2324G>C p.Cys775Ser 15 20 Peters et al.3
178 c.2815T>C p.Cys939Arg 18 24 Testi et al.21
179 c.2857G>T p.Gly953Cys 18 24 Markus et al.14
180 c.2923G>T p.Gly975Cys 18 25 Kotorii et al.72
181 c.2929T>A p.Cys977Ser 18 25 Lee et al.26
182 c.2951T>G p.Phe984Cys 18 25 Escary et al.9
183 c.2953C>T p.Arg985Cys 18 25 Joutel et al.8
184 c.2963G>A p.Cys988Tyr 18 25 Kim et al.67






































change Amino acid change Exon EGFR Reference
186 c.3011G>A p.Cys1004Tyr 19 26 Guerrot et al.73
187 c.3016C>T p.Arg1006Cys 19 26 Joutel et al.8
188 c.3037G>T p.Gly1013Cys 19 26 Testi et al.21
189 c.3043T>C p.Cys1015Arg 19 26 Lesnik Oberstein et al.41
190 c.3062A>G p.Tyr1021Cys 19 26 Kalimo et al.17
191 c.3065G>T p.Cys1022Phe 19 26 Vedeler et al.74
192 c.3084G>T p.Trp1028Cys 19 26 Viana-Babtista et al.75
193 c.3091C>T p.Arg1031Cys 19 26 Joutel et al.8
194 c.3172G>T p.Gly1058Cys 20 27 Kalimo et al.17
195 c.3182G>A p.Cys1061Tyr 20 27 LOVD
196 c.3206A>G p.Tyr1069Cys 20 27 Tikka et al.1
197 c.3226C>T p.Arg1076Cys 20 27 Lesnik Oberstein et al.33
198 c.3296G>A p.Cys1099Tyr 20 28 Ferreira et al.76
199 c.3393C>G p.Cys1131Trp 21 29 Pescini et al.77
200 c.3427C>T p.Arg1143Cys 21 29 HGMD
201 c.3691C>T p.Arg1231Cys 22 31 Joutel et al.8
202 c.3750C>G p.Cys1250Trp 23 32 Del Rio-Espínola et al.78
203 c.3781T>C p.Cys1261Arg 23 32 Joutel et al.13
204 c.3782G>A p.Cys1261Tyr 23 32 Peters et al.3, Opherk et al.4
205 c.3893G>T p.Cys1298Phe 24 33 Rinnoci et al.79
206 c.3944G>A p.Cys1315Tyr 24 33 Valenti et al.80
Supplementary table 1. Currently known cysteine altering missense mutations in NOTCH3 
causing CADASIL. This list is compiled data from a list of CADASIL causing mutations 
described by Tikka et al.1 in 2009, supplemented with mutations described thereafter. All 
mutations are described according to HGVS nomenclature, and may therefore differ from the 
mutation description in the original research article. LOVD= leiden open variation database 




































No Amino acid change Exon EGFR Reference
1 p.Arg103Gln 3 2 Schmidt et al.81
2 p.His170Arg 4 4 Joutel et al.8
3 p.Pro496Leu 9 12 Joutel et al.8
4 p.Ser497Leu 9 12 Schmidt et al.81
5 p.Ser502Phe 9 12 Schmidt et al.81
6 p.Val764Ala 14 19 Schmidt et al.81
7 p.His981Tyr 18 25 Ross et al.82
8 p.Ala1020Pro 19 26 Schmidt et al.81
9 p.His1133Gln 21 29 Joutel et al.8
10 p.Val1183Met 22 30 Joutel et al.8
11 p.His1235Leu 22 31 Schmidt et al.81
12 p.Arg1262Leu 23 32 Schmidt et al.81
Supplementary table 2. NOTCH3 missense variants not involving a cysteine residue 
described as non- pathogenic. In healthy individuals, variants have been detected which 
lead to an amino acid change in the EGFR encoding exons of NOTCH3, but which do 
not involve a cysteine residue. Some of these polymorphisms, namely pHis170Arg and 
p.Ala1020Pro have also erroneously been reported to be pathogenic. Note: this list 
results from polymorphisms described in larger studies in healthy individuals, and  is not a 
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Cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy (CADASIL) is caused by stereotyped missense mutations 
in  NOTCH3. Whether these mutations lead to the CADASIL phenotype via a 
neomorphic effect, or rather by a hypomorphic effect, is subject of debate. Here, 
we report two novel NOTCH3 mutations, both leading to a premature stop codon 
with predicted loss of NOTCH3 function. The first mutation, c.307C>T, p.Arg103*, 
was detected in two brothers aged 50 and 55 years, with a brain MRI and skin 
biopsy incompatible with CADASIL. The other mutation was found in a 40-year-old 
CADASIL patient compound heterozygous for a pathogenic NOTCH3 mutation 
(c.2129A>G, p.Tyr710Cys) and an intragenic frameshift deletion. The deletion was 
inherited from his father, who did not have the skin biopsy abnormalities seen in 
CADASIL patients. These individuals with rare NOTCH3 mutations indicate that 







































INTrODuCTION, reSuLTS AND DISCuSSION
CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy) is a monogenic disorder caused by mutations in the NOTCH3 
gene (MIM #600276).1 CADASIL patients typically present with stroke and cognitive 
decline at a mean age of 45–50 years. Migraine with aura and mood disturbances 
occurs in up to 40% of patients. Disease severity and age of onset is variable, also 
within families, and the clinical presentation can be atypical. The invariable and 
preclinical presence of a recognizable pattern of white matter hyperintensities 
(WMH) on brain MRI plays a key role in clinical diagnosis, seen in all individuals 
with a CADASIL causing NOTCH3 mutation from at least 35 years of age. Next to 
increasingly extensive WMH, subcortical infarcts are typically seen in symptomatic 
patients, whereas cortical and cerebellar lesions are rare.2 The clinical diagnosis 
is confirmed by NOTCH3-sequencing analysis, with the detection of a typical 
cysteine-altering mutation.3 If the clinical or molecular results are inconclusive, 
immunohistochemistry and electron microscopy (EM) can be performed on a skin 
biopsy, to determine the presence of pathognomonic vessel wall abnormalities. 
These consist of positive NOTCH3 staining, electron microscopic deposits of 
granular osmiophilic material (GOM), and vascular smooth muscle cell (VSMC) 
degeneration.4,5 Next to a compatible clinical and family history, the trias of brain 
MRI, molecular NOTCH3 analysis, and, if necessary, skin biopsy usually allows for 
conclusive confirmation or rejection of CADASIL diagnosis.
NOTCH3 encodes the NOTCH3 protein, a transmembrane protein that, in 
adults, is predominantly expressed in the vasculature by VSMC and pericytes.6 The 
ectodomain of NOTCH3 (NOTCH3ECD) consists of 34 epidermal growth factor-like 
repeat (EGFr) domains, which each contain exactly six highly conserved cysteine 
residues. NOTCH3 mutations in CADASIL are located in the exons encoding the 
NOTCH3ECD (exons 2–24),2 and invariably lead to an uneven number of cysteine 
residues, typically five or seven, in the corresponding EGFr. This leaves one cysteine 
unpaired and has been shown to lead to increased multimerization of the mutated 
protein.7 In more than 95% of cases, the cysteine amino acid change is caused 
by a missense mutation.2 Despite the stereotyped nature of NOTCH3 mutations 
in CADASIL, it is still unknown whether the primary determinant of the CADASIL 
phenotype is a hypomorphic or rather a neomorphic effect. The most adhered 
to hypothesis is that there is a neomorphic effect, with toxic accumulation of the 
mutated protein at the VSMC membrane.6 However, in a recent study, the loss-of-
function hypothesis is revived, as a reduced NOTCH3 signaling was found to be 
associated with CADASIL pathophysiology in vitro and in vivo.8
Here, we describe individuals from two families with NOTCH3 mutations that are 







































radiological, and pathological investigations to determine whether patients with 
these hypomorphic mutations have a CADASIL phenotype.
The index patient of family 1, a 55-year-old Caucasian male (index, II-2, Fig. 1A), 
was referred to our multidisciplinary CADASIL out-patient clinic, because a novel 
NOTCH3 variant with unknown pathogenicity had been detected in a laboratory 
elsewhere. The variant, a  NOTCH3nonsense mutation in exon 3 (c.307C>T, 
p.Arg103*) (NM_000435.2), was confirmed in the Leiden Laboratory for Diagnostic 
Genome Analysis in genomic DNA and in mRNA isolated from blood (Fig. 1B) 
(www.lovd.nl/NOTCH3). The case history reported a polyneuropathy, migraine with 
aura, and ischemic strokes at the age of 50 and 52 years. Neurological examination 
revealed mild motor weakness of the left hallux, absence of vibration sense in 
feet, difficulty in fine motor tasks of the left hand, and a bilateral action tremor. 
Mini-mental state examination (MMSE) was normal (30/30). Brain MRI (axial FLAIR 
and T2* gradient echo, sagittal T1 and coronal FLAIR, and T2 weighted images) 
was reviewed by a neuroradiologist specialized in CADASIL and showed three old 
infarctions, respectively, in the right and left occipital cortex and in the left parietal 
cortex, consistent with large vessel stroke. Furthermore, a few small circumscript 
WMH were seen. There were no lacunar infarctions and no WMH in a distribution 
or extent consistent with CADASIL (Fig. 1C). A skin biopsy was then taken from the 
inner side of the forearm, which showed a normal vessel wall structure, negative 
NOTCH3 staining (Novus Biologicals, Littleton, CO; dilution 1:2000) and no electron 
microscopic GOM deposits or VSMC degeneration (Supp. Fig. S1 A and B). Family 
history was negative for stroke and dementia. The index has three siblings, all older 
than 45 years of age. They all have a history of migraine but no other neurological 
symptoms. His mother (I-2) was tested negative for the NOTCH3 mutation and his 
father (I-1) is deceased, but had no medical history of stroke or dementia. His 50-
year-old brother (II-3) had received genetic counselling elsewhere and had opted 
for predictive NOTCH3 mutation testing, showing the presence of the familial 
NOTCH3 nonsense mutation. This brother was then also referred to our CADASIL 
clinic, where neurological examination and brain MRI (axial T1, T2, FLAIR weighted 
images) were found to be completely normal (Fig. 1D).
In the second family, the index patient is a 40-year-old male (index, II-1; Fig. 2A), 
with a medical history of migraine with aura, bipolar disorder, and sarcoidosis. There 
was no history of (transient) neurological deficits. Neurological examination was 
normal, his MMSE was 28/30. Brain MRI (axial T1, T2, proton density, and sagittal 
FLAIR weighted images) had been made at a hospital elsewhere and showed 
partly confluent WMH in a pattern consistent with CADASIL, including the anterior 
temporal lobes (Supp. Fig. S2). To confirm the clinical diagnosis, blood was sent 







































analysis. Sequence analysis was performed of exons 2–23, including intron/exon 
boundaries. A characteristic CADASIL causing NOTCH3 mutation (c.2129A>G, 
p.Tyr710Cys) was detected in exon 13 (Fig. 2B), which appeared to be homozygous. 
To exclude the possibility of a NOTCH3 deletion as the reason for the absence 
of the wild-type allele, multiplex ligation-dependent probe amplification (MLPA) 
analysis was performed using a homemade MLPA kit containing probes for all 
coding exons (2–33) of NOTCH3. This revealed the presence of a large intragenic 
heterozygous frameshift deletion of exons 3–16 (Fig. 2B). This patient is, therefore, 
compound heterozygous for a typical CADASIL-causing missense mutation and a 
large intragenicNOTCH3 deletion. Although the clinical diagnosis of CADASIL was 
figure  1.  family 1: A NOTCH3 nonsense mutation in the absence of a CADASIL 
phenotype. A: Pedigree of family 1. The index patient (II-2) has a history of ischemic stroke 
but no abnormalities on skin biopsy. His brother (II-3) has no history of neurological deficits. +, 
presence of p.Arg103* mutation; –, absence of p.Arg103* mutation. B: Sequencing analysis 
of the index showing a NOTCH3 nonsense mutation in exon 3 (c.307C>T, p.Arg103*). C: 
Brain MRI (FLAIR) of the 55-year-old index (individual II-2) showing cortical defects with 
surrounding gliosis, consistent with old ischemic infarcts (shown here in the occipital lobes). 
A few minor nonspecific subcortical WMH are present. No WMH are present in the anterior 








































confirmed by the detection of the NOTCH3 missense mutation, a family study was 
performed to determine the pathogenicity of the intragenic NOTCH3 deletion. 
NOTCH3 mutation analysis of the patient’s parents showed that the p.Tyr710Cys 
mutation was inherited from his mother (I-2) and the NOTCH3 deletion was 
inherited from his father (I-1). A comprehensive medical assessment of the parents 
was complicated by the fact that they live in the former Dutch colonies. The 
medical history of the mother, however, was notable for a brain scan made around 
the age of 40 years after transient functional deficit of the arm. This scan was no 
longer available and she did not consent to further medical investigations. The 
65-year-old father ostensibly has a history of psychiatric problems, but he has no 
history of stroke or dementia. He did not consent to brain imaging, but he did 
agree to have a skin biopsy taken, which was sent to us for pathological analysis 
and fibroblast culture. NOTCH3 staining of skin vasculature was negative and 
EM showed no GOM, VSMC degeneration, or other abnormalities (Supp. Fig. S1 
C and D). To further determine the breakpoints of the NOTCH3 deletion, we 
performed NOTCH3 RT-PCR on RNA derived from the father’s fibroblasts, using 
an exon 2 forward and an exon 18 reverse primer. Sequencing of the obtained 
RT-PCR product showed that exons 3–16 are completely missing as a result of the 
deletion (Fig. 2D). This is predicted to lead to a disruption of the NOTCH3 reading 
frame and a premature stop codon in exon 17 (r.198_2566del, p.Cys67ProfsX34) 
(www.lovd.nl/NOTCH3).
The novel NOTCH3 mutations detected in the two families described above 
are a nonsense mutation and an intragenic frameshift deletion, respectively. Both 
mutations are predicted to lead to a truncation at the protein’s N-terminus, which 
then lacks essential domains required for NOTCH3 processing and signaling, 
including the transmembrane and intracellular domains. Therefore, these mutations 
must result in hypomorphic alleles, that is, alleles that have reduced gene activity. 
One individual with the nonsense mutation (c.307C>T, p.Arg103*; family 1, II-2) 
has a history of stroke, but his brain imaging is inconsistent with CADASIL and, 
moreover, his skin biopsy was negative for CADASIL vessel wall pathology. His 
brother (II-3), with the same nonsense mutation, was healthy at the age of 50 years 
and had a normal brain MRI. Together, these findings indicate that the NOTCH3 
nonsense mutation is a coincidental finding and does not cause CADASIL. In family 
2, the father of the index (I-1) has a NOTCH3 deletion of exon 3 through 16 on 
one allele. He allegedly has a history of psychiatric problems, but at the age of 
65 years he has no medical history of stroke or dementia. Although a brain MRI 
would have contributed to a confirmation or exclusion of the diagnosis CADASIL, 
a skin biopsy was made that did not show any of the abnormalities consistently 







































intragenic NOTCH3 deletion do not lead to a CADASIL phenotype, we conclude 
that hypomorphic NOTCH3 alleles do not cause CADASIL. This conclusion is 
further strengthened by the fact that frameshift and nonsenseNOTCH3 variants 
have been reported previously in public databases and in an exome resequencing 
study on colorectal cancer patients (http://www.ncbi.nlm.nih.gov/snp/).9,10 
Whole NOTCH3 gene deletions have also been reported in humans, but only 
in the context of contiguous gene deletions in patients with multiple congenital 
figure 2. family 2: A characteristic NOTCH3 mutation and a NOTCH3 deletion. A: 
Pedigree of family 2. The index patient is II-1. D, presence of del 3–16; +, presence of 
p.Tyr710Cys mutation. B: Sequencing analysis of the index (II-1) showing the presence of 
a characteristic NOTCH3 missense mutation (c.2129A>G, p.Tyr710Cys), with absence of a 
wild-type allele. C: MLPA analysis of the index (II-1) revealing the presence of a large internal 
heterozygous deletion of exons 3–16. Exons with corresponding MLPA ratios are depicted 
graphically as well as summarized in a table. D: Sequencing analysis of cDNA derived from 
cultured fibroblast RNA of the father (I-1), showing a complete deletion of exons 3 up to 







































anomalies (http://decipher.sanger.ac.uk). In contrast to our findings, small out-of-
frame NOTCH3 deletions, resulting in hypomorphic alleles, have been previously 
reported to be associated with CADASIL.11,12 However, in these reports, the 
association of the hypomorphic allele with CADASIL is questionable; as the clinical 
diagnosis was not confirmed by skin biopsy, segregation analysis was not possible 
and in one study mutation analysis of the NOTCH3 gene was incomplete. The few 
small NOTCH3 deletions or insertions that have been proven to be the cause of 
CADASIL are all in-frame and typically affect cysteine residue number, or in one 
case, cysteine spacing.5,13-16 The fact that only cysteine-altering mutations have 
been found to be unequivocally associated with CADASIL, strongly supports 
the concept that cysteine-altering NOTCH3 mutations are a conditio sine qua 
non for CADASIL. In the clinical setting, mutations detected in NOTCH3 should 
therefore be carefully evaluated for their effect on cysteine residues in the 
NOTCH3 protein. If the mutation, be it missense or otherwise, does not affect the 
number of cysteines in an EGFr domain, then this mutation should be interpreted 
with great caution and CADASIL diagnosis should only be confirmed based on 
additional investigations, such as a skin biopsy. Also, when there is an apparent 
homozygous mutation, the presence of a deletion on one of the alleles should 
be excluded. An experienced team is important for the correct interpretation 
of atypical NOTCH3 mutations, to prevent an erroneous diagnosis of CADASIL. 
Such a team, in our opinion, should consist at least of a clinical geneticist, clinical 
laboratory geneticist, neurologist, genetic psychologist, (neuro)pathologist, and 
neuroradiologist.
Notably, we report herein the first CADASIL patient who is compound 
heterozygous for a typical cysteine-altering NOTCH3 mutation on one allele and 
a large intragenic NOTCH3 deletion on the other allele. Interestingly, this patient 
has a phenotype within the normal CADASIL spectrum.
In conclusion, our findings indicate that hypomorphic NOTCH3 alleles do 
not cause CADASIL in humans, which has important implications for diagnostic 
interpretation of NOTCH3 mutations. Furthermore, this can refine the focus of 
future studies on the effect of CADASIL-causing mutations on the NOTCH3 protein 
and the development of rational therapeutic approaches.
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Supplementary figure 1. Pathological analysis of skin biopsies in family 1 and family 2.
The skin biopsies of individual II-2 in family 1 (panel A and B)  and individual I-1 in figure 3A 
(panel C and D) do not reveal the abnormalities typically seen in CADASIL. No GOM is seen 
on electron microscopy (panel A and C) and  NOTCH3 staining is negative (panel B and D). 
Positive control skin biopsy of a CADASIL patient shows both GOM (panel E) and positive 








































Supplementary figure 2. family 2: brain imaging.
Brain MRI (T2) of individual II-1 in family 2 at 37 years of age, showing subcortical WMH 
located in the semioval centre, with the highest load in the frontal lobes. WMH are also 
present in the anterior temporal lobes, as is typically seen in CADASIL (right more than left). 
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Cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy, or CADASIL, is a hereditary cerebral small vessel disease, 
caused by characteristic cysteine altering missense mutations in the NOTCH3 gene. 
NOTCH3 mutations in CADASIL result in an uneven number of cysteine residues in 
one of the 34 epidermal growth factor like- repeat (EGFr) domains of the NOTCH3 
protein. The consequence of an unpaired cysteine residue in an EGFr domain 
is an increased multimerization tendency of mutant NOTCH3, leading to toxic 
accumulation of the protein in the (cerebro)vasculature, and ultimately reduced 
cerebral blood flow, recurrent stroke and vascular dementia. There is no therapy 
to delay or alleviate symptoms in CADASIL. We hypothesized that exclusion of the 
mutant EGFr domain from NOTCH3 would abolish the detrimental effect of the 
unpaired cysteine and thus prevent toxic NOTCH3 accumulation and the negative 
cascade of events leading to CADASIL. To accomplish this NOTCH3 cysteine 
correction by EGFr domain exclusion, we used pre-mRNA antisense-mediated 
skipping of specific NOTCH3 exons. Selection of these exons was achieved using 
in silico studies and based on the criterion that skipping of a particular exon or 
exon pair would modulate the protein in such a way that the mutant EGFr domain 
is eliminated, without otherwise corrupting NOTCH3 structure and function. 
Remarkably, we found that this strategy closely mimics evolutionary events, where 
the elimination and fusion of NOTCH EGFr domains led to the generation of four 
functional NOTCH homologues. We modelled a selection of exon skip strategies 
using cDNA constructs and show that the skip proteins retain normal protein 
processing, can bind ligand and be activated by ligand. We then determined the 
technical feasibility of targeted NOTCH3 exon skipping, by designing antisense 
oligonucleotides targeting exons 2-3, 4-5 and 6, which together harbor the 
majority of distinct CADASIL causing mutations. Transfection of these antisense 
oligonucleotides into CADASIL patient derived cerebral vascular smooth muscle 
cells resulted in successful exon skipping, without abrogating NOTCH3 signalling. 
Combined, these data provide proof of concept for this novel application of exon 
skipping, and are a first step towards the development of a rational therapeutic 
approach applicable to up to 94% of CADASIL causing mutations.
Key words: CADASIL, NOTCH3, exon skipping, therapy, cysteines
Abbreviations: CADASIL= cerebral autosomal dominant arteriopathy with 
subcortical infarcts and leukoencephalopathy,  VSMC= vascular smooth muscle 
cell, NOTCH3ECD= NOTCH3 extracellular domain, EGFr = epidermal growth factor- 














































CADASIL is a hereditary vascular dementia and stroke syndrome, caused by 
cysteine-altering missense mutations in the NOTCH3 gene.1, 2 
NOTCH3 is a single pass transmembrane receptor which is required for 
VSMC differentiation and maturation,3 and integrity of especially resistance 
arterioles.4, 5 The NOTCH3ECD contains 34 EGFr domains, which are approximately 
40 amino acid long modular protein subunits, characterized by a conserved 
position and number of six cysteine residues (Fig. 1A). In pairs, these cysteines 
form three disulphide bridges which stabilize EGFr domain structure. NOTCH3 
mutations in CADASIL are found throughout exons 2-24, which are the exons 
that encode the EGFr domains, with a strong clustering of mutations in exon 4.2 
As a result of the mutation, the number of cysteine residues in one of the 
34 EGFr domains is typically altered to an uneven number of five or seven 
cysteines (Fig. 1B). This results in an unpaired cysteine residue and disrupted 
disulphide bridge formation in mutant NOTCH3ECD, which has been shown to 
have increased multimerization properties compared to wildtype NOTCH3ECD.6 
This increased multimerization leads to toxic aggregation of NOTCH3ECD in 
and around VSMCs in small- to medium sized arteries of especially the brain, 
but also in arteries of other organs and tissues.3, 7 NOTCH3ECD aggregation is 
associated with pathological vessel wall changes including degeneration of 
VSMCs and deposition of granular osmiophilic material visualised by electron 
microscopy.8 Clinical symptoms seem to be confined to the brain, where 
impaired cerebrovascular reactivity 9 and decreased cerebral blood flow 10 lead 
to chronic hypoxia, recurrent subcortical infarctions and vascular dementia. 
Typically, patients suffer from progressive cognitive and physical decline from a 
mean age of 45-50 years, preceded by at least a decade of progressive ischemic 
MRI abnormalities.11 To date, there is no therapy available to alleviate or delay 
the onset of symptoms. 
As a mutant NOTCH3 EGFr domain with an uneven number of five or seven 
cysteines appears to be the common CADASIL instigator, a rational therapeutic 
approach would be to eliminate this mutant EGFr domain. We hypothesized that 
exclusion of the mutant EGFr domain from NOTCH3 would abolish the detrimental 
effect of the unpaired cysteine and thus prevent toxic NOTCH3ECD accumulation 
and the negative cascade of events leading to CADASIL. To accomplish this 
NOTCH3 cysteine correction by EGFr domain exclusion, we used pre-mRNA 
antisense-mediated skipping of specific NOTCH3 exons. Selection of these exons 
was achieved using in silico studies and based on the criterion that skipping of 
a particular exon or exon pair would modulate the protein in such a way that 













































figure 1. Schematic representation of wildtype and mutant NOTCH3. (A) The ectodomain 
of the wildtype NOTCH3 protein contains 34 EGFr domains, each with six cysteine residues 
forming three disulphide bridges between specific pairs of cysteine residues. (B) In mutant 
NOTCH3, there is an unpaired cysteine residue in the EGFr domain affected by the mutation. 
The example shown in this figure is the common p.Arg153Cys mutation in exon 4 (indicated 
in red). As a result of the mutation, EGFr 3 contains seven cysteine residues, resulting in an 
unpaired cysteine and disrupted disulphide bridge formation.
structure and function. Exon skipping is accomplished by using AONs, which 
are small synthetic RNA or DNA oligomers designed to hybridize to specific 
sequences of pre-mRNA. Using AONs, pre-mRNA splicing can be strategically 
manipulated, as targeted exons are hidden from the splicing machinery and 
thereby excluded from the mature mRNA. An antisense drug (Mipomersen) has 
been approved by the Food and Drug Administration for the treatment of familial 
hypercholesterolemia 12 and AON administration has shown promising results 
in clinical trials for multiple hereditary disorders, such as Duchenne Muscular 
Dystrophy and Spinal Muscular Atrophy.13,14 In silico predictions show that the 
majority of CADASIL causing mutations are eligible for cysteine corrective exon 
skipping. As a proof of concept for this therapeutic approach, we modelled the 
NOTCH3 ‘skip’ proteins using cDNA constructs and show that these modified 
proteins are expressed, undergo normal protein processing and retain both 
ligand binding capacity and ligand induced activation. Next, we designed AONs 
targeting frequently mutated NOTCH3 exons, and show that CADASIL patient 
derived VSMCs transfected with the NOTCH3 AONs produce the anticipated 
skipped NOTCH3 RNA products. Taken together, these results provide a first 
proof of concept for a rational therapeutic strategy for CADASIL, in which the 
corruptive unpaired cysteine in mutant NOTCH3 is abolished by targeted EGFr 














































In silico analysis to determine the effect of NOTCH3 exon exclusion on 
EGFr domain structure
In order to identify NOTCH3 exons eligible for our cysteine correction approach, 
we determined the consequence of targeted NOTCH3 exon exclusion on EGFr 
domain primary, secondary and tertiary structure. Specifically, we determined 
the effect of exon exclusion on the NOTCH3 open reading frame, on cysteine 
number and spacing within EGFr domains, and on the formation of disulphide 
bridges within EGFr domains. As CADASIL causing mutations can be found 
throughout exons 2-24 of the NOTCH3 gene, all these exons were considered 
as potential target exons. First, the effect of exon exclusion on EGFr domain 
primary and secondary structure was analysed using Ensembl (http://www.
ensembl.org) and the online protein prediction program Prosite (http://prosite.
expasy.org). Selection of exons or exon pairs was based on the following criteria: 
a) the exclusion of the exon(s) from pre-mRNA does not disrupt the open reading 
frame b) skipping of the exon(s) results in exclusion of the mutated EGFr and the 
formation of a novel EGFr (fusion) domain with six normally spaced cysteines 
and c) the EGFr fusion domain follows the EGFr domain consensus sequence. 
(http://smart.embl-heidelberg.de/smart/do_annotation.pl?DOMAIN=SM00181) 
Next, 3D homology modelling was performed to analyse the tertiary structure 
of predicted favourable EGFr fusion domains, using the YASARA & WHAT IF 
Twinset (www.YASARA.org).15 This modelling was performed for the EGFr domains 
separately, as no continuous template was available.16-18 The sequence identity 
between the NOTCH3 domains and modelling templates varied from 39% to 
46%. Finally, we determined which exons would be eligible for cysteine corrective 
exon skipping, when formulating the selection criteria less stringently, i.e. exon 
skipping resulting in exclusion of a mutated EGFr domain and formation of an 
EGFr fusion domain containing six cysteines, but where the cysteine spacing 
within the EGFr fusion domain may differ to some degree from cysteine spacing 
in wildtype EGFr.
Expression and functional analysis of the NOTCH3 skip proteins
To study the expression, localization, ligand binding capacity and signalling 
function of the NOTCH3 proteins formed after targeted exon exclusion 
(NOTCH3 ‘skip’ proteins), NOTCH3 cDNA constructs were generated mimicking 
exon 2-3 skipping, exon 4-5 skipping and exon 6 skipping, respectively (for 
cloning details, see supplementary material). In addition, we generated cDNA 














































Expression analysis using Western Blotting
To determine NOTCH3 skip protein expression, the NOTCH3 wildtype and skip 
cDNA constructs were transfected into HEK293 cells, and protein lysates were 
analysed using Western Blot analysis. HEK293 cells were seeded in a poly-l-lysin 
coated 6-wells plate and transfected with 1 µg of NOTCH3 cDNA using 2 µl of 
lipofectamine 2000 (Life Technologies, Bleiswijk, The Netherlands). Seventy-
two hours after transfection, cells were scraped and pelleted in ice-cold PBS. 
Pellets were lysed in 100 µl TNT lysis buffer (50 mM Tris-HCl, 200 mM NaCl, 
0.5% Nonidet P40) with protease inhibitor (Roche Diagnostics, Mannheim, 
Germany) for 20 minutes. Lysates were centrifuged at 16000g for 20 minutes 
and supernatants were used for protein concentration determination using the 
BCA assay following the manufacturer’s instructions (Pierce, Rockford, USA). 
Protein isolates were electrophoresed on a 3-8% Tris acetate polyacrylamide 
gradient gel. Western blotting was performed on the transblot turbo system, 
using nitrocellulose membranes (all from Biorad, Veenendaal, the Netherlands). 
Membranes were blocked for 1 hour at room temperature using 25% seablock 
(Thermo Scientific, Rockford, USA) in PBS, and were incubated overnight with 
a primary antibody directed against the intracellular domain of NOTCH3 (anti 
NOTCH3ICD, Cell Signaling, Danvers, USA, dilution 1:1000). The secondary 
antibody (IRDye 680 labelled goat anti mouse, Licor, Lincoln, USA, dilution 
1:10000) was incubated for 1 hour at room temperature. Imaging was performed 
on the Odyssey scanner (Licor). 
Localization analysis using immunocytochemistry
To determine cellular NOTCH3 skip protein localization, human fibroblasts were 
transfected with the NOTCH3 skip constructs, and analysed using NOTCH3 
immunocytochemistry. Fibroblasts were seeded onto gelatin (from porcine, Sigma-
Aldrich, Zwijndrecht, The Netherlands) coated coverslips in a 24-wells plate, and 
transfected with 0.8 µg of the respective NOTCH3 cDNA constructs using 2 µl of 
lipofectamine 2000. Twenty-four hours after transfection, cells were fixated for 
15 minutes with 4% paraformaldehyde and 0.1% triton X-100 in PBS. For analysis 
of cell surface localization of the NOTCH3 skip proteins, cells were fixated without 
triton permeabilization, using 4% paraformaldehyde in PBS. Cells were blocked 
with 1% BSA in PBS during 20 minutes and were incubated overnight at 4ºC with 
an antibody against the extracellular part of NOTCH3 (anti NOTCH3ECD, Novus 
Biologicals, Littleton, USA, dilution 1:5000). The next day, the secondary antibody 
(Alexa488 goat anti rabbit, Life Technologies, dilution 1:1000) was incubated 
for 1 hour at room temperature. Cells were washed with PBS and mounted with 













































Immunofluoresence imaging was performed on a Leica DM5500 microscope (Leica, 
Wetzlar, Germany).
Ligand binding capacity of the NOTCH3 skip proteins 
To determine the ability of the NOTCH3 skip proteins to bind to the canonical 
NOTCH3 ligand Jagged1, ligand binding assays were performed as described 
by Hicks et al.19 Jagged1-Fc peptide (Life technologies) was preclustered to goat 
anti-human IgG Fc (cross adsorbed Dylight 594, ThermoFisher Scientific, Naarden, 
The Netherlands, dilution 1:100) in blocking mixture (DMEM/F12, 10% goat serum, 
1% BSA), for 1 hour at room temperature. Fibroblasts were transfected with one of 
the respective NOTCH3 cDNA constructs. To allow ligand binding, the NOTCH3 
cDNA transfected fibroblasts were incubated with the pre-clustered Jagged1-Fc 
peptide 24 hours after transfection for 1 hour at 37°C at a final concentration of 
0.05 µg/ml. Cells were then washed in a HEPES-based buffer (10 mM HEPES, 1 mM 
MgCl2, 5 mM CaCl2, 150 mM NaCl), and subsequently in the same buffer without 
Ca2+, and fixed for 15 minutes at room temperature with 4% paraformaldehyde in 
PBS and stained with the anti NOTCH3ECD antibody.
Ligand induced signalling capacity of the NOTCH3 skip proteins
To determine the ligand-induced signalling function of the NOTCH3 skip proteins, 
a luciferase assay was performed using a hexamerized CBF1 reporter plasmid. 
NIH3T3 cells were seeded in a 24-wells plate at a density of 8x104 cells per well, 
and co-transfected with 0.4 µg of NOTCH3 cDNA and 20 ng of pGL4.74 (hRluc/
TK) Renilla luciferase expression vector. NOTCH3 signalling was induced twenty-
four hours after transfection, by co-culturing the NOTCH3 transfected cells with 
3T3 cells expressing human Jagged1 (105 cells per well). As a negative control for 
Jagged1 induced signalling, the NOTCH3 transfected cells were co-cultured with 
mock- transfected 3T3 cells not expressing Jagged 1 (105 cells per well). After 
30 hours of co-culture, luciferase activity was measured using a dual luciferase assay 
kit (Promega, Madison, USA) following the manufacturer instructions. Experiments 
were performed in duplicate. 
NOTCH3 AON design and multimerization analysis
NOTCH3 AON design was based on guidelines for dystrophin exon skipping,20,21 
using the splice site prediction program ‘Human Splicing Finder’ (http://www.umd.
be/HSF/). AONs were designed against exons 2 to 6, which collectively harbour 
the majority of CADASIL causing mutations. All AONs used for exon skipping 
(Supplementary table 1) contain 2’-O-methyl modified ribose molecules and a 
full-length phosphorothioate backbone (2OMePS) (Eurogentec, Maastricht, The 













































skipping, an AON targeting the DMD gene was used (h56AON1).20 A RNase 
H inducing gapmer AON, containing a 10 nucleotide stretch of DNA without 
a 2OMe modification (GUCGUCaatgttcactUCGCAG) was used as a control for 
downregulation of NOTCH3 expression. The sequence of the gapmer AON was 
scrambled to generate a negative control AON for downregulation (control gapmer 
AON, CGUCGUaatgttcactCGACGU). To assess unfavourable AON multimerization 
properties, 2 µg of each AON was incubated at 37ºC during 20 minutes, and 
subsequently run on a novex® TBE gel containing 20% acrylamide (Life 
Technologies) (Supplementary fig. 1). 
Generation of CADASIL patient derived cerebral vascular smooth 
muscle cells
Informed consent was given by the patient and family members for the use 
of patient arteries to generate primary vascular smooth muscle cell cultures. 
Primary vascular smooth muscle cells were cultured from umbilical cord arteries 
(VSMCCys162Trp) and from arachnoid arteries (VSMCArg153Cys), both with a pathogenic 
cysteine altering missense mutation in exon 4 of NOTCH3. The umbilical cord 
arteries were obtained from a foetus with a NOTCH3 mutation (c.486C>G, 
p.Cys162Trp) after elective termination of pregnancy. The arachnoid arteries 
were obtained from a deceased CADASIL patient (female aged 57, NOTCH3 
mutation c.457C>T, p.Arg153Cys). The arachnoid mater was dissected from the 
dorsal region of the frontal lobe by an experienced neuropathologist. Connective 
tissue and arachnoid mater surrounding the arteries were removed. Arteries were 
washed in sterile phosphate buffered saline (PBS) and dissected longitudinally. 
The endothelial layer was removed mechanically by scraping the luminal side of 
the vessels across the bottom of a Petri dish, and the arterial sections were fixed 
to the bottom of a sterile cell culture flask containing culture medium (DMEM-
F12, glutaMAX), supplemented with 10% fetal calf serum (heat inactivated), 2 μM 
MEM sodium pyruvate, 0.5 U/ml penicillin, and 0.5 μg/ml streptomycin) (all from 
Life Technologies). First cellular outgrowth was seen within 2 weeks after vessel 
isolation. Cells were stained the anti NOTCH3ECD antibody (Novus Biologicals, 
dilution 1:1000) and with an anti-actin, α-smooth muscle antibody (Sigma- Aldrich, 
dilution 1:500) to confirm the smooth muscle cell phenotype (Supplementary 
fig. 2). Control arachnoid VSMCs (VSMCcontrol) were generated from a deceased 
individual without CADASIL (male aged 48), following the same protocol. For cell 
storage, cells were re-suspended in culture medium supplemented with 20% 
foetal calf serum and 10% DMSO, then stored in liquid nitrogen. Cell culturing 
was performed in the culture medium described above. All VSMCs used in the 













































AON transfection and RT-PCR analysis of exon skipping
To determine the technical feasibility of NOTCH3 exon skipping, the AONs were 
first transfected into primary human fibroblasts. The AONs that were able to 
induce the desired exon skip, were next transfected into the CADASIL patient 
derived vascular smooth muscle cells. Exon skipping was analysed using RT-PCR. 
For transfection, AONs were diluted in serum free DMEM and were complexed 
to lipofectamin 2000 (Life Technologies) at a lipofectamin:DNA ratio of 2.67:1, 
according to the manufacturer’s instructions. Cultures of ~90% confluent cells 
were transfected with the NOTCH3 AONs at a final concentration of 100 nM 
per AON. Cells were harvested for RNA isolation 24 and 48 hours after AON 
transfection. RNA isolation and cDNA synthesis were performed using the ‘high 
pure RNA isolation kit’ and the ‘transcriptor first strand cDNA synthesis kit’ (Roche 
Diagnostics) following the manufacturer’s protocols. For cDNA synthesis, 300 ng 
of RNA was used in a 20 μl reaction with random hexamer primers at 55°C for 
30 minutes. For exon 4-5 skip detection, PCR amplification was performed using an 
exon 3 forward (3F) and an exon 6 reverse (6R) primer at an annealing temperature 
of 63°C. For exon 6 skip detection, PCR amplification was performed using an 
exon 5 forward (5F) and an exon 7 reverse (7R) primer at an annealing temperature 
of 65°C. For exon 2-3 skip detection, PCR amplification was performed in the 
presence of 1:5 diluted GC-rich buffer solution (Roche Diagnostics) using an exon 
1 forward (1F) and an exon 5 reverse (5R) primer at an annealing temperature 
of 62°C and an annealing time of 45 seconds instead of the 30 seconds used 
in exon 4-5 and exon 6 skip detection (primer sequences see Supplementary 
table 2). PCR products were analysed on 1.5% agarose gels. The PCR fragments 
that corresponded to the expected fragment lengths after exon skipping were 
excised and purified from gel using the zymoclean Gel DNA Recovery kit (Zymo 
research, Irvine, USA). Direct DNA sequencing was carried out by the Leiden 
Genome Technology Center using the BigDye Terminator Cycle Sequencing Ready 
Reaction kit and analysed on an ABI 3730 Sequencer (both PE Applied Biosystems, 
Carlsbad, USA). 
Quantitative PCR analysis after exon skipping
To analyse the effect of NOTCH3 AON transfection on the expression of NOTCH3 
and its downstream target genes, quantitative PCR analysis was performed using 
2x Sensimix SYBR Hi-ROX (Bioline, Taunton, Massachusetts, USA) and primers at 
a final concentration of 1 pmol/µl (primer sequences see Supplementary table 3). 
Amplification was performed on the  LightCycler® 480 II realtime PCR (Roche) 
using a thermal profile of 10 min at 95°C followed by 45 cycles of 10 s at 95°C, 













































reaction dissociation analysis. Data were analysed using LinReg PCR,22 and relative 
expression levels were determined based on N0 values normalized to HPRT1. 
Due to between-experiment variability in NOTCH3 expression levels inherent to 
the use of the primary VSMCs, each experiment was normalized to the control 
AON individually. 
Statistical analyses
The unpaired students t-test was used to compare expression levels of NOTCH3 
and NOTCH3 downstream target genes after exon skipping, and to determine 
the increase in luciferase activity after co-culture with Jagged1- expressing cells.
reSuLTS
The majority of CADASIL causing mutations are eligible for cysteine 
corrective exon skipping
Based on the NOTCH3 open reading frame and in silico protein predictions we 
identified nine exons or exon pairs, encompassing a total of 12 exons, which are 
eligible for cysteine corrective exon skipping (Fig. 2A). Skipping these exons 
or exon pairs is predicted to lead to the exclusion of the mutant EGFr and the 
formation of an EGFr fusion domain containing exactly six correctly spaced 
cysteines (Table 1). This panel of eligible exons includes exon 4, which harbours the 
majority of CADASIL- causing mutations. When applying less stringent selection 
criteria for cysteine spacing in the EGFr fusion domain, we identified another six 
eligible exons (Supplementary fig. 3A). Therefore, a total of 18 out of 23 mutation-
harbouring exons are potential candidates for cysteine corrective exon skipping, 
covering 94% of known CADASIL causing mutations.
Formation of EGFr fusion domains after targeted NOTCH3 exon skipping
The most favourable exon skips are predicted to lead to the exclusion of the mutant 
EGFr domain and the concomitant formation of a novel ‘EGFr fusion domain’ 
figure 2. NOTCH3 cysteine correction using exon skipping. (A) Schematic overview of 
the open reading frame of exons 2-24 of NOTCH3. The vertical boxes indicate the number 
of reported distinct CADASIL causing mutations in each exon.23 All CADASIL-causing 
mutations are located in exons 2- 24, the exons which encode the epidermal growth factor 
like repeat (EGFr) domains of NOTCH3. The nine exon skip strategies which are predicted 
to accomplish NOTCH3 cysteine correction with correct cysteine spacing, including a 
total of 12 exons skipped singly or in pairs, are underlined in green. (B) and (C) illustrate 
NOTCH3 cysteine correction for exon 4-5 skipping, as the seminal model for this approach. 













































EGFr 6. Pre- mRNA NOTCH3 exon 4-5 skipping using antisense oligonucleotides (AONs) 
thus leads to the exclusion of the mutated EGFr 3 (shown in red) from the protein, as well as 
the complete exclusion of EGFr domains 4 and 5, and a partial exclusion of EGFr domains 
2 and 6. The remaining amino acids of EGFr domains 2 and 6 (encoded by exons 3 and 6 
respectively), form an EGFr 2-6 fusion domain with six cysteine residues that are correctly 
spaced within the domain. The fusion site of this domain is located between the 5th cysteine 
derived from EGFr 2 and the 6th cysteine derived from EGFr 6. The number of amino acids 
between the 5th and 6th cysteine is exactly according to wildtype, namely eight. (C) 3D 
homology modelling of the EGFr 2-6 fusion domain predicts a stable conformation and 
normal disulphide bridge formation. Disulphide bridges formed between cysteines are 
shown in yellow. The unpaired cysteine originating from the Arg153Cys mutation is shown 
in red. The disulphide bridge formed between the 5th and 6th cysteine in the EGFr 2-6 













































containing exactly six correctly spaced cysteines. The formation of the EGFr fusion 
domain is a result of the fact that each of the NOTCH3 exons 2-24 does not encode 
a single EGFr domain, but rather one or more (parts of) EGFr domains. Therefore, 
cysteine spacing in the EGFr fusion domain is critically dependent on which 
(combination of) exon(s) is skipped. This can be illustrated by the example of skipping 
only exon 4. Although isolated exon 4 skipping maintains the open reading frame 
and results in an EGFr fusion domain with six cysteines (Supplementary Fig. 3B), 
the spacing of these cysteines differs from wildtype EGFr domain cysteine spacing. 
An EGFr fusion domain with correct cysteine spacing is attained, however, when 
exon 4 is skipped together with exon 5 (Fig. 2B). Joint skipping of exons 4 and 5 
is predicted to lead to the fusion of the part of EGFr 2 encoded by exon 3 to the 
part of EGFr 6 encoded by exon 6, creating the novel EGFr 2-6 fusion domain. The 
fusion site within this novel EGFr 2-6 fusion domain is located between the 5th and 
6th cysteine, with cysteine spacing exactly according to cysteine spacing in wildtype 
EGFr domains, i.e. there are eight amino acids between the 5th and 6th cysteine. 
The favourable prediction of joint exon 4-5 skipping is further supported by 3D 
homology modelling, which predicts normal disulphide bridge formation within 
the EGFr 2-6 fusion domain (Fig. 2C). For the other cysteine corrective exon skips, 
similar EGFr fusion domains are predicted to be formed (Table 1). One exception is 
exon 2-3 skipping, in which the first two EGFr domains are excluded, but skipping 
does not lead to the formation of an EGFr fusion domain (Supplementary fig. 4). 
Using this cysteine corrective exon skipping approach, slightly shorter NOTCH3 
proteins are formed which lack the equivalent of one to four EGFr domains, but in 
which the pathogenic unpaired cysteine has been eliminated.
NOTCH3 skip proteins are expressed and localize at the cell membrane
To study the synthesis and processing of NOTCH3 skip proteins, we used cDNA 
constructs mimicking a selection of three exon skip strategies, namely skipping 
of exons 2-3, exons 4-5 and exon 6. Exon 4-5 skipping was selected because this 
would target the majority of CADASIL- causing mutations. Exon 6 was selected 
because in this case, skipping of a single exon leads to cysteine correction, which 
can have technical advantages over joint exon skipping. Joint exon 2-3 skipping 
was selected because this is the only skip strategy which does not lead to the 
formation of an EGFr fusion domain, but rather to the complete exclusion of EGFr 
1 and all but four amino acids of EGFr 2, leaving EGFr 3 as the first domain in 
the skip protein (Supplementary fig. 4). To model these three skip strategies, 
NOTCH3 cDNA constructs were generated lacking exons 2-3, exons 4-5  or exon 
6, respectively. First, the cDNA constructs were transiently transfected into HEK293 
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Table 1. egfr fusion domains predicted to form after cysteine corrective exon skipping
The EGFr fusion domains predicted to form after the respective cysteine corrective exon 
skips, each contain six correctly spaced cysteine residues. Cysteine corrective exon skipping 
is predicted to lead to the exclusion of the mutant EGFr domain, and the formation of a novel 
EGFr fusion domain. For each fusion domain, the fusion site is between the 5th cysteine of the 
N-terminal contributing EGFr and the 6th cysteine of the C-terminal contributing EGFr (e.g. in 
the EGFr 2-6 fusion domain formed after exon 4-5 skipping, the fusion site is between the 5th 
cysteine of EGFr 2 and the 6th cysteine of EGFr 6). Amino acids originating from the C-terminal 
contributing EGFr are underlined. The number of amino acids between the 5th and 6th cysteine 
in the fusion EGFr  is according to canonical EGFr cysteine spacing, namely eight. * Skipping 
of exons 2 and 3 does not lead to the formation of an EGFr fusion domain, but rather to the 
exclusion of EGFr 1 and 2, leaving EGFr 3 as the first EGFr domain in the skip protein. One 
cysteine amino acid from EGFr 2 is retained, but is predicted not to be included in any EGFr 
domain. ** Skipping of exon 9 may interfere with the NOTCH3 ligand binding, as it results in 
exclusion of a part of the ligand binding domain (EGFr 10-11).
showed that the NOTCH3 skip proteins are expressed by the HEK293 cells (Fig. 3A). 
Both the full length precursor protein and the NOTCH3 intracellular domain were 
detected, indicating a correct S1 cleavage of the skip proteins. Next, we performed 
immunofluorescence analysis of fibroblasts transfected with the NOTCH3 cDNA 
constructs, to analyze the cellular localization and processing of skip proteins. 
Staining of permeabilized cells with an antibody against the NOTCH3ECD showed 
that all full length NOTCH3 skip proteins had a similar intracellular localisation to 
wildtype NOTCH3 i.e. predominantly perinuclear (Fig. 3B). This pattern of NOTCH3 
intracellular staining, reflecting accumulation in the endoplasmatic reticulum or 
the Golgi network, has been previously described for both wildtype and mutant 
NOTCH3 in over-expression systems.24,25 Next, we stained unpermeabilized cells 
to determine whether the NOTCH3 skip proteins are present at the cell surface, 
and found a positive NOTCH3 staining for all skip proteins at the cell surface, 
comparable to wildtype. Together, these results indicate that NOTCH3 skip 
proteins are expressed and correctly processed, with localization at the cell surface, 













































NOTCH3 skip proteins show normal ligand binding and ligand induced 
signalling
Activation of the NOTCH3 protein is induced by the binding of a ligand (Jagged1/
Delta) to the ligand binding domain of NOTCH3, comprised of EGFr 10-11. To 
determine whether excluding EGFr domains other than EGFr domain 10-11, 
interferes with normal ligand binding, NOTCH3 cDNA transfected fibroblasts 
were incubated with soluble Jagged1 peptide. We found that all skip proteins 
co-localized with Jagged1 at the cell surface, comparable to wildtype NOTCH3 
figure 3. expression and cell surface localization of NOTCH3 skip proteins
(A) Western blot analysis demonstrating expression of NOTCH3 skip proteins, after transient 
transfection of NOTCH3 cDNA constructs in HEK293 cells. NOTCH3 detection with an 
antibody against the NOTCH3 intracellular domain reveals the presence of the unprocessed 
full length protein (FL), as well as the intracellular domain (IC). The full length skip proteins run 
slightly lower on the gel than the wildtype NOTCH3, as a result of the small size difference. 
(B) Immunocytochemical analysis of fibroblasts transfected with the same NOTCH3 cDNA 
constructs. Staining of permeabilized cells with an antibody directed against the extracellular 
part of the protein shows a cytoplasmic NOTCH3 staining, which is predominantly perinuclear 
and is comparable between the wildtype NOTCH3 and NOTCH3 skip proteins. Staining 













































protein (Fig. 4A). In contrast, NOTCH3 lacking the ligand binding domain did not 
show this co-localization, and cells transfected with an empty vector only showed 
a weak Jagged1 signal (Supplementary fig. 5). Finally, we analysed whether the 
NOTCH3 skip proteins can be activated by ligand, using a luciferase reporter assay. 
We observed a significant increase in luciferase activity of skip-protein expressing 
cells upon co-culture with Jagged1- expressing cells, which was not seen in the 
cells expressing NOTCH3 protein lacking the ligand binding domain (Fig. 4B). The 
activation rate of the exon 2-3 skip and exon 4-5 skip proteins did not differ from 
wildtype NOTCH3, whereas the exon 6 skip protein showed a lower activation rate 
compared to wildtype. Taken together, these results indicate that NOTCH3 skip 
proteins retain ligand binding capacity and can be activated successfully by ligand.
Successful exon 2-3, 4-5 and 6 skipping in CADASIL patient derived 
vascular smooth muscle cells
Given the promising results of correct processing and functionality of NOTCH3 
skip proteins, we next set out to determine the technical feasibility of targeted 
NOTCH3 exon skipping. We started with testing exon 4-5 skipping, as this targets 
the majority of CADASIL causing mutations. Multiple AONs targeting exons 4 and 
5 were designed (Supplementary table 1) and were tested in control fibroblasts 
(data not shown). The AONs with the most favourable exon skipping results were 
then transfected into VSMCArg153Cys. Joint exon 4-5 skipping was successfully 
achieved using a combination of three AONs: two AONs targeting exon 4 (h4cSD 
and h4c12) and one AON targeting exon 5 (h5c1) (Fig. 5A). The exon 4-5 skipping 
was also successful in patient derived VSMCs with another exon 4 mutation 
(VSMCCys162Trp) (Supplementary fig. 6). After establishing the feasibility of exon 4-5 
skipping, we proceeded with skipping of exon 6 and joint skipping of exons 2 
and 3. For each of these exons, a total of three potentially effective AONs were 
designed (Supplementary table 1). For exon 2-3 skipping, the most efficient skip 
was induced with the AON combination h2c1 and h3c3 (Fig. 5B). Exon 6 skipping 
was accomplished with all three tested exon 6 AONs individually, but was most 
efficient when using a combination of AONs h6c2 and h6c7 (Fig. 5C). For all skips, 
cell viability was comparable between cells transfected with control AON and cells 
transfected with the NOTCH3 AONs. These results show that both single and joint 
NOTCH3 exon skipping is feasible in CADASIL patient derived VSMCs. 
AON- induced exon skipping does not reduce expression levels of 
NOTCH3 or NOTCH3 target genes 
The full length 2’-O-methyl modification of the AONs we used, protects the 
RNA-AON hybrids from RNase H cleavage, which is essential here, because the 













































figure 4. Ligand binding and ligand induced signalling of NOTCH3 skip proteins 
(A) Fibroblasts were transfected with NOTCH3 cDNA and incubated with a Jagged1-Fc 
peptide to allow for ligand binding. The Jagged1-Fc peptide was preclustered to an anti-Fc 
antibody (red fluorescence). The NOTCH3 expressing cells are visualized using an anti 
NOTCH3ECD antibody (green fluorescence). Cells transfected with wildtype NOTCH3 cDNA 
show an increased Jagged1 staining where the NOTCH3 protein is expressed, whereas this 
staining is absent in the cells transfected with NOTCH3 lacking the ligand binding domain 
(del EGFr 10-11). The cells expressing the NOTCH3 skip proteins all show an increased 
Jagged1 staining similar to wildtype NOTCH3, indicating normal ligand binding. Images 
are shown from one representative experiment at a 40x magnification. (B) NIH3T3 cells 
transiently transfected with NOTCH3 cDNA, were co-cultured with Jagged1 expressing cells 













































reporter plasmid. Cells transfected with wildtype NOTCH3 cDNA show a significant increase 
in luciferase activity upon co-culture with 3T3 cells expressing human Jagged1, compared 
to co-culture with mock- transfected 3T3 cells not expressing human Jagged1. The cells 
transfected with the respective skip NOTCH3 cDNA also showed a significant increase in 
luciferase activity. There was no significant increase in luciferase activity in cells expressing 
NOTCH3 lacking the ligand binding domain. The increase in luciferase activity for the exon 
6 skip cDNA construct was slightly lower than for the other skips and wildtype. The activity 
is expressed as relative luciferase units, data are normalized for activity measured in empty 
vector transfected cells +hJagged1. Results are the mean ±SEM from eight independent 
experiments,***p<0.001, *p<0.05, ns= not significant. 
figure 5. Successful AON-induced NOTCH3 exon skipping in VSmCArg153Cys  
RT-PCR and sequencing analysis of RNA from VSMCArg153Cys transfected with NOTCH3 AONs 
or control AON. Depicted are results from (A) exon 4-5 skipping, (B) exon 2-3 skipping and (C) 
exon 6 skipping. The RT-PCR of the samples transfected with the NOTCH3 AONs show that 
the intensity of the wildtype band is decreased and an additional, smaller product is present, 
which corresponds to the expected fragment length after exon skipping. Sequencing 
analysis of these smaller fragments confirmed that all 3 exon skips were successful. For the 













































of transcripts. Therefore, exon skipping should not alter total NOTCH3 expression 
levels. Using qPCR, we show that transfection with the NOTCH3 exon skipping 
AONs indeed did not reduce total NOTCH3 expression levels, as opposed to 
transfection with RNaseH inducing NOTCH3 gapmer AONs, which did reduce 
total NOTCH3 expression levels (Fig. 6A). To determine whether transfection 
with exon skipping AONs had an effect on canonical NOTCH3 signalling, we also 
determined the expression levels of NOTCH3 downstream target genes HES1, 
HEYL, PDGFR-β and Jagged1. No significant changes were found in expression 
levels of these target genes after transfection with exon skipping AONs, as 
opposed to transfection with gapmer AONs, which did lead to reduced expression 
levels of NOTCH3 target genes HES1 (p=0.009) and HEYL (p=0.09) (Fig. 6B and 
Supplementary fig. 7). These results show that transfection of patient derived 
VSMCs with NOTCH3 exon skipping AONs achieves the anticipated exon skips, 
without reducing total NOTCH3 expression levels and without affecting expression 
of NOTCH3 downstream target genes.
DISCuSSION
In this study, we introduce the novel approach of cysteine corrective NOTCH3 
exon skipping. We show that this targeted NOTCH3 exon skipping is technically 
feasible and that NOTCH3 skip proteins undergo normal processing and retain 
ligand binding capacity and ligand induced activation.
Cysteine corrective exon skipping could in theory be applicable to 18 out of 
23 EGFr domain encoding exons, covering 94% of CADASIL causing mutations. 
To determine the feasibility of our approach, we selected skipping of exons 2-3, 
4-5 and 6, and tested AONs targeting these exons in patient derived VSMCs, 
which all showed effective exon skipping. Cysteine corrective exon skipping results 
in a modified NOTCH3 protein from which the mutant EGFr has been excluded 
and in which an EGFr fusion domain is created, with predicted normal disulphide 
bridge formation. We modeled the skip proteins of the three tested exon skips 
using cDNA constructs, and show that the skip proteins display normal processing, 
ligand binding and ligand induced activation, comparable to wildtype NOTCH3. 
Therefore, although the NOTCH3 skip proteins in this cysteine corrective model 
lack the equivalent of up to four EGFr repeats and contain a novel EGFr fusion 
domain, this does not seem to interfere with NOTCH3 processing and function. 
This finding is consistent with NOTCH data from various scientific fields, which also 
provide evidence for a redundancy in the number of NOTCH EGFr domains. A prime 
example is that, during evolution, duplication events and (partial) NOTCH deletions 
have occurred, which have resulted in four functional human NOTCH homologues 













































figure 6. expression of NOTCH3 and NOTCH3 target genes after exon skipping
(A) NOTCH3 qPCR analysis of VSMCcontrol transfected with NOTCH3 AONs. After exon skipping, 
total NOTCH3 expression levels are unaltered, whereas transfection with a downregulating 
NOTCH3 gapmer AON results in decreased NOTCH3 expression levels (Unpaired student’s 
t-test, p=0.04). (B) qPCR analysis of NOTCH3 downstream target gene expression in VSMCcontrol 
transfected with NOTCH3 AONs. Transfection with NOTCH3 exon skipping AONs did not affect 
the expression levels of the canonical NOTCH3 downstream target genes HES1 and HEYL, 
as opposed to transfection with downregulating NOTCH3 gapmer AONs, which did lead to 
reduced expression of NOTCH3 target genes (Unpaired student’s t-test, HES1 p=0.009, HEYL 













































nlm.nih.gov).26 In fact, EGFr 2 of NOTCH3 was generated during evolution by 
a deletion event in a genomic copy of NOTCH2, resulting in a fusion of part of 
NOTCH2-derived EGFr 2 and part of NOTCH2-derived EGFr 3.27, 28 Interestingly, this 
evolutionarily formed EGFr 2-3 fusion domain is structurally almost identical to the 
EGFr 2-6 fusion domain, which is formed after exon 4-5 skipping (Supplementary 
fig. 8). Further support for redundancy in the number of EGFr domains in NOTCH3, 
is the report of a rare human NOTCH3 splice site mutation leading to skipping of 
exon 16, showing compatibility of this protein, lacking EGFr domain 21 and parts 
of EGFr domains 20 and 22, with normal embryological development, growth and 
human reproduction.29 
In this study we have not yet been able to address the effect of cysteine 
corrective exon skipping on vascular NOTCH3 aggregation. A reliable evaluation 
of this important aspect can only be provided by in vivo studies, as cell models 
do not recapitulate the CADASIL pathological hallmarks such as NOTCH3ECD 
aggregation, GOM formation and VSMC degeneration. For example, the CADASIL- 
patient derived VSMCs we use to test exon skipping do not show consistent 
differences in NOTCH3 staining between patient and control cells (Supplementary 
fig. 2). Likewise, the NOTCH3 cDNA transfection approach we used is inherently 
associated with NOTCH3 overexpression and intracellular NOTCH3 aggregation, 
confounding any read-out of CADASIL-associated NOTCH3ECD aggregation. 
To assess the feasibility and efficacy of NOTCH3 exon skipping in vivo and to 
determine the effect on vascular NOTCH3 aggregation, we are in the process of 
characterizing a mouse model we generated. This mouse model is transgenic for 
the genomic full length human NOTCH3 gene and shows the typical CADASIL- 
associated cerebrovascular NOTCH3 aggregation. We will first need to optimize 
in vivo AON administration by testing various AON chemistries and administration 
routes,30,3132 and develop relevant therapeutic read-outs, before we can set out to 
assess a therapeutic effect of cysteine corrective exon skipping. 
AONs are emerging as a promising treatment modality for genetic disorders, 
and can be used either to change the expression levels of mutant proteins or to 
restore the structure of deleterious proteins. An alternative AON-based approach 
to NOTCH3 cysteine correction could be NOTCH3 downregulation, as previous 
studies have shown that there is some redundancy in the amount of NOTCH3 
signalling required for normal functioning.33 In that case, AONs would need to 
be used that induce RNase H mediated degradation of RNA, thus leading to a 
reduction in the total load of mutant NOTCH3 protein expression and potentially 
therefore also NOTCH3 aggregation load. We used RNase H inducing gapmer 
AONs as a control for our exon skipping experiments, which showed an effective 













































and AON-mediated downregulation have been proven to be safe and effective 
upon both local and systemic AON administration in multiple clinical trials.32 
In conclusion, we developed the concept of NOTCH3 cysteine correction as 
a potential therapeutic strategy for CADASIL. This concept, namely restorative 
protein modification through cysteine corrective exon skipping, may be added 
to the growing list of potential therapeutic applications of exon skipping.34 These 
in vitro studies form the basis for planned in vivo studies in human NOTCH3 
transgenic mice, aimed at determining whether this approach leads to a delay or 
reduction of NOTCH3 aggregation in the cerebrovasculature, as a marker for a 
therapeutic effect.
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Cloning of NOTCH3 cDNA constructs 
NOTCH3 cDNA constructs mimicking the various skip strategies were generated by 
excluding the respective exons from wild type human NOTCH3 cDNA constructs. All 
the targeted exon exclusions were generated by performing inverse PCRs on smaller 
human NOTCH3 subclones in pSE280 (Invitrogen). Inverse PCR’s were performed with 
Phusion high fidelity DNA polymerase (Fermentas, Bleiswijk, The Netherlands), using 
phosphorylated primers to allow self-ligation of the PCR products. First, a cDNA construct 
lacking exons 4 and 5 was generated. For this construct, a fragment of the NOTCH3 
cDNA was synthesized using RT-PCR on mRNA obtained from cell line HCC2429 (a kind 
gift from Professor D.P. Carbone, USA),  using an exon 1 forward primer with an EcoRI 
restriction site (5’-GGAATTCATGGGGCCGGGGG-3’) and an exon 6 reverse primer 
(5’-GGCAGGCACAGTAGAAAGAA-3’).This fragment was cloned into the pSE280 vector 
using EcoRI and ClaI. The exon 4-5 deletion was introduced in this fragment using primers 
at the 3’ end of exon 3 (5’-CTCGGAAGCCACGGGGGCAC-3’) and at the 5’ end of exon 
6 (5’phosphorylated -GCCAGTTCTGCACGGAGGACGTG-3’). A second fragment was 
generated using an exon 6 forward primer (3’- AGGTGAGAGCTGCAGTCAGAAT-5’) 
and an exon 15 reverse primer (3’-AGGGGGAGAGGAGTTCACACT-5’). This was 
cloned into pSE280 using ClaI and AatII. Next, both fragments were cloned into 
the pET28a vector using EcoRI and ClaI for the first fragment, and ClaI and SalI for 
the second fragment. Sequence analysis revealed that the first 96 bp after the ATG 
start codon were missing. Therefore, the skip region was amplified from  the large 
construct in pET28a using a forward primer containing a Nhe1 restriction site in exon 
1 (5’-CTGCT-GCTAGC-GGGGCCGGGGGCTGCAG-3’)  and a reverse primer in exon 
6 (5’-GGCCACCCAGCGTGTTGA-3’). The NheI and KpnI restriction sites within this 
fragment were used to replace the corresponding region in a pTT5-based eukaryotic 
expression vector containing NOTCH3 EGFr 1-9. Finally, the missing 3’ sequence was 
added from a pcDNA3.1 construct containing full-length human NOTCH3 35 using 
restriction sites KpnI and BamHI. The complete coding sequence of both the wild 
type and the skip construct was sequenced. 
To generate the cDNA construct lacking exons 2 and 3, an inverse PCR was performed 
on an EcoRI, KpnI subclone containing NOTCH3 exons 1 to 5 from pTT5hN3FLwt, 
using primers at the 3’ end of exon 1 (5’-CTGCAGCCCCCGGCCCCGCTA-3’) and 
at the 5’ end of exon 4 (5’ phosphorylated-GCCCTGACTGCTCCCTGCCAGATCC
CTG-3’). After verification of the skip clone by sequencing analysis, the missing 3’ 
sequences was added by cloning in the 6309 bp KpnI fragment of  pTT5hN3FLwt. 
Subsequently, the complete NOTCH3 gene with the exon 2-3 deletion was cloned 
into pTT5 using EcoRI and BglII. The cDNA construct lacking exon 6 was made using 













































at the 3’end of exon 5 (5’-CTGTCCACTCAGGAGGGCA-3’) and at the 5’ end of 
exon 7  (5’ phosphorylated GCCTCCTGTGTCACCTGGAT-3’). After verification of 
the skip clone by sequence analysis the 2344bp EcoRI-AatII fragment containing 
the exon 6 deletion was ligated together with the 4813bp AatII, BglII fragment of 
pTT5hN3FLwt, into the EcoRI and  BglII digested pTT5 vector. Finally, as a negative 
control a cDNA construct lacking the exons which encode the ligand binding 
domain (EGFr 10-11) was generated. This deletion, encoded by a part of exon 7, 
complete exon 8 and a part of exon 9, was introduced in the EcoRI-AatII subclone 
containing exons 1 to 14, using primers in exon 7 (5’-CTGGTCACATGCCCCACC-3’) 
and in exon 9 (5’ phosphorylated GTGGACATTGACGAGTGTCAGAG-3’). For all 
cDNA constructs, plasmid mini preparations (Nucleospin, Macherey-Nagel, Düren, 







































































Supplementary table 1. NOTCH3 antisense oligonucleotides (AONs) used for exon skipping
Primer name Primer sequence Detects
1F CAGGGAAGGAGGGAGGA Exon 2-3 skipping
5R GCACTGGCAGTTATAGGTGTT
3F GAGGACCCCTGTCACTCAG Exon 4-5 skipping
6R GACTGCAGCTCTCACCTGTC
5F TGAGGGTCAGAATTGTGAAGTG Exon 6 skipping
7R GTCATCCAGGTGACACAGGAG







































































































Supplementary figure 1. multimerization analysis of the AONs used for exon skipping. 
All AONs that showed multimerization (h4cSA, h4c12, h4c23) were excluded from further 
analysis, as AON multimerization is known to diminish efficacy and may cause aggregation 
in vivo. AONs h5c1and h2c3 form dimers, but some dimerization of AONs has been shown 













































Supplementary figure 2. NOTCH3 and smooth muscle actin staining of CADASIL patient 
derived VSmCs. (A) NOTCH3 immunofluorescence analysis of VSMCArg153Cys and VMSCcontrol. 
Staining of unpermeabilized VSMCArg153Cys with an antibody against the extracellular part of 
NOTCH3 showed a granular staining pattern at the cell surface, which was comparable to 
that seen in VSMCcontrol. (B) Immunofluorescence analysis using a anti – smooth muscle actin 













































Supplementary figure 3. exons eligible for cysteine corrective exon skipping with 
altered cysteine spacing in the egfr fusion domain.
(A) In addition to the 12 exons eligible for cysteine corrective exon skipping with correct 
cysteine spacing (underlined in green), there are also additional exons of which skipping 
leads to cysteine correction, but with altered cysteine spacing in the resultant EGFr fusion 
domain (dashed green underlining). Taken together, 18 out of 23 mutation-encoding exons 
can be targeted, covering 94% of known CADASIL –causing mutations. The vertical boxes 
indicate the number of reported distinct CADASIL causing mutations in the exon 23. (B) As 
an example of exon skipping leading to cysteine correction with altered cysteine spacing, 













































Supplementary figure 4. Predicted effect of NOTCH3 exon 2-3 skipping.
The NOTCH3 protein contains a signal peptide (SP), located N-terminal to EGFr 1. Joint 
exon 2-3 skipping leads to the complete exclusion of EGFr1, and the exclusion of all except 
4 amino acids of EGFr2. EGFr 3 is predicted to be the first EGFr domain in the skip protein. 
The remaining cysteine from EGFr 2 is predicted not to be included in any domain, but to 
reside N-terminal to EGFr 3.  
 
Supplementary figure 4 Predicted effect of NOTCH3 exon 2-3 skipping 
The NOTCH3 protein contains a signal peptide (SP), located N-terminal to EGFr 1. Joint exon 
2-3 skipping leads to the complete exclusion of EGFr1, and the exclusion of all except 4 
amino acids f EGFr2. EGFr 3 is predicted to be the first EGFr domain in the skip protein. The 
remaining cysteine from EGFr 2 is predicted not to be included in any domain, but to reside 














































Supplementary figure 5. endogenous NOTCH3 expression and Jagged1 ligand binding 
in fibroblasts.
Fibroblasts transfected with an empty vector and incubated with a Jagged1-Fc show a weak 













































Supplementary figure 6. Successful exon 4-5 skipping in VSmCCys162Trp.
RT-PCR analysis, confirming effective exon 4-5 skipping in a second CADASIL cell model 















































Supplementary figure 7.  EGFr fusion of NOTCH in evolution is similar to EGFr fusion after 
cysteine corrective NOTCH3 exon skipping.  
The ectodomain of the NOTCH2 protein consists of 36 EGFr domains. Evolutionarily, 
duplication of the NOTCH2 gene led to the emergence of NOTCH3 26 The ectodomain of 
NOTCH3 has 34 instead of 36 EGFr domains, as a result of two internal deletions which 
occurred during evolution 27 One deletion included a part of EGFr 2 and a part of EGFr 3 of 
NOTCH2, resulting in an EGFr 2-3 fusion that is now NOTCH3 EGFr 2. The EGFr 2-3 domain is 
fused between the 5th and 6th cysteine, with preserved canonical spacing between the 
cysteines (mouse NOTCH3 EGFr 2 and 3 amino acid sequence shown). The second deletion is 
a complete deletion of EGFr 21.  
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Supplementary figure 8. Expression of NOTCH3 target genes after exon skipping 
qPCR analysis of VSMCcontrol transfected with NOTCH3 AONs. Exon skipping does not alter 
expression levels of NOTCH3 downstream target genes Jagged1 and PDGFR-β. Transfection 
with a gapmer AON shows some reduction in expression of Jagged1 and PDGFR-β, but this 
did not reach statistical significance compared to the control gapmer AON. (Unpaired 
student’s t-test). 
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CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and 
Leukoencephalopathy) is a hereditary small vessel disease caused by mutations in 
the NOTCH3 gene, leading to toxic NOTCH3 protein accumulation in the small- 
to medium sized arterioles. The accumulation is systemic but most pronounced 
in the brain vasculature where it leads to clinical symptoms of recurrent stroke 
and dementia. There is no therapy for CADASIL, and therapeutic development is 
hampered by a lack of feasible clinical outcome measures and biomarkers, both 
in mouse models and in CADASIL patients. To facilitate pre-clinical therapeutic 
interventions for CADASIL, we aimed to develop a novel, translational CADASIL 
mouse model. To this end, we generated transgenic mice in which we overexpressed 
the full length human NOTCH3 gene from a genomic construct with the archetypal 
c.544C>T, p.Arg182Cys mutation. The four mutant strains we generated have 
respective human NOTCH3 RNA expression levels of 100%, 150%, 200% and 350% 
relative to endogenous mouse Notch3 RNA expression. Immunohistochemistry 
on brain sections shows characteristic vascular human NOTCH3 accumulation in 
all four mutant strains, with human NOTCH3 RNA expression levels correlating 
with age at onset and progression of NOTCH3 accumulation. This finding was the 
basis for developing the ‘NOTCH3 score’, a quantitative measure for the NOTCH3 
accumulation load. This score proved to be a robust and sensitive method to assess 
the progression of NOTCH3 accumulation, and a feasible biomarker for pre-clinical 
therapeutic testing. In conclusion, this novel, translational CADASIL mouse model is 
a suitable model for pre-clinical testing of therapeutic strategies aimed at delaying 







































Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and 
Leukoencephalopathy (CADASIL) is a hereditary small vessel disease caused by 
mutations in the NOTCH3 gene, leading to mid-adult onset stroke and dementia.1 
CADASIL is characterized by accumulation of the extracellular domain of the 
NOTCH3 protein (NOTCH3ECD) in the media of small- to medium-sized arterioles.2 
In addition, electron dense deposits (granular osmiophilic material, GOM) are seen 
in close vicinity to the vascular smooth muscle cells (VSMCs).3 The arteriopathy 
is systemic but most pronounced in the brain where it leads to degeneration of 
VSMCs3 and a disturbed cerebral blood flow regulation.4 This causes recurrent 
ischemic strokes and cognitive decline, starting at a mean age of 45-50 years.5 To 
date, there is no therapy to prevent or delay symptoms in CADASIL. 
NOTCH3 targeting therapies are in the pre-clinical phase of development 
(Rutten et al., unpublished, patent no. WO 2010085151 A2). The hitherto available 
CADASIL mouse models have important limitations with respect to their feasibility 
for testing such therapeutic strategies. Available models include transgenic 
models overexpressing human NOTCH3 from a cDNA construct6-8 or rat Notch3 
from a genomic construct,9 and models in which a mutation was introduced into 
the endogenous Notch3 gene.10,11 The first and often only sign of CADASIL in 
these models is the presence of NOTCH3 accumulation in the vasculature,12 
and in all human NOTCH3 transgenic models, the NOTCH3 accumulation only 
becomes apparent at a high age.6-8 Only the mouse model that expresses mutant 
rat Notch3 protein from a genomic DNA construct shows early onset vascular 
Notch3 accumulation with subsequent development of brain parenchymal lesions.9 
However, this model is less suitable as a translational CADASIL model due to 
the species difference, which creates an additional hurdle in bringing therapeutic 
compounds to clinical trials. For example, this would be the case for antisense 
therapeutic strategies targeting mutated pre-mRNA, a therapeutic approach which 
is being developed for increasing numbers of CNS disorders.13 
For therapeutic development, feasible clinical outcome measures and biomarkers 
are imperative, both in mouse disease models and in patients. In CADASIL patients, 
the variability in age at onset and progression of clinical symptoms, including the 
major symptoms of stroke and cognitive decline, limits their use as an outcome 
measure in clinical trials, because of the large number of patients that would have to 
be included to detect a treatment effect within a typical trial-timeframe of 2 years.14 
White matter lesions, detected on T2 weighted brain MRI images, are present prior 
to the onset of clinical symptoms and correlate with disease severity,15 but are 
not a reliable predictor of disease progression.16 Changes in magnetic resonance 






































been studied in symptomatic patients.16,17 Ideally, CADASIL therapies would be 
initiated in the pre-symptomatic disease phase, i.e. in young adults with a proven 
familial NOTCH3 mutation. Vascular NOTCH3 protein accumulation could be an 
interesting therapeutic biomarker for CADASIL, as increased vascular NOTCH3 
staining and GOM are consistently found in skin arterioles of pre-symptomatic 
patients, decades before onset of stroke and cognitive decline.18,19 
In this study, we set out to generate a novel, translational CADASIL mouse 
model and to develop a relevant biomarker in this model. We generated a series 
of human NOTCH3 transgenic mouse strains, with various expression levels of 
mutant NOTCH3. These mice develop cerebrovascular NOTCH3 accumulation 
characteristic of CADASIL at an early age, and the NOTCH3 expression level 
correlates with both the age at onset and progression of vascular NOTCH3 
accumulation. We developed a quantitative measure for the vascular NOTCH3 
accumulation load, which we show to be a sensitive and robust biomarker for 
CADASIL in these mice.  
mATerIALS AND meTHODS
Generation of NOTCH3 transgenic mice
For transgenesis, a 142,63 kb BAC clone was used (RP11-456N16 BAC, Bacpac 
resources, Oakland, USA) (Ensemble release 59). The BAC contains the full-length 
human genomic NOTCH3 gene and 44kb of upstream and 67kb of downstream 
sequence, including flanking genes SYDE1, ILVBL, EPHX3 and a part of the 
BRD4 gene (Figure 1A). The c.544C>T (p.Arg182Cys) mutation was introduced 
using two-step Red-mediated recombination as previously described 20. BAC 
constructs were injected into fertilized C57BL/6J Ico oocytes. Positive transgenic 
founder mice were identified by PCR on DNA isolated from mouse ears using 
human specific primers (for primer sequences see Additional file 1: Table S1). The 
presence of the mutation was confirmed by direct Sanger sequencing analysis 
of PCR products (Figure 1B). Five transgenic mouse strains were generated: one 
carrying the wild-type NOTCH3 transgene (tgN3WT) and four carrying the mutant 
NOTCH3 transgene (tgN3MUT). In each strain, integration of the BAC was confirmed 
by PCR analysis of NOTCH3 and the flanking genes SYDE1, ILVBL and EPHX3 (for 
primer sequences see Additional file 1: Table S1). All transgenic mouse strains 
bred normally. All experiments described in this study were approved by the local 
ethical committee for animal experimentation. 
NOTCH3 expression analysis in NOTCH3 transgenic mice
Total RNA was extracted from a brain hemisphere using RNA-Bee (Tel-test Inc., 






































oligo (dT) primers. RT-PCR analysis was performed with primers across the human 
NOTCH3 transcript (exons 2-4, exons 14-16, exons 30-32, exons 32-33, and the 
3’UTR). For qPCR analysis, cDNA synthesis was performed with random hexamer 
primers, using the Revert Aid H Minus first strand kit (Thermo Scientific, Waltham, 
USA). Quantitative PCR was performed in four 10-week-old male and female 
transgenic mice and non-transgenic littermates, using both human- (exons 7-9, 
216 bps) and mouse-specific (exons 6-8, 220 bps) primers. Mouse Gapdh was used 
as a reference gene, and human NOTCH3 expression levels were calculated relative 
to endogenous mouse Notch3 expression levels. A possible effect of differences 
in primer efficiencies of human- and mouse-specific NOTCH3/Notch3 primersets 
was excluded by LinregPCR.21 
NOTCH3 immunohistochemistry and quantification in NOTCH3 
transgenic mice
Vascular NOTCH3 accumulation in brain was analysed prospectively in groups of 
three mice, at age 4 weeks, 6 weeks, 12 weeks, 24 weeks, 52 weeks and 82 weeks. In 
addition, vascular NOTCH3 accumulation was assessed in heart, aorta, liver, kidney, 
skin and tail at age 20 months. NOTCH3 immunohistochemistry was performed 
on cryosections that were fixated in acetone and incubated overnight with an 
antibody directed against the human NOTCH3ECD (Novus Biologicals, Littleton, 
USA; dilution 1:2000). The following day, sections were incubated with peroxidase 
labelled polymer conjugated to anti-rabbit immunoglobulins (Envision kit, Dako, 
Glostrup, Denmark), and developed using 3,3’-diaminobenzidine. Quantification 
of the vascular NOTCH3 accumulation load was performed on brain cryosections. 
Per time point (6 weeks, 24 weeks, 52 weeks and 82 weeks), three tgN3MUT350 mice 
and three tgN3MUT150 mice were analysed. For each mouse, four frontal lobe brain 
sections were NOTCH3 immunostained simultaneously. Sectionswere scanned 
using the Ultra Fast Scanner (Philips, Eindhoven, The Netherlands), from which 
10 images representative for the NOTCH3 accumulation observed in that mouse 
were obtained. To exclude a possible bias in image selection, a second, blinded 
observer was asked to obtain images independently (Additional file 1: Figure S1). 
ImageJ analysis was performed as follows: the image was converted into an 8-bit 
image, and filtered using the unsharp mask filter (radius 1, mask 0.60). Next, a 
threshold was set to a signal intensity of 150 to determine the NOTCH3-positive 
area. Within the NOTCH3-positive area, individual NOTCH3 particles were 
identified based on size and circularity (size=0-30, circularity=0.50-1.00). Finally, 
the NOTCH3 score was determined by quantifying the total area of the NOTCH3 
positive particles within the image. The average of the three mice per time point 






































NOTCH3 immunohistochemistry and quantification in human material
We used paraffin embedded frontal lobe brain sections from three deceased 
CADASIL patients (I: female age 59, p.Arg153Cys; II: female age 57, p.Arg153Cys; 
III: male age 70, p.Cys446Phe) and three deceased controls with no known 
cerebrovascular disorders (I: male age 67, II: male age 58, III: male age 53). Sections 
were de-waxed, rinsed with ethanol and blocked with methanol/H2O2. After heat-
induced antigen retrieval in 0,01M citrate buffer pH 6, slices were washed three 
times with PBS, and incubated overnight at room temperature with a 1:1 cocktail of 
anti-NOTCH3ECD (dilution 1:500) and anti-CD31 (Dako, Glostrup, Denmark; dilution 
1:50) The following day, sections were washed and incubated for 1 hour at room 
temperature with a 1:1 cocktail of anti-rabbit Envision/HRP (Dako) and goat anti-
mouse alkaline phosphatase (Vector Laboratories, Burlingame, CA, USA; dilution 
1:25). Finally, sections were sequentially developed with 3,3’-diaminobenzidine 
solution and Vector Blue (Vector laboratories). Per individual, four images were 
taken at a 400x magnification on a Leica IM 500 microscope and analysed using 
ImageJ software. The vessel area was selected manually based on a positive 
CD31 staining. Within the vessel area, the NOTCH3 score was calculated using an 
intensity threshold of 100. 
Electron microscopy in NOTCH3 transgenic mice
Brain tissue was fixed in 1,5% glutaraldehyde and 1% paraformaldehyde in 0,1M 
cacodylate buffer, post-fixed in a solution of 2% osmium tetroxide and 2% potassium 
ferrocyanide, dehydrated and embedded in epon 812 (LX112). After selection of areas 
of interest on 1µm toluidine stained sections, ultrathin sections were cut, contrasted 
with 3% uranylacetate and Reynolds lead citrate and examined with a JEOL JEM-1011 
electron microscope (Advanced Microscopy Techniques, Woburn, USA).
Statistical analysis
Statistical analyses were performed using Graphpad Prism. Differences in NOTCH3 
score between the two mouse strains at a given time point were analysed using the 
unpaired student’s t-test. Differences in NOTCH3 score between time points were 
analysed using One-Way ANOVA and Fishers least significant difference post-hoc 
analysis. Differences in slope (i.e. the rate of increase of the NOTCH3 score) over 
time were analysed using linear regression.
Brain MRI of NOTCH3 transgenic mice
Brain MRI was performed in 15 mice at 20 months of age; six TgN3MUT350 mice, 
five tgN3WT mice, and four non-transgenic littermates. Mice were anesthetised 
by inhalation of 2% isoflurane in a 1:1 mixture of oxygen and air. Respiration rate 






































per minute by adjusting the isoflurane concentration. T2 weighted imaging was 
performed on a 7 Tesla Bruker Pharmascan using a 23 mm quadrature coil with 
the following parameters: TE=12 ms, RARE factor=8, effective TE=48 ms, TR=4 
s, 8 averages. Field-of-view= 19x19 mm, matrix= 196x196, resulting in an in-plane 
resolution of 97 μm. Slice thickness=0.5 mm, with 32 slices. 
Analysis of brain parenchyma in NOTCH3 transgenic mice
After MRI, anesthetised mice were sacrificed using cardial perfusion with ice-cold 
phosphate buffered saline. One brain hemisphere was formalin fixated and paraffin 
embedded. Sections were stained with hematoxylin and eosin (H&E) to analyse the 
presence of infarctions, with Kluver Barrera Luxol fast blue to visualise myelin and 
with Perl’s iron to assess the presence of microbleeds. Astrogliosis was analysed 
using an anti-glial fibrillary acidic protein (GFAP) antibody (rabbit anti-GFAP, Dako; 
dilution 1:1000), which was incubated overnight at room temperature. As a secondary 
antibody, biotin labelled swine-anti Rabbit (Dako; dilution 1:600) was used, this 
was incubated 1 hour at room temperature. Finally, sections were incubated with 
avidin-biotin complex (Vectastain ABC-Elite Kit, Vector Lab, Burlingame, USA) 
for 30 minutes at room temperature and developed in 3,3′-diaminobenzidine 
solution. The detection of macrophages and myelin was performed using the 
Animal Research Kit peroxidase (Dako). Biotinylated primary antibodies against 
CD68 (anti-CD68 clone KP-1, Dako; dilution 1:1000) and myelin proteolipid protein 
(anti-PLP, clone plpc-1, Serotec, Kidlington, UK; dilution 1:500) were incubated 
overnight after heat-induced antigen retrieval in 0.01M EDTA pH 8.0. The following 
day, sections were incubated with HRP- conjugated streptavidin for 30 minutes at 
room temperature and developed in 3,3′-diaminobenzidine solution. 
reSuLTS
Four mutant human NOTCH3 transgenic mouse strains with distinct 
NOTCH3 expression levels
Using qPCR analysis on RNA isolated from brain of 10-week old mice, we found 
that the four mutant NOTCH3 p.Arg182Cys transgenic mouse strains (tgN3MUT) had 
human NOTCH3 expression levels of 100%, 150%, 200% and 350%, respectively, 
compared to endogenous mouse Notch3 expression (Figure 1C). Human NOTCH3 
expression in the lowest expressing tgN3MUT strain, was comparable to that in the 
wild-type strain (tgN3WT), i.e. ~100%. RT-PCR analysis with multiple NOTCH3 primer 
sets spanning the complete transcript, showed that the complete human NOTCH3 
cDNA was present in the transgenic transcript (Additional file 1: Figure S2). There 
was no difference in endogenous mouse Notch3 expression between transgenic 





































l Age at onset of vascular NOTCH3 protein accumulation correlates with 
NOTCH3 expression levels
To analyse the presence and onset of a CADASIL vascular phenotype, NOTCH3 
immunohistochemistry was performed on brain slices from mice between the 
ages of 4 weeks and 20 months. This showed that all tgN3MUT strains developed 
cerebrovascular NOTCH3 accumulation, as seen by a positive, granular NOTCH3 
staining of the vessel wall (Figure 2A), similar to that which is seen in CADASIL 
patients (Figure 2B). There was a considerable difference in age at onset of positive 
NOTCH3 staining per mouse strain, ranging from 6 weeks in tgN3MUT350 mice to 
12 months in tgN3MUT100 mice. The age at onset directly correlated with the level 
of human NOTCH3 RNA expression for all four tgN3MUT strains i.e. the higher the 
NOTCH3 RNA expression level, the earlier the onset of NOTCH3 accumulation 
(Table 1). Furthermore, in each mutant strain, the positive NOTCH3 immunostaining 
became progressively more intense and granular with age (Figure 2A). The 
figure 1. generation of transgenic human NOTCH3 mice. (A) Schematic representation 
of the BAC construct containing the human NOTCH3 gene and flanking regions, used for 
generation of tgN3WT and tgN3MUT (c.544C>T, p.Arg182Cys) mice. (B) Sequencing analysis 
of PCR products of the human NOTCH3 gene in transgenic mice confirmed the presence 
of the c.544C>T mutation in tgN3MUT mice. (C) qPCR analysis of human and mouse NOTCH3 
expression in brain. In strain tgN3WT, human NOTCH3 expression was comparable to 
endogenous mouse Notch3 expression. The four mutant strains showed human NOTCH3 
expression levels of 350%, 200%, 150% and 100%, as compared to endogenous mouse 
Notch3 expression. Endogenous mouse Notch3 expression was comparable between the 






































individual granular NOTCH3 deposits increased not only in number, but also in size. 
This was most prominent in mice with the highest NOTCH3 RNA expression level 
(tgN3MUT350), in which the NOTCH3 protein accumulation progressively evolved 
to a vessel wall packed with intense and big granular NOTCH3 deposits at age 
20 months. 
Mouse strain NOTCH3 expression level* Age at onset NOTCH3 accumulation**
tgN3MUT 350 350% 6 weeks
tgN3MUT 200 200% 3 months
tgN3MUT 150 150% 5 months
tgN3MUT 100 100% 12 months
Table 1. The NOTCH3 rNA expression level correlates with the age at onset of 
cerebrovascular NOTCH3 protein accumulation. * mRNA NOTCH3 expression levels 
relative to endogenous mouse Notch3 expression levels ** first sign of positive, granular 
NOTCH3 staining in brain vessels, as determined by an experienced neuropathologist 
(S.v.D).  
Characteristic granular NOTCH3 staining was also present in arterioles of the 
heart, liver, kidney, skin and tail, but not in the aorta (Figure 2C, data not shown). 
Overall, the NOTCH3 accumulation observed in the extra-cerebral arterioles was 
less pronounced than in the brain. Electron microscopy of brain arterioles revealed 
characteristic electron dense deposits within the basement membrane (Figure 2D) 
reminiscent of GOM deposits seen in CADASIL patients (Figure 2E). Neither GOM 
nor increased cerebrovascular NOTCH3 staining was found in tgN3WT mice at 
20 months of age (Figure 2A). Taken together, these analyses show that transgenic 
human NOTCH3 p.Arg182Cys mice develop an early and progressive systemic 
arteriopathy which closely resembles the vascular pathology seen in CADASIL 
patients, with age-at-onset correlating with the respective levels of mutant human 
NOTCH3 expression.
Development of the NOTCH3 score, a quantitative biomarker for 
CADASIL
As we observed such an early and clear age- and NOTCH3 expression level- 
dependent vascular NOTCH3 accumulation load, we set out to objectify this by 
developing a quantitative measure for NOTCH3 staining. This was accomplished by 
capturing and measuring the surface area of CADASIL specific granular NOTCH3 
deposits within brain sections using ImageJ software (Figure 3A), which we called 











































































which clearly showed that the NOTCH3 score increased with age, confirming our 
qualitative observations (Figure 3B). Next, we validated the NOTCH3 score in a 
second mouse strain, tgN3MUT150, in which the same age-dependent increase 
in the NOTCH3 score was seen. At each time-point, the NOTCH3 score was 
lower for the tgN3MUT150 mice compared to the tgN3MUT350 mice, reflecting the 
correlation between NOTCH3 expression level and NOTCH3 accumulation load 
(score at age 20 months: 659 ±51 vs. 1150 ±107, p=0.002) (Figure 3C). Furthermore, 
progression of NOTCH3 accumulation was slower in tgN3MUT150 mice compared to 
tgN3MUT350 mice, as shown by a significant difference in the slope of the NOTCH3 
scores between the two mouse strains (11.1 ±0.5 vs. 6.2 ±0.3, p=0.002). Finally, 
we tested the approach in brain sections of three unrelated CADASIL patients. 
Measurement of the NOTCH3 accumulation load using the NOTCH3 score was 
technically feasible in human tissue (Figure 3D) and showed a significantly higher 
NOTCH3 score in patients than in controls (score 3.81 ±1.85 vs. 0.24 ±0.17, p=0.02) 
(Figure 3E).
No clear brain parenchyma phenotype in tgN3MUT mice
Finally, to determine whether we could correlate the NOTCH3 score to a brain 
phenotype in tgN3MUT mice, we performed brain MRI and histopathology in mice 
aged 20 months (Additional file 1, Figure S4, S5). In two of the six tgN3MUT350 mice, 
figure 2. Vascular NOTCH3 protein accumulation and gOm deposits in transgenic 
human NOTCH3 p.Arg182Cys mice. (A) NOTCH3 immunostaining on brain sections of 
human NOTCH3 transgenic mice. All four tgN3MUT mouse strains developed a characteristic 
granular NOTCH3 staining pattern in the brain vasculature. TgN3WT mice showed only a 
weak, diffuse NOTCH3 staining pattern, which did not increase with age (comparable 
to non-transgenic litter-mates, data not shown). The NOTCH3 accumulation load in the 
tgN3MUT strains correlates well with the NOTCH3 expression level and increases with age; in 
tgN3MUT350 mice, first granular staining is already visible at 6 weeks of age; at 20 months of 
age nearly the whole vessel wall is packed with big granular NOTCH3 deposits. In the strains 
with a lower NOTCH3 expression level, the NOTCH3 accumulation starts at a later age and 
the granular deposits remain smaller. (B) Positive NOTCH3 staining in a brain vessel of a 
CADASIL patient. (C) NOTCH3 immunostaining of extra-cerebral arteries of 20-month-old 
tgN3MUT350 mice showing clear granular NOTCH3 staining in vessels of the heart, liver and 
skin. The aortic wall shows a diffuse and faint NOTCH3 staining pattern comparable to that 
seen in non-transgenic littermates, whereas the smaller vessels around the aorta do show 
characteristic granular NOTCH3 staining. (D) Electron microscopy on brain vessels from 
12-month-old tgN3MUT350 mice shows characteristic electron dense deposits reminiscent 
of granular osmiophilic material (GOM). GOM deposits were first seen at 5-6 months of 
age. (E) Electron microscopy on brain tissue from a deceased CADASIL patient shows 
pathognomonic GOM deposits, adjacent to the basement membrane surrounding the 







































figure 3. Quantitative analysis of vascular NOTCH3 protein accumulation in transgenic 
human NOTCH3 p.Arg182Cys mice and in brain tissue of CADASIL patients. (A) Image-J 
processing of NOTCH3-immunostained brain sections of tgN3MUT350 mice. The images were 
filtered to reduce background signal and a standardised threshold was applied to determine 
the NOTCH3- positive area composed of individual granular NOTCH3 deposits, resulting in 
the NOTCH3 score. (B) Quantitative analysis of NOTCH3 accumulation in tgN3MUT350 mice. 
The NOTCH3 score shows an age-dependent increase and allows for a sensitive discrimination 
between age groups (One-Way ANOVA, Fishers least significant difference). (C) Validation 
of the NOTCH3 score in tgN3MUT150 mice, also showing an age-dependent increase. 
At each time point, the score is lower in tgN3MUT150 than in tgN3MUT350 mice (unpaired 
t-test), reflecting the correlation between NOTCH3 RNA expression and NOTCH3 protein 
accumulation. Data represent the average +/- SD of the three mice analysed per time point. 
(D) ImageJ analysis of human brain sections double stained with NOTCH3 and CD31. The 
vessel area was selected based on the staining with the endothelial cell marker CD31, and 
within this area, the NOTCH3 score was determined. (E) CADASIL patients show a significantly 
higher NOTCH3 score than age-matched controls. (unpaired t-test) Data represent the 






































hyperintensities were seen on T2 weighted images, cranial to the corpus callosum 
and around the ventricles in the frontal lobe. However, similar hyperintensities 
were found in one non-transgenic littermate. Histopathological examination did 
not show any signs of astrogliosis or white matter lesions in the mutant mice. 
The absence of consistent and specific brain abnormalities in tgN3MUT mice 
prohibited the testing of a potential correlation between NOTCH3 score and 
brain phenotype.  
DISCuSSION
To facilitate the testing of pre-clinical therapeutic interventions for CADASIL, we 
generated a translational, human genomic NOTCH3 transgenic mouse model 
with an early vascular phenotype, and developed a biomarker in this model. 
The mutant mice recapitulate the CADASIL vascular phenotype with early onset 
and progressive cerebrovascular NOTCH3 accumulation and GOM deposits in 
arterioles. The respective NOTCH3 RNA expression levels in the four mouse 
strains correlate strongly and consistently with the age at onset and progression 
of NOTCH3 protein accumulation, with the highest expressing mouse strain 
developing vascular NOTCH3 accumulation as early as 6 weeks of age. The 
quantitative biomarker we developed, the NOTCH3 score, allows for a sensitive 
and objective measure of NOTCH3 accumulation, which can therefore be used 
for pre-clinical testing of therapeutic strategies aimed at delaying or reversing 
NOTCH3 accumulation.  
Cerebrovascular NOTCH3 accumulation was selected as a potential biomarker 
because it was consistently and specifically found in tgN3MUT mice, and showed 
an early age at onset and clear progression. Also, NOTCH3 accumulation is a 
plausible surrogate marker for CADASIL because it is universally present in the 
cerebrovasculature of CADASIL patients and is believed to play an important role 
in disease pathophysiology.22 Because of the lack of consistent brain abnormalities 
in our mice, we were unable to correlate the NOTCH3 score to a brain phenotype. 
However, an early age at onset of NOTCH3 accumulation has previously been found 
to be associated with the development of brain parenchymal damage in mice.9 
Moreover, age is one of the most important predictors of CADASIL disease severity 
and progression,14,23 implicating that the age-dependent increase in NOTCH3 score 
is a relevant surrogate marker for disease progression. Sample size calculations 
we performed show that the NOTCH3 score is a feasible biomarker for pre-clinical 
therapeutic studies, as an effect on NOTCH3 accumulation can be assessed in 
relatively small groups of mice. For example, treatment of 7 mice allows for the 
detection of a 50% effect on the progression of the NOTCH3 score, when treating 






































We found that the NOTCH3 score can also be measured in the cerebrovasculature 
of deceased CADASIL patients. Evidently, a NOTCH3 score in brain sections is not 
a feasible biomarker in clinical trials. However, vascular NOTCH3 accumulation 
has been extensively demonstrated in skin biopsies of CADASIL patients and is 
detectable decades before the onset of clinical symptoms.18 In a single family 
study, an age-dependent increase in GOM deposits in skin biopsies was found up 
to 50 years of age.24 Although previous studies did not find a correlation between 
skin biopsy NOTCH3 immunostaining and disease severity, these studies were 
limited by a qualitative assessment of the NOTCH3 staining intensity.18,19  Whether 
such a correlation can be established using our quantitative NOTCH3 score, will 
have to be assessed in future prospective studies.
This novel CADASIL mouse model is especially suitable for testing therapeutic 
strategies for a number of reasons. The presence of the human NOTCH3 gene in 
our mouse model allows for testing compounds specifically directed at human 
NOTCH3, thereby avoiding an additional hurdle in the translation from pre-clinical to 
clinical trials. The fact that we used a genomic NOTCH3 construct allows for testing 
therapeutic interventions that target mutant NOTCH3 at the genomic or (pre-) 
mRNA level. Such interventions, for example using antisense oligonucleotides to 
reduce or modify mutant NOTCH3 protein, are being developed in our lab (Rutten 
et al., unpublished, patent no. WO 2010085151 A2). Another practical advantage 
is that in this early onset model, treatment can be initiated at an early age. 
CONCLuSIONS
In conclusion, we developed a novel, unique human NOTCH3 transgenic mouse 
model and a NOTCH3 score which is a robust and sensitive biomarker for CADASIL. 
This translational model is ideally suited for pre-clinical testing of therapeutic 
strategies aimed at delaying or reversing NOTCH3 protein accumulation.
AbbreVIATIONS
CADASIL: Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and 
Leukoencephalopathy; NOTCH3ECD: extracellular domain of the NOTCH3 protein; 
GOM: granular osmiophillic material; VSMCs: vascular smooth muscle cells; MRI: 
magnetic resonance imaging.
COmPeTINg INTereSTS
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Supplementary figure 1. Validation of NOTCH3 protein quantification in transgenic 
human NOTCH3 mice. No differences in NOTCH3 score were seen upon image selection by 
two independent observers (score tgN3MUT350: 1572 ±448 vs. 1394 ±318 p=0.54, unpaired 
t-test). Data represents the mean ±SD of 4 images. 
Supplementary figure 2. NOTCH3 rNA expression in transgenic human NOTCH3 mice. 
RT-PCR analysis using primers spanning the NOTCH3 gene showed that the complete 

























Figure S1 Validation of NOTCH3 protein quantification in transgenic human NOTCH3 mice. No 
differences in NOTCH3 score were seen upon image selec ion by two independent observers (score 




Figure S2 NOTCH3 RNA expression in transgenic human NOTCH3 mice. RT-PCR analysis using 
primers spanning the NOTCH3 gene showed that the complete NOTCH3 transcript is expressed in all 

























Figure S1 Validation of NOTCH3 protein quantification i  transgenic human NOTCH3 mice. No 
differences in NOTCH3 score were seen upon image selection by two independent observers (score 




Figure S2 NOTCH3 RNA expression in transgenic human NOTCH3 mice. RT-PCR analysis using 
primers spanning the NOTCH3 gene showed that the complete NOTCH3 transcript is expressed in all 






































Supplementary figure 3. endogenous Notch3 rNA expression in transgenic human 
NOTCH3 mice. qPCR analysis shows similar Notch3 expression levels in brain tissue of 






































Supplementary figure 4. brain mrI of  transgenic human NOTCH3 p.Arg182Cys mice. 
(A-F) T2 weighted brain MRI images of mice aged 20 months. Six tgN3MUT mice, five tgN3WT 
mice and four non-transgenic littermates were analysed. Brain MRI abnormalities (indicated 
by the arrows) were detected in two of the six tgN3MUT350 mice, and in one of the four 
non-transgenic mice. All mice with hyperintensities also had enlarged ventricles, which is a 
common finding in C57Bl/6J mice (The laboratory mouse, 2nd edition) (A-B) Representative 
pictures of one of the two tgN3MUT350 mice with brain MRI abnormalities. T2 weighted brain 
MRI showed hyperintensities cranial to the corpus callosum, and in the frontal lobe around 
the ventricles. (C-D) Similar hyperintensities, although less severe, were seen in one of the 






































Supplementary figure 5. brain parenchyma stainings of tgN3muT350 and tgN3wT 
mice. No consistent differences were seen for any of the stainings analysed. Moreover, 
no histopathologic substrate for the observed MRI abnormalities was seen. All images are 
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Objective: To determine the frequency of distinctive EGFr cysteine altering 
NOTCH3 mutations in the 60,706 exomes of the exome aggregation consortium 
(ExAC) database.
Methods: ExAC was queried for mutations distinctive for CADASIL, namely 
mutations leading to a cysteine amino acid change in one of the 34 EGFr domains 
of NOTCH3. The genotype-phenotype correlation predicted by the ExAC data 
was tested in an independent cohort of Dutch CADASIL patients using NOTCH3 
genotype and quantified MRI lesions. The Dutch CADASIL registry was probed for 
paucisymptomatic individuals older than 70 years. 
Results: We identified 206 EGFr cysteine altering NOTCH3 mutations in ExAC, 
with a total prevalence of  3.4/1000. More than half of the distinct mutations have 
been previously reported in CADASIL patients. Despite the clear overlap, the 
mutation distribution in ExAC differs from that in reported CADASIL patients, as 
mutations in ExAC are predominantly located outside of EGFr domains 1-6. In an 
independent Dutch CADASIL cohort, we found that patients with a mutation in 
EGFr domains 7-34 have a significantly lower MRI lesion load than patients with a 
mutation in EGFr domains 1-6. 
Interpretation: The frequency of EGFr cysteine altering NOTCH3 mutations is 
100-fold higher than expected based on estimates of CADASIL prevalence. This 
challenges the current CADASIL disease paradigm, and suggests that certain 
mutations may more frequently cause a much milder phenotype, which may even go 
clinically unrecognized. Our data suggest that individuals with a mutation located 
in EGFr domains 1-6 are predisposed to the more severe ‘classical’ CADASIL 
phenotype, whereas individuals with a mutation outside of EGFr domains 1-6 can 





































Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and 
Leukoencephalopathy (CADASIL) is a dominant, monogenic small vessel disease 
caused by highly distinctive mutations in the NOTCH3 gene.1 NOTCH3 mutations 
in CADASIL lead to (cerebro)vascular NOTCH3 protein aggregation, compromised 
cerebral blood flow, mid-adult onset of stroke and vascular cognitive impairment, 
and migraine with aura. Although most patients experience their first stroke 
at 45-50  years of age, there is a wide variability in age of onset and disease 
progression,2 and a later-onset, milder disease course is increasingly recognised.3 
CADASIL patients have progressive ischemic brain MRI abnormalities which 
correlate with disease severity.4-6 In the pre-symptomatic stage of the disease, 
up to decades before onset of symptoms, symmetric periventricular white matter 
hyperintensities (WMH) are observed,7,8 often also affecting the anterior temporal 
lobes. The MRI in symptomatic individuals often reveals multiple lacunar infarcts, 
microbleeds and brain atrophy.9,10 
CADASIL has been reported worldwide, but only some countries in Europe 
and East Asia have compiled large series of CADASIL patients and their NOTCH3 
mutations.11-17 Prevalence studies have been performed in relatively small 
populations, with a reported minimum prevalence of 2-5/100,000.3,18,19 This number 
is held to be an underestimation.3
Over 98% of CADASIL patients have a distinctive missense mutation in one of 
NOTCH3 exons 2-24, invariably leading to the gain or loss of a cysteine residue 
in one of the 34 epidermal growth factor- like repeat (EGFr) domains of the 
NOTCH3 protein. This changes the canonical number of six cysteines in one of 
these EGFr domains to an uneven number of five or seven cysteines.12 The resultant 
unpaired cysteine is predicted to lead to abnormal disulphide bridge formation 
and NOTCH3 protein aggregation.20 More than 200 distinct NOTCH3 mutations 
have been identified in CADASIL patients, dispersed across EGFr domains 1-34, 
but with the highest prevalence in EGFr domains 1-6.21 Non-penetrance has never 
been reported for this specific type of NOTCH3 mutations. A definite, clinically 
relevant genotype-phenotype correlation has never been found.13,14
In this study, we determined the prevalence of EGFr cysteine-altering NOTCH3 
mutations in the large, publicly accessible exome sequencing dataset ExAC and 
performed comparative analyses with the over 200 NOTCH3 mutations reported in 
both the Dutch and international CADASIL population. The genotype-phenotype 
association predicted by comparing ExAC and CADASIL mutation spectra was 
assessed in an independent cohort of Dutch CADASIL patients. We discuss the 
implications of our findings for the prevalence of CADASIL, the ever-broadening 





































The Exome Aggregation Consortium dataset
NOTCH3 mutation frequencies were assessed using the browser of the Exome 
Aggregation Consortium (ExAC) (Lek et al.; http://dx.doi.org/10.1101/030338; 
http://exac.broadinstitute.org; accessed Oct/Nov 2015). This publicly accessible 
database contains exome data of 60,706 unrelated individuals; 33,644 males and 
27,062 females. The exome data are compiled from 14 independent disease and 
control cohorts. No specific stroke or dementia cohorts are included in ExAC. 
Individuals in ExAC are assigned to one of six populations: European (n=36,677; 
Finnish n=3307, Non-Finnish n=33,370), Latino (n=5789), African/African American 
(n=5203), South Asian (n=8256), East Asian (n=4327) and Other (n=454). Data in 
ExAC are based on genome build GRCh37/hg19.
NOTCH3 variant ascertainment in ExAC 
We queried ExAC for missense mutations in NOTCH3 that passed all ExAC quality 
checks (Lek et al.; http://dx.doi.org/10.1101/030338). Next, these variants were filtered 
using stringent criteria for pathogenicity in CADASIL, namely missense mutations 
leading to the gain or the loss of a cysteine residue in one of the 34 EGFr domains 
of the NOTCH3 protein (amino acid residues 40-1373) (http://www.uniprot.org). 
Mean coverage of the NOTCH3 canonical transcript in ExAC is 35.72x. Most of the 
EGFr encoding exons (exons 2-24) have a coverage of at least 10x, except for exon 
15 and a part of exon 24, which have a coverage below 10x. Four independently 
accessible cohorts contributing to the ExAC database were also individually queried 
for pathogenic NOTCH3 mutations: 1000 Genomes (http://www.1000genomes.org); 
NHLBI-GO Exome Sequencing Project (http://evs.gs.washington.edu); Sequencing 
Initiative Suomi (http://www.sisuproject.fi/) and Type 2 DiabetesGenetics 17k exome 
sequence analysis (http://www.type2diabetesgenetics.org).
Comparison of NOTCH3 mutations in ExAC to those reported in 
CADASIL patients
NOTCH3 mutations present in ExAC were compared to those reported in the 
Dutch CADASIL registry and the international CADASIL literature. To avoid bias 
through incomplete reporting of mutation frequencies or founder effects, the 
comparative analysis of the mutation distribution across the 34 EGFr domains was 
performed using distinct mutations rather than the prevalence of these mutations 
(i.e. each mutation was included only once in all analyses, independent of its total 
frequency in the CADASIL population). Next to a comparison with the mutation 
spectrum reported worldwide, we also separately compared the spectrum of 




































other countries, the NOTCH3 mutation spectrum in the Dutch population is well 
characterized and complete, NOTCH3 mutation screening in the Netherlands 
is comprehensive for exons 2-24, has been operational for more than 15 years 
and molecular diagnostics are readily accessible to all Dutch citizens. Moreover, 
all Dutch NOTCH3 mutations are registered in a single national registry, which 
includes 383 individuals with 45 distinct mutations from 163 families. For mutation 
annotation, the reference sequence NM_000435.2 was used and sequence variants 
were described according to the HGVS nomenclature recommendations. 
Genotype-phenotype analysis
The confirmation of an EGFr- location dependent genotype-phenotype correlation 
was performed in an independent CADASIL cohort, a detailed characterization 
of this cohort has been described elsewhere.10 A standardized MRI protocol was 
performed at a field strength of 1.5T (Philips Medical System). Image acquisition 
and volumetric analysis of WMH, brain parenchyma, and lacunar infarcts were 
performed as previously described.4 Briefly, WMHs were defined as white matter 
areas with increased signal intensity on T2-w MRI and FLAIR. WMH volume was 
calculated as a percentage of the brain parenchyma volume. Lacunar infarcts were 
defined as parenchymal defects not extending to the cortical grey matter, with a 
signal intensity corresponding to that of cerebrospinal fluid and having a diameter 
between 2 mm and 1.5 cm. Statistical analysis was performed using the SPSS 
statistical software package (version 23) (SPSS Inc., Chicago, USA). Comparison of 
quantitative brain MRI variables was performed using linear regression, co- varying 
for age, sex, smoking and hypertension. 
NOTCH3 phenotypic spectrum in over 70 year olds
As ExAC genotypes cannot be traced back to the phenotypic data of individuals, we 
could not assess the correlation of genotype with (possible) CADASIL phenotype in 
ExAC. To determine whether NOTCH3 mutations can be present in asymptomatic 
or paucisympomatic individuals and whether non-penetrance may occur, we 
queried our Dutch CADASIL registry for individuals of at least 70 years of age at 
the time of DNA-testing. We selected only those individuals with an available brain 
MRI or CT scan, determined the reason for NOTCH3 mutation testing and reviewed 
their clinical records and brain scans. 
reSuLTS
High frequency of EGFr cysteine altering NOTCH3 mutations in ExAC
We found a total number of 642 NOTCH3 missense variants in ExAC, of which 




































an uneven number of 5 or 7 cysteine amino acids in one of the 34 EGFr domains 
of the NOTCH3 protein (Table 1). The frequency of these mutations in ExAC is 
therefore 206 in 60,706 exomes, i.e. 3.4/1000. This is 100-fold higher than what 
would be expected based on the current CADASIL prevalence estimations of 
2-5/100,000.3,18,19 In the four independently accessible ExAC cohorts, we found 
the following frequencies of pathogenic NOTCH3 mutations: Type 2 diabetes 
cohort (n=16,857): 3.9/1000; NHLBI-GO Exome Sequencing Project (n=6503): 
1.2/1000; Sequencing Initiative Suomi (n=6118): 0.7/1000; 1000 Genomes (n=2504): 
3.6/1000. This confirmation of high mutation frequencies in all four independently 
accessible cohorts shows that the high NOTCH3 mutation frequency in ExAC is 
not attributable to a specific ExAC cohort. 
Characteristics of NOTCH3 mutations in ExAC
The 206 EGFr cysteine altering missense mutations in ExAC are underlain by 25 
distinct mutations (Table 1). Fourteen of the 25 distinct mutations are present in 
ExAC only once. The other mutations are recurrent, and are present between two 
and eight times, except for two mutations which have high frequencies of 32x and 
120x. These two mutations are found across ethnicities, but are most frequent in 
the East Asian (p.Arg544Cys) and South Asian (p.Arg1231Cys) populations (Fig 1). 
The most frequent mutation (p.Arg1231Cys) is present in a homozygous state in 
three individuals, in a population reported to be high in consanguinity (Lek et 
al.; http://dx.doi.org/10.1101/030338).The mutations are located in 10 different 
NOTCH3 EGFr encoding exons, encoding a total of 12 EGFr domains. Exons 11 
and 22 harbor the most distinct mutations, namely six each, followed by exons 4 
and 12 with three distinct mutations each. Overall, 17 of the 25 mutations lead to 
the gain of a cysteine residue in an EGFr domain and eight to the loss of a cysteine. 
Comparison of NOTCH3 mutations in ExAC to those reported in 
CADASIL patients
We found pathogenic NOTCH3 mutations in each of the populations included in 
ExAC (Fig 1). Mutation frequencies, however, differ between the populations and 
range from 0.4/1000 in African/African Americans to 11.7/1000 in South Asians. Some 
mutations are present in many different populations; the p.Arg578Cys mutation and the 
p.Arg1231Cys mutation, for example, are each found in four of the six ExAC populations. 
Mutations found in specific ethnic populations in ExAC have also been reported in 
CADASIL patients from the same ethnicity or geographical region. For example, the 
p.Arg544Cys mutation which is very frequent in East Asians in ExAC, has also been 
described frequently in CADASIL patients from Taiwan 22 and from Korea.11 Likewise, 
the p.Arg1231Cys mutation, which is the most frequent mutation in Europeans in ExAC, 




































cDNA Protein Exon EGFr Frequency in ExAC
Mutation previously 
reported in CADASIL
c.350G>T p.Cys117Phe 4 2 1 yes 31
c.619C>T p.Arg207Cys 4 5 1 yes 32
c.635G>A p.Cys212Tyr 4 5 1 yes 33
c.931T>G p.Cys311Gly 6 7 1 No
c.1045T>A p.Cys349Ser 7 8 1 No
c.1630C>T p.Arg544Cys 11 14 32 yes 32
c.1672C>T p.Arg558Cys 11 14 5 yes 12
c.1732C>T p.Arg578Cys 11 14 5 yes 12
c.1759C>T p.Arg587Cys 11 15 2 yes 34
c.1819C>T p.Arg607Cys 11 15 1 yes 35
c.1823G>A p.Cys608Tyr 11 15 1 No
c.1871G>C p.Cys624Ser 12 16 1 No
c.1903C>T p.Arg635Cys 12 16 1 No
c.1918C>T p.Arg640Cys 12 16 3 yes [LOVD]
c.2149C>T p.Arg717Cys 14 18 3 yes [HGMD]
c.2824G>T p.Gly942Cys 18 24 1 No
c.2851C>T p.Arg951Cys 18 24 1 No
c.3427C>T p.Arg1143Cys 21 29 2 yes [HGMD]
c.3568C>T p.Arg1190Cys 22 30 5 No
c.3601C>T p.Arg1201Cys 22 30 7 No
c.3605G>C p.Cys1202Ser 22 30 1 No
c.3628C>T p.Arg1210Cys 22 31 1 yes [Netherlands]
c.3664T>G p.Cys1222Gly 22 31 8 yes3
c.3691C>T† p.Arg1231Cys† 22 31 120 yes 12
c.3724C>T p.Arg1242Cys 23 31 1 No
Total 206
Table 1. Twenty-five distinct cysteine altering NOTCH3 mutations in the exAC database. 
Fourteen of the 25 mutations have been previously described in CADASIL patients. The 
others all fit the criteria for pathogenicity in CADASIL, namely leading to a cysteine amino 
acid change in one of the 34 EGFr domains of the NOTCH3 protein. Previously reported 
NOTCH3 mutations in CADASIL patients are shown in bold. † Mutation reported three 
times in a homozygous state. LOVD= Leiden Open Variation Database (www.lovd.nl). 




































NOTCH3 mutations in ExAC are predominantly located outside of 
EGFr domains 1-6
Next, we compared the distribution of mutations in ExAC to those in the well 
characterized Dutch CADASIL registry and to those reported in CADASIL 
patients worldwide. In the Dutch CADASIL registry there are 45 distinct cysteine 
altering NOTCH3 mutations, of which six have not been previously reported 
(Supplementary table 1). The distribution of Dutch CADASIL-causing NOTCH3 
mutations largely overlaps with those reported worldwide,21 with the largest 
percentage of distinct mutations located in exon 4 (Fig 2). In ExAC, the percentage 
of distinct mutations in exon 4 is three times lower than in the Dutch CADASIL 
registry (12% versus 38%). Conversely, the percentage of distinct mutations in 
exon 22 is ten times higher in ExAC than in the Dutch CADASIL registry (24% 
versus 2%). There is a relatively high percentage of distinct mutations in exon 11 
in both ExAC and the Dutch CADASIL registry (24% and 16%, respectively). Of 
note, although the distribution of mutations in ExAC differs from the distribution 
found in reported CADASIL patients, the majority of the exact same distinct EGFr 
figure 1. High frequency of cysteine altering NOTCH3 mutations in all populations in 
the exAC database. Frequencies range from 0.4/1000 individuals in the African/African 
American population to 11.7/1000 in the South Asian population, with an overall frequency 
of 3.4/1000.*: Mutation previously described in CADASIL patients; †: Mutation reported 




































figure 2. Distribution of distinct cysteine altering NOTCH3 mutations in exAC compared 
to those reported in CADASIL patients. Schematic representation  of  the NOTCH3 
protein with 34 epidermal growth factor-like repeat domains (EGFr) and the NOTCH3 EGFr 
encoding exons (exon 2-24). Exons 25-33 (and part of exon 24) encode the transmembrane 
and intracellular domains of NOTCH3; these have never been found to harbour CADASIL-
causing mutations. In the Dutch CADASIL registry and in CADASIL patients worldwide, most 
mutations are in exon 4, which largely accounts for the predominance of mutations in EGFr 
domains 1-6. In ExAC, this predominance is not seen, as mutations are most frequent in 
exons 11-12 and 22, encoding EGFr domains 14-16 and 29-31, respectively. Pink bars above 
the EGFr domains represent the distribution of mutations across EGFr domains, where the 
height of the pink bar reflects the percentage of mutations in the respective EGFr domain. 
Exon colours reflect the number of mutations in each exon: grey indicates exons without 
mutations; blue indicates exons with mutations. The darker the colour blue of the exon, the 
higher the number of distinct mutations.
cysteine altering NOTCH3 mutations in ExAC, namely 14 out of 25 (56%), have 
been previously reported in CADASIL patients (Table 1). Finally, we compared 
the mutation spectrum at the protein level using the distribution across the 34 
NOTCH3 EGFr domains. This shows that mutations in ExAC are mostly clustered 
in EGFr domains 14-16 and 29-31, whereas reported CADASIL mutations cluster 




































NOTCH3 mutations outside of EGFr domains 1-6 are correlated with a 
lower MRI lesion load
The observed difference in mutation distribution between NOTCH3 mutations in 
ExAC and reported CADASIL mutations led us to hypothesize that a genotype-
phenotype correlation may play a role. Specifically, we hypothesized that mutations 
outside of EGFr domains 1-6, the classical CADASIL predominance region, 
predispose to a less severe phenotype. To test this hypothesis, we compared 
the WMH lesion load and number of lacunar infarcts between patients with a 
figure 3. Correlation between egfr location of the NOTCH3 mutation and mrI lesion 
load in CADASIL patients.
MRI quantification data from patients with a mutation in EGFr domains 1-6 (n=32) compared 
to patients with a mutation in EGFr domains 7-34 (n=8). (A) White matter hyperintensity 
volume (expressed as the % of total brain parenchymal volume), was significantly higher 
in patients with mutations in EGFr domains 1-6 than in patients with mutations in EGFr 
domains 7-34 (8.0% vs. 4.3%, p=0.01). (B) The number of lacunar infarcts showed a similar 





































mutation in EGFr domains 1-6 to patients with a mutation in EGFr domains 7-34. We 
found that patients with mutations in EGFr domains 1-6 had a significantly higher 
WMH lesion load than patients with mutations in EGFr domains 7-34 (Fig 3A). A 
similar trend was seen for the number of lacunar infarcts, almost reaching statistical 
significance (Fig 3B). Although group size for this analysis is relatively small, these 
results suggest that mutations outside of NOTCH3 EGFr domains 1-6 are associated 
with a less severe brain MRI phenotype. 
NOTCH3 mutations are penetrant on brain imaging in 
paucisymptomatic elderly individuals 
To determine whether NOTCH3 mutations can be associated with non-penetrance 
or an undiagnosed phenotype, possibly explaining the high ExAC mutation 
frequency, we selected individuals from the Dutch CADASIL registry who were 
70 years or older at the time of DNA-testing and in whom a recent brain scan was 
available. We identified four such individuals. The reasons for DNA-testing were 
either predictive-testing because of the diagnosis of CADASIL in a family member, 
or because of a chance finding of WMHs on brain imaging, performed for unrelated 
signs or symptoms, such as hearing loss. The mutations in these patients were in 
exon 10 (p.Cys531Gly) and in exon 11 (p.Arg587Cys). None of them had a history 
of stroke. One patient reported mild complaints of memory loss, the other three 
had no cognitive complaints at all and no cognitive deficits were reported by their 
partners. All individuals lived at home and were fully independent for activities of 
daily living. One patient had a history of hypertension and hyperlipidemia, and 
one patient had a history of hypercholesterolemia. Their further clinical work-up 
and medical history was unremarkable. Extensive WMHs consistent with CADASIL 
were observed on brain imaging in all four patients. None of the patients had 
lacunes, which are typically seen up to 3 decades earlier in patients with classical 
CADASIL (Fig 4 A to C). The individuals who had an MRI scan, made at age 78 and 
58 respectively, showed symmetric WMHs in both and microbleeds in one (Fig 4D 
to I). These individuals illustrate that NOTCH3 mutations can be present in clinically 
asymptomatic or paucisymptomatic individuals over 70 years of age, who for this 
reason can easily remain undiagnosed with respect to CADASIL. 
DISCuSSION
The frequency of EGFr cysteine altering NOTCH3 mutations in the public exome 
database ExAC is 3.4/1000. This frequency is 100-fold higher than the current estimated 
prevalence of CADASIL. Although CADASIL is classically described as a mid-adult 
onset severe stroke and dementia syndrome, a later onset and milder disease course 




































figure 4. brain mrI of elderly asymptomatic and  paucisymptomatic individuals with 
a NOTCH3 mutation compared to mrI in classical CADASIL. (A-C) Brain MRI images of 
a classical CADASIL phenotype in the 6th decade. (A-B) FLAIR images showing extensive 
confluent symmetric white matter hyperintensities and multiple lacunar infarcts (arrows 
indicate random samples). (C) T2*-weighted MRI showing multiple microbleeds (open arrows 
indicate random samples). (D-F) Brain MRI images of a female, diagnosed with CADASIL 
after predictive DNA testing at 78 years of age, with only very mild clinical symptoms. (D, E) 
FLAIR images showing symmetric white matter hyperintensities, but no lacunar infarcts. (F) 
T2- weighted MRI showing some small microbleeds (open arrows). (G-I) Dual echo images 
of a female who was still clinically asymptomatic at 73 years of age. MRI images were made 
at 58 years of age, showing very mild symmetric white matter hyperintensities, no lacunar 
infarcts and no microbleeds.
be indistinguishable from signs and symptoms of sporadic geriatric cerebral small 
vessel disease, is much more prevalent than recognised to date. 
There are four possible explanations for the unexpected high frequency of 
NOTCH3 mutations in ExAC, namely 1) the mutations in ExAC differ from those 
found in CADASIL  and are not pathogenic; 2) all the individuals with a NOTCH3 
mutation in ExAC have an undiagnosed or unreported classical CADASIL; 3) some 




































populations; 4) a late-onset, mild CADASIL phenotype which is less readily 
diagnosed, is much more prevalent than recognised to date.
The limitation of this study is that no phenotypic information is available for 
individuals in the ExAC database and we therefore cannot definitively confirm or 
reject any of these possible explanations. However, non- pathogenicity of any of 
the 25 EGFr cysteine altering NOTCH3 mutations found in ExAC is highly unlikely, 
as more than half have been previously reported in CADASIL patients, all obey 
the criteria used by DNA-diagnostic laboratories to establish pathogenicity of 
a NOTCH3 mutation and novel NOTCH3 mutations in CADASIL are reported at 
a steady rate, with over 200 distinct EGFr cysteine altering missense mutations 
reported to date.21 
As ExAC consists of various disease and control cohorts and does not contain 
any stroke or dementia cohorts, it is unlikely that the 206 individuals with a NOTCH3 
mutation in ExAC all have an undiagnosed classical mid-adult onset CADASIL 
phenotype. Non-penetrance in these individuals cannot be excluded but is also 
unlikely, as this has never been reported for this highly specific type of NOTCH3 
mutation and we did not find non-penetrance in asymptomatic or paucisymptomatic 
elderly individuals with a NOTCH3 mutation in our Dutch registry. Therefore, in our 
opinion, the most likely explanation for the observed high mutation frequency in 
ExAC is a much higher prevalence than recognized to date of a very mild, late-onset 
NOTCH3 mutation associated cerebral small vessel disease, which may remain 
undiagnosed into old age.23 
Our finding that the EGFr distribution of mutations in ExAC differs from 
that found in diagnosed CADASIL patients, suggested a possible genotype-
phenotype correlation. We hypothesized that mutations located in EGFr domains 
1-6 predispose to ‘classical’ CADASIL and, conversely, mutations outside of EGFr 
domains 1-6 predispose to a much milder phenotype. This would also explain why 
most CADASIL patients diagnosed to date have a mutation in exon 4, as these have 
a more severe phenotype and are therefore much more readily diagnosed. As we 
could not confirm this EGFr- dependent genotype- phenotype correlation in the 
ExAC cohort, we confirmed our hypothesis in a well-characterized independent 
Dutch CADASIL cohort.7 In this cohort, we found that patients with a mutation 
in EGFr domains 1-6 have a significantly higher MRI lesion load than those with 
mutations in EGFr domains 7-34. Interestingly, the paucisymptomatic elderly 
individuals in our Dutch cohort all had a mutation outside of EGFr domains 1-6, 
which is also the case in other mildly affected CADASIL patients reported in the 
literature.23,24
We can only speculate as to why mutations in certain EGFr domains may have 




































domains 1-6, at the N-terminus of the NOTCH3 extracellular domain, may more 
readily interact with other proteins, leading to a stronger effect on CADASIL-
associated protein multimerization.25,26  Although this novel genotype-phenotype 
correlation may help predict a predisposition to a milder or a more severe CADASIL 
phenotype, this needs further delineating in larger cohorts before it can be used 
in the clinical setting. Also, clearly, factors other than NOTCH3 genotype play an 
important role in CADASIL. For example, smoking and hypertension have been 
shown to be associated with CADASIL disease severity.13
A worldwide prevalence of pathogenic NOTCH3 mutations of 3.4/1000 
individuals, implies that these mutations may be a major contributor to cerebral 
small vessel disease in the general population. Indeed, a recent study in patients 
with adult-onset leukoencephalopathy showed that 21% of these individuals had 
a pathogenic NOTCH3 mutation.27 Similarly, high NOTCH3 mutation frequencies 
(18%) were found in a Korean cohort of patients with subcortical vascular 
cognitive impairment.28 Conversely, in a cohort of individuals with confluent 
white matter lesions or lacunes, no cysteine altering NOTCH3 mutation was 
found.29  Future studies in large, well-characterized cohorts are needed to 
determine the role of cysteine altering NOTCH3 mutations in the development 
of white matter hyperintensities and vascular cognitive impairment in the 
general population. 
Our study illustrates how large whole exome datasets can alter mutation- 
disease paradigms. This was recently also illustrated by a study reporting an 
unexpected high frequency of prion disease- associated PRNP mutations in 
ExAC.30 Although our finding of high NOTCH3 mutation frequencies shows 
some similarities to this study, there are also fundamental differences between 
NOTCH3 mutations in CADASIL and PRNP mutations in prion disease. The most 
important difference is the fact that many different types of PRNP variants have 
been described, with variable levels of evidence for pathogenicity. This is in sharp 
contrast to the highly stereotyped nature of pathogenic NOTCH3 mutations in 
CADASIL.
In conclusion, we show that the frequency of EGFr cysteine altering NOTCH3 
mutations in a large exome dataset is 3.4/1000 and we discovered the first 
genotype-phenotype correlation in CADASIL, which is related to the distribution 
of mutations across NOTCH3 EGFr domains. These findings fundamentally change 
the CADASIL disease paradigm and cause us to re-define and the phenotypic 




































No. Exon Nucleotide change Amino Acid change Number of patients Number of families
1 2 c.160C>T p.Arg54Cys 5 2
2 2 c.179C>G p.Ser60Cys 1 1
3 3 c.227G>A* p.Cys76Tyr* 2 1
4 3 c.328C>T p.Arg110Cys 11 5
5 4 c.350G>A p.Cys117Tyr 2 1
6 4 c.353C>G p.Ser118Cys 1 1
7 4 c.397C>T p.Arg133Cys 12 4
8 4 c.402C>G p.Cys134Trp 1 1
9 4 c.421C>T p.Arg141Cys 42 17
10 4 c.431G>T p.Cys144Phe 2 1
11 4 c.457C>T p.Arg153Cys 35 8
12 4 c.464G>A p.Cys155Tyr 1 1
13 4 c.486C>G p.Cys162Trp 18 3
14 4 c.505C>T p.Arg169Cys 3 2
15 4 c.544C>T p.Arg182Cys 32 10
16 4 c.548G>A* p.Cys183Tyr* 2 1
17 4 c.566A>G p.Tyr189Cys 2 1
18 4 c.619C>T p.Arg207Cys 39 20
19 4 c.634T>A p.Cys212Ser 9 3
20 4 c.665G>A p.Cys222Tyr 6 2
21 4 c.671G>A p.Cys224Tyr 3 1
22 5 c.699T>G p.Cys233Trp 2 2
23 5 c.773A>G p.Tyr258Cys 1 1
24 6 c.953G>T* p.Cys318Phe* 3 2
25 6 c.994C>T p.Arg332Cys 4 1
26 6 c.1010A>G p.Tyr337Cys 2 2
27 6 c.1019G>T* p.Cys340Phe* 1 1
28 8 c.1241C>G p.Ser414Cys 4 1
29 8 c.1261C>T p.Arg421Cys 1 1
30 8 c.1337G>T p.Cys446Phe 2 1
31 8 c.1345C>T p.Arg449Cys 2 1
32 11 c.1630C>T p.Arg544Cys 8 3
33 11 c.1645T>C p.Cys549Arg 2 1
34 11 c.1672C>T p.Arg558Cys 5 4
35 11 c.1732C>T† p.Arg578Cys† 62 27
36 11 c.1759C>T p.Arg587Cys 3 2




































No. Exon Nucleotide change Amino Acid change Number of patients Number of families
38 11 c.1819C>T p.Arg607Cys 5 5
39 12 c.1918C>T p.Arg640Cys 2 1
40 13 c.1999G>T p.Gly667Cys 5 4
41 13 c.2129A>G p.Tyr710Cys 2 1
42 14 c.2182C>T p.Arg728Cys 2 2
43 19 c.3043T>C p.Cys1015Arg 30 10
44 20 c.3226C>T p.Arg1076Cys 3 2
45 22 c.3628C>T* p.Arg1210Cys* 1 1
Supplementary table 1. Pathogenic NOTCH3 mutations in the Netherlands. Between 
1998 and 2014, 45 distinct mutations have been detected in the Netherlands. Six mutations 
are especially prevalent (shown in bold), these include both (Dutch) founder mutations and 
recurrent mutations (Unpublished). *mutations which have not been previously reported, 
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The aim of this thesis was to work towards pre-clinical proof-of-concept for 
NOTCH3 cysteine corrective exon skipping as a rational therapeutic approach 
for CADASIL. To address all aspects required for therapeutic development, the 
work performed for this thesis included not only in vitro testing of NOTCH3 exon 
skipping in CADASIL patient derived vascular smooth muscle cells and studies 
into the function of the cysteine corrected proteins, but also the generation of 
a relevant humanized in vivo model, pre-clinical biomarker development, and 
studies defining prevalence, spectrum and characteristics  of NOTCH3 mutations 
worldwide.
There is a high unmet medical need in CADASIL. Currently, only palliative 
care and symptomatic treatment can be offered,1 and there are no effective 
therapies that can delay the onset or progression of physical and cognitive 
dysfunction. The window of opportunity for treatment probably spans mainly 
the pre-symptomatic and early symptomatic stages of the disease, when no or 
only minimal brain white matter hyperintensities are present, and presumably no 
or only little irreversible damage has occurred in the vessel wall or to the brain 
tissue. The fact that asymptomatic family members of a CADASIL patient can have 
predictive molecular genetic testing, in young adults sometimes decades prior 
to the onset of clinical symptoms, in principle permits therapeutic intervention 
before irreversible damage has been done. The therapeutic approach described 
in this thesis is an antisense oligonucleotide- based strategy. However, many of the 
steps needed to bring this approach to clinical trial readiness also apply to other 
potential therapeutic approaches. Developing a more comprehensive framework 
for CADASIL therapeutic development is thus of wider benefit. 
Cysteine correction of NOTCH3 is a therapeutic approach which directly targets 
the underlying defect in CADASIL: and uneven number of cysteines within EGFr. 
We have found that correcting the uneven number of cysteines using antisense- 
mediated exon skipping is feasible in vitro and does not abrogate normal protein 
processing and functionality. The crucial question that remains to be addressed 
is whether the modified NOTCH3 proteins formed after cysteine corrective exon 
skipping indeed have a reduced multimerization tendency and reduced aggregation 
properties. To address this question, we have generated stable cell lines with an 
inducible NOTCH3 skip protein expression. These cell lines can be used to measure 
NOTCH3 protein solubility and degradation as a read-out for protein aggregation.2-4 
An important limitation of such cell models, however, is protein overexpression. 
NOTCH3 overexpression is inherently associated with intracellular NOTCH3 protein 
aggregation, which may confound a reliable assessment of CADASIL- associated 
NOTCH3 protein aggregation. We are currently investigating an alternative in 
























NOTCH3 expression, using CRISPR-Cas9 genome editing technology.5 Although 
potentially a more representative model, this approach is challenging as primary 
cells have a limited life-span and genome editing is not always efficient. Finally, 
we are collaborating with the LUMC mass-spectrometry group to apply advanced 
mass-spectrometry techniques in order to assess disulphide bridge formation in 
cysteine corrected NOTCH3 protein fragments.6 
Proof of concept for the hypothesis that NOTCH3 cysteine correction reduces 
vascular toxic NOTCH3 aggregation will have to come from in vivo studies. Studies 
towards this in vivo proof of concept are now enabled by the human NOTCH3 
transgenic mouse model we generated (Chapter 5). The NOTCH3 score which 
we developed in this model can be used to determine the effect of a therapeutic 
intervention on NOTCH3 accumulation, as a marker for therapeutic efficacy. More 
detailed characterization of the NOTCH3 transgenic mice is ongoing, including 
assessment of vascular smooth muscle cell degeneration and cerebrovascular 
reactivity. So far, the human NOTCH3 transgenic mice have not shown any obvious 
signs of stroke or cognitive impairment. Studies formally assessing cognition 
and motor function are on-going, but we expect that, analogous to most other 
CADASIL mouse models, these mice will not develop measurable motor deficits or 
cognitive dysfunction. A different genetic background or additional aggravating 
factors, such as hypertension or nicotine exposure,7, 8 may be needed to provoke 
a clinical phenotype in the mice. The role of hypotension in CADASIL is not well 
studied, but could theoretically provoke the occurrence of lacunar infarcts in 
watershed areas of the brain. However, the short life span and the anatomy of the 
mouse brain may be the most important limiting factors in recapitulating the full 
CADASIL phenotypic spectrum in mice. This is an important limitation, as stroke or 
cognition can therefore not be used as therapeutic read-outs.  Given this limitation 
and considering the window of opportunity for pre-symptomatic intervention in 
CADASIL, it may be more important to focus on translational markers for disease 
progression in the pre- and early symptomatic stages of the disease. If these 
markers prove to correlate with disease severity and progression in humans, they 
can then be used as pre-clinical and clinical surrogate markers. The NOTCH3 
score we developed in the mice is such a potential translatable biomarker, as it 
progresses as the mouse ages and this same NOTCH3 accumulation can also 
be detected in skin arterioles of CADASIL patients, decades before the onset of 
clinical symptoms.9, 10 We are currently investigating whether the NOTCH3 score 
can be reliably measured in CADASIL skin biopsies and whether it correlates with 
disease severity and progression. 
Although cysteine corrective exon skipping is an elegant strategy to bypass 
























it still remains to be determined whether this approach indeed reduces NOTCH3 
aggregation in vivo. Also, the cysteine corrective exon skips we optimized require 
a combination of AONs for effective exon skipping and skipping efficiencies are 
not always high enough to ensure therapeutic efficacy. An alternative treatment 
strategy, which we are testing in parallel, is NOTCH3 downregulation. Our study 
on individuals with a NOTCH3 stop mutation (Chapter 3) provides a solid rationale 
for this approach and has the added advantage that a single effective RNAse H 
inducing AON could be used for all CADASIL patients, irrespective of their mutation. 
The underlying concept is that a reduced expression of total NOTCH3 will also 
lower the amount of mutant NOTCH3, thereby theoretically decreasing NOTCH3 
protein aggregation. However, a potential pitfall of this approach is that adult 
exposure to pharmacologically induced reduction of NOTCH3 is not comparable to 
a congenitally reduced NOTCH3 expression due to a stop mutation, with potential 
compensatory mechanisms. Moreover, a complete absence of NOTCH3, due to 
a homozygous stop mutation, does cause a severe cerebrovascular phenotype in 
humans,11 and it is not well known how much NOTCH3 is required for normal vessel 
wall function in adults. Finally, it should be noted that the exact same stop mutation 
we identified in healthy individuals, was later found in a family with cerebral small 
vessel disease.12 Therefore, although most studies indicate that there is some 
flexibility in the amount of NOTCH3 needed for normal functioning, the exact 
effects of loss of NOTCH3 function, both in the context of CADASIL and in the 
context of blood vessel development and maintenance, requires further study. 
The major hurdle faced in obtaining in vivo proof of concept for NOTCH3 
cysteine correction or NOTCH3 downregulation, is to attain sufficient levels of exon 
skipping or downregulation in the target cells, namely the vascular smooth muscle 
cells in the small-to medium sized arteries of the brain. Experiments are on-going 
in our lab to determine which route is most optimal for NOTCH3 AON delivery 
into the cerebrovasculature, via the systemic circulation, or via the cerebrospinal 
fluid. Systemic administration of AONs, through intravenous, intraperitoneal of 
subcutaneous injection, is technically most straightforward. However, systemic 
administration causes the vast majority of AONs to be taken up by the liver and 
kidneys.13 While the blood brain barrier precludes most AON chemistries from 
entering the brain, the cerebral vascular smooth muscle cells should in principle 
be accessible, but little is known about vessel wall delivery.14 Administration to the 
cerebrospinal fluid, via intraventricular injection in mice or intrathecal injection in 
humans, is a more invasive administration route, but has the advantage that high 
concentrations of AONs in cerebrospinal fluid are easily achieved and half-life of 
AONs in cerebrospinal fluid is longer than in serum.15 Next to delivery route, other 
























being developed. For example, AONs with a 2’-O-methoxy-ethyl chemistry may be 
better tolerated in the cerebrospinal fluid than 2OMePS AONs, and a recent study 
demonstrated uptake of tricyclo AONs in the brain after systemic administration.16
Another challenge in CADASIL therapeutic development is the lack of feasible 
clinical read-outs. Clinical read-out development is hampered by a pronounced 
clinical variability, likely attributable to genetic and environmental modifiers. 
Despite studies in large groups of patients, feasible clinical read-outs or biomarkers 
have not yet been identified. Our finding of an unexpected high population 
frequency of NOTCH3 mutations (Chapter 6) may have far-reaching implications 
for our understanding of CADASIL disease variability, as it shows that we have 
currently only identified a small subset of (severe) CADASIL patients. Probably 
most individuals with a NOTCH3 mutation who have not yet been diagnosed, 
have a milder disease course than the classical mid-adult onset CADASIL. Such a 
milder disease course has been described18, 19 and is increasingly encountered in 
our CADASIL outpatient clinic. A strong genotype-phenotype correlation would 
enable classification of NOTCH3 mutations into predisposing to severe disease 
or predisposing to mild disease. In this way we might be able to specifically enrol 
only patients predisposed to severe disease into biomarker studies, which should 
be facilitated  by the more narrow severe disease spectrum and reduced disease 
variability. 
In the not so distant future, it is likely that every individual will have his or her 
exome or genome sequenced. For NOTCH3 specifically, routine exome or genome 
sequencing will expose the large number of individuals with a cysteine altering 
NOTCH3 mutation who now remain undiagnosed. Identification of these individuals 
will be important in our further understanding of the phenotypic spectrum 
associated with NOTCH3 mutations and the identification of other genetic and 
environmental factors which mitigate disease progression, some of which may 
























key meSSAgeS Of THIS THeSIS
•	 Only cysteine altering NOTCH3 mutations are indisputably causative of 
CADASIL, other variants should be considered polymorphisms until proven 
otherwise. Classification of non-cysteine altering NOTCH3 mutations can only 
be attained in the context of brain MRI, clinical and family history and skin 
biopsy including NOTCH3 immunohistochemistry and electron microscopy 
analysis. (Chapter 2)
•	 NOTCH3 loss of function mutations do not cause CADASIL and there is flexibility 
in the amount of NOTCH3 needed for normal health and development. 
(Chapter 3)
•	 Cysteine correction of NOTCH3 can be achieved via antisense- mediated exon 
skipping in CADASIL patient derived VSMCs. A cysteine corrected NOTCH3 
protein lacks the corruptive mutated EGFr domain, whilst retaining functionality. 
(Chapter 4)
•	 Human genomic NOTCH3 transgenic mice recapitulate the CADASIL vascular 
phenotype, and are a good model for studying therapies that target human 
NOTCH3 at the genomic, (pre-)mRNA or protein level. (Chapter 5)
•	 The NOTCH3 score is a quantitative measure for progressive NOTCH3 
accumulation in mice, and can potentially be translated to humans. (Chapter 5)
•	 EGFr cysteine altering NOTCH3 mutations have a worldwide frequency of 
3.4/1000. The phenotypic spectrum associated with these NOTCH3 mutations 
is probably much broader and milder than currently recognized. (Chapter 6)
•	 Mutations in EGFr domains 1-6 predispose to a more severe disease course, 
whilst mutations outside of these domains predispose to a milder disease 
course. This genotype-phenotype correlation may partially explain CADASIL 
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CADASIL is een erfelijke ziekte van de kleine hersenvaten, die leidt tot beroertes en 
cognitieve achteruitgang vanaf een gemiddelde leeftijd van 50 jaar. De ziekte erft 
autosomaal dominant over: dit betekent dat elk kind van een ouder met CADASIL 
50% kans heeft om de ziekte te erven. Er is op dit moment geen medicijn dat het 
ziekteproces bij CADASIL kan vertragen. Het overkoepelende doel van de studies 
beschreven in dit proefschrift is het zetten van de eerste stappen richting een 
therapie voor CADASIL patiënten.
Hoofdstuk 1 bevat een algemene introductie over de ziekte CADASIL en 
beschrijft verschillende aspecten die van belang zijn bij het ontwikkelen van een 
therapie. De oorzaak van CADASIL is een verandering (mutatie) in een specifiek deel 
van de erfelijke code: het NOTCH3 gen. Dit gen bevat de code voor het NOTCH3 
eiwit, wat van belang is voor een goede aanleg en functie van bloedvaten. CADASIL 
patiënten hebben een mutatie in het NOTCH3 gen, waardoor het NOTCH3 eiwit 
niet goed vouwt en gaat stapelen in de vaatwand. Dit zorgt voor een verstoorde 
bloedtoevoer naar de hersenen, met beroertes en dementie tot gevolg (Figuur 1). 
In het LUMC wordt gewerkt aan een mogelijke therapie voor CADASIL, genaamd 
‘cysteine correctie’. Het doel van cysteine correctie is de verkeerde vouwing van het 
NOTCH3 eiwit te voorkomen, om zo de schadelijke eiwitstapeling in de hersenvaten 
tegen te gaan en het ontstaan van beroertes en dementie uit te stellen. 
figuur 1. De oorzaak van CADASIL is een mutatie in het NOTCH3 gen. Deze mutatie zorgt 
voor verkeerde vouwing en stapeling van het NOTCH3 eiwit in de vaatwand. Dit leidt tot een 
verstoorde bloedtoevoer naar de hersenen, waardoor de hersenen te weinig zuurstof krijgen.
CADASIL is een erfelijke ziekte van de kleine hersenvaten, die leidt tot beroertes en 
cognitieve achteruitgang vanaf een gemiddelde leeftijd van 50 jaar. De ziekte erft 
autosomaal dominant over: dit betekent dat elk kind van een ouder met CADASIL 50% kans 
heeft om de ziekte te erven. Er is op dit moment geen medicijn dat het ziekteproces bij 
CADASIL kan vertragen. Het overkoepelende doel van de studies beschreven in dit 
proefschrift is het zetten van de eerste stappen richting een therapie voor CADASIL 
patiënten. 
Hoofdstuk 1 bevat een algemene introductie over de ziekte CADASIL en beschrijft 
verschillende aspecten die van belang zijn bij het ontwikkelen van een therapie. De oorzaak 
van CADASIL is een verandering (mutatie) in een specifiek deel van de erfelijke code: het 
NOTCH3 gen. Dit gen bevat de code voor het NOTCH3 eiwit, wat van belang is voor een 
goede aanleg en functie van bloedvaten. CADASIL patiënten hebben een mutatie in het 
NOTCH3 gen, waardoor het NOTCH3 eiwit niet goed vouwt en gaat stapelen in de vaatwand. 
Dit zorgt voor een verstoorde bloedtoevoer naar de hersenen, met beroertes en dementie 
tot gevolg (Figuur 1).   
 
Figuur 1 De oorzaak van CADASIL is een mutatie in het NOTCH3 gen. Deze mutatie zorgt voor 
verkeerde vouwing en stapeling van het NOTCH3 eiwit in de vaatwand. Dit leidt tot een verstoorde 
bloedtoevoer naar de hersenen, waardoor de hersenen te weinig zuurstof krijgen. 
In het LUMC wordt gewerkt aan een mogelijke therapie voor CADASIL, genaamd ‘cysteine 
correctie’. Het doel van cysteine correctie is de verkeerde vouwing van het NOTCH3 eiwit te 
voorkomen, om zo de schadelijke eiwitstapeling in de hersenvaten tegen te gaan en het 




















Om te kunnen onderzoeken of cysteine correctie in de toekomst als therapie 
voor CADASIL zou kunnen worden gebruikt, moeten velen stappen worden gezet in 
het wetenschappelijk onderzoek. Zo moet er voldoende kennis zijn over de mutaties 
die de ziekte veroorzaken en hoe deze mutaties tot de ziekte leiden. Daarnaast 
moet cysteine correctie uitgebreid getest worden in cel- en muismodellen, en zijn 
uitleesmaten nodig om de effectiviteit van het medicijn te kunnen meten. Tot slot 
moet de variabiliteit in het natuurlijk beloop van de ziekte bekend zijn, alsmede 
welke factoren van invloed zijn op het ziektebeloop. De hoofdstukken van dit 
proefschrift gaan over deze verschillende aspecten die van belang zijn voor het 
begrijpen van de ziekte en de ontwikkeling van een therapie.  
Hoofdstuk 2 beschrijft welke onderzoeken belangrijk zijn voor het stellen 
van de diagnose CADASIL. Hierbij ligt de nadruk op de genetische diagnose: 
welk type mutaties in NOTCH3 veroorzaakt CADASIL, en welke veranderingen 
in NOTCH3 leiden niet tot ziekte. Er zijn inmiddels meer dan 200 NOTCH3 
mutaties bekend die CADASIL kunnen veroorzaken. Al deze mutaties hebben één 
belangrijke overeenkomst: ze zorgen voor een cysteine aminozuurverandering 
in het NOTCH3 eiwit. Elk eiwit in het lichaam is opgebouwd uit aminozuren. 
Cysteine is één van deze aminozuren, en is belangrijk voor een normale vouwing 
van het eiwit. Wanneer het aantal cysteines in het NOTCH3 eiwit verandert, 
veroorzaakt dit een verkeerde vouwing en schadelijke stapeling van het eiwit in 
de vaatwand. 
Het vinden van een cysteine- veranderende mutatie in het NOTCH3 gen bij 
een patiënt bevestigt de diagnose CADASIL. Er zijn in de literatuur ook een aantal 
patiënten beschreven met een mutatie in het NOTCH3 gen die niet tot een cysteine- 
aminozuurverandering leidt. Deze niet-cysteine veranderende mutaties worden 
echter ook vaak gevonden in gezonde personen. Er is discussie over de vraag of 
deze niet- cysteine veranderende mutaties ook tot CADASIL kunnen leiden. 
Wanneer een niet-cysteine veranderende mutatie wordt gevonden in een patiënt, 
is er aanvullend onderzoek nodig om te bepalen of er wel of niet sprake is van 
CADASIL. De medische voorgeschiedenis van de patiënt moet goed in kaart gebracht 
worden, alsmede de familiegeschiedenis. Een her-beoordeling van de MRI scan 
door een in CADASIL gespecialiseerd radioloog en het afnemen van een huidbiopt 
geven vaak belangrijke informatie. In het huidbiopt wordt gekeken of er sprake 
is van NOTCH3 eiwitstapeling. Wanneer de uitkomsten van al deze onderzoeken 
passen bij CADASIL, dan moet met aanvullende technieken gekeken worden of er 
kleine stukken van het NOTCH3 gen ontbreken (deletie) of juist dubbel aanwezig zijn 
(duplicatie). In zeldzame gevallen kunnen dergelijke deleties en duplicaties namelijk 
ook CADASIL veroorzaken. De conclusie van hoofdstuk 2 is dat er tot op heden 




















kunnen veroorzaken. Wanneer een dergelijke mutatie wordt gevonden, is er altijd 
aanvullend onderzoek nodig voordat de diagnose kan worden gesteld.
Hoofdstuk 3 beschrijft de identificatie van een aantal personen met een 
speciaal type NOTCH3 mutatie, namelijk een zogenoemde hypomorfe mutatie. 
Deze mutaties leiden niet tot een cysteine aminozuurverandering, maar zorgen 
ervoor dat er minder NOTCH3 eiwit wordt aangemaakt. Hoofdstuk 3 toont aan 
dat dergelijke hypomorfe mutaties geen CADASIL veroorzaken, en ook niet tot 
duidelijke andere symptomen leiden. Deze bevinding is van belang voor het correct 
interpreteren van NOTCH3 mutaties, en geeft daarnaast belangrijke inzichten in 
het ontstaan van CADASIL en mogelijkheden voor therapieën. De personen met 
een hypomorfe NOTCH3 mutatie zijn gezond, hetgeen suggereert dat een lagere 
hoeveelheid NOTCH3 eiwit al voldoende is voor normaal functioneren. Een mogelijk 
aangrijpingspunt voor therapie, naast cysteine correctie, zou daarom NOTCH3 
downregulatie kunnen zijn. Hierbij wordt de totale productie van het NOTCH3 
eiwit verminderd, waardoor in theorie de schadelijke NOTCH3 eiwitstapeling ook 
minder zal zijn. 
In hoofdstuk 4 wordt de rationale achter de genetische interventie cysteine 
correctie beschreven en wordt getest of cysteine correctie werkt in cellen van 
CADASIL patiënten. Het idee voor cysteine correctie is voortgekomen uit het 
gegeven dat NOTCH3 mutaties bij CADASIL patienten altijd leiden tot een 
verandering in het aantal cysteines in het NOTCH3 eiwit. Met cysteine correctie 
wordt geprobeerd dit aantal cysteines te herstellen, om zo de schadelijke NOTCH3 
eiwitstapeling tegen te gaan. Cysteine correctie kan worden bereikt met behulp 
van antisense oligonucleotiden (AONs). AONs binden aan het RNA, dit is een 
tijdelijke kopie van het DNA die nodig is om eiwitten te kunnen produceren. Door 
aan het RNA te binden kunnen de AONs ervoor zorgen dat de mutatie uit het RNA 
geknipt wordt (Figuur 2). Hierdoor wordt een korter NOTCH3 eiwit aangemaakt, 
met het correcte aantal cysteines. Software programma’s die de vouwing van het 
NOTCH3 eiwit kunnen voorspellen laten zien dat dit kortere eiwit een normale 
vouwing zou moeten hebben. In theorie zou dit herstelde NOTCH3 eiwit dus niet 
gaan stapelen in de vaatwand. De experimenten beschreven in hoofdstuk 4 tonen 
aan dat NOTCH3 cysteine correctie technisch mogelijk is in cellen van CADASIL 
patiënten. Daarnaast  wordt aangetoond dat het herstelde NOTCH3 eiwit dat 
gevormd wordt zijn normale functie in de cellen behoudt.
Om cysteine correctie verder te kunnen ontwikkelen is een relevant muismodel 
nodig. Het genereren en karakteriseren van een dergelijk muismodel is beschreven 
in hoofdstuk 5. Dit CADASIL muismodel is  gemaakt door het menselijke NOTCH3 
gen in een bevruchte eicel van een muis te injecteren. Hierdoor wordt het menselijke 




















het muizen-Notch3 eiwit aan, maar ook het menselijke NOTCH3 eiwit. Omdat het 
menselijke NOTCH3 gen permanent is ingebouwd in de erfelijke code van de 
muis, wordt het ook doorgegeven aan de volgende generatie: hierbij spreken we 
van een muizenlijn. Met deze techniek zijn in totaal 5 verschillende muizenlijnen 
gemaakt: 1 lijn die een normaal menselijk NOTCH3 gen bevat en 4 lijnen die het 
menselijke NOTCH3 gen met een mutatie bevatten. De muizen die het NOTCH3 
gen met een mutatie hebben krijgen dezelfde NOTCH3 eiwitstapeling als ook bij 
CADASIL patiënten wordt gezien. De NOTCH3 stapeling is hoger naarmate er 
meer mutant NOTCH3 eiwit wordt aangemaakt, en neemt duidelijk toe met de 
leeftijd. Om de NOTCH3 stapeling te kunnen kwantificeren is de ‘NOTCH3 score’ 
ontwikkeld: een maat voor de hoeveelheid NOTCH3 stapeling in de hersenvaten. 
Omdat het nieuwe CADASIL muismodel het menselijke NOTCH3 gen bevat en al 
op jonge leeftijd NOTCH3 eiwitstapeling laat zien, is het een goed model voor 
het testen van mogelijke therapieën voor CADASIL, zoals bijvoorbeeld cysteine 
correctie. Hierbij kan NOTCH3 score kan worden gebruikt als een uitleesmaat om 
het effect van de therapie op NOTCH3 eiwitstapeling te meten. 
figuur 2. Cysteine correctie met behulp van AONs. 
 
Figuur 2 Cysteine correctie met behulp van AONs.  
Om cysteine correctie verder te kunnen ontwikkelen is een relevant muismodel nodig. Het 
genereren en karakteriseren van een dergelijk muismodel is beschreven in hoofdstuk 5. Dit 
CADASIL muismodel is  gemaakt door het menselijke NOTCH3 gen in een bevruchte eicel van 
een muis te injecteren. Hierdoor wordt het menselijke gen in de erfelijke code van de muis 
ingebouwd, en maakt de muis niet alleen het muizen-Notch3 eiwit aan, maar ook het 
menselijke NOTCH3 eiwit. Omdat het menselijke NOTCH3 gen permanent is ingebouwd in 
de erfelijke code van de muis, wordt het ook doorgegeven aan de volgende generatie: 
hierbij spreken we van een muizenlijn. Met deze techniek zijn in totaal 5 verschillende 
muizenlijnen gemaakt: 1 lijn die een normaal menselijk NOTCH3 gen bevat en 4 lijnen die 
het menselijke NOTCH3 gen met een mutatie bevatten. De muizen die het NOTCH3 gen met 
een mutatie hebben krijgen dezelfde NOTCH3 eiwitstapeling als ook bij CADASIL patiënten 
wordt gezien. De NOTCH3 stapeling is hoger naarmate er meer mutant NOTCH3 eiwit wordt 
aangemaakt, en neemt duidelijk toe met de leeftijd. Om de NOTCH3 stapeling te kunnen 
kwantificeren is de ‘NOTCH3 score’ ontwikkeld: een maat voor de hoeveelheid NOTCH3 
stapeling in de hersenvaten. Omdat het nieuwe CADASIL muismodel het menselijke NOTCH3 
gen bevat en al op jonge leeftijd NOTCH3 eiwitstapeling laat zien, is het een goed model 
voor het testen van mogelijke therapieën voor CADASIL, zoals bijvoorbeeld cysteine 
correctie. Hierbij kan NOTCH3 score kan worden gebruikt als een uitleesmaat om het effect 




















De tot op heden geschatte prevalentie van CADASIL is 2-5 per 100.000 
personen. Echter, de ziekte wordt vaak niet herkend door artsen, hetgeen leidt tot 
onder-diagnostiek. CADASIL komt dus waarschijnlijk veel vaker voor. Hoofdstuk 6 
laat zien dat de frequentie van CADASIL- veroorzakende mutaties 100-maal hoger 
ligt dan de tot nu toe geschatte prevalentie van de ziekte. Deze bevinding toont 
aan dat er waarschijnlijk veel meer CADASIL patiënten zijn dan gedacht, maar 
ook dat veel van deze patiënten waarschijnlijk een relatief mild beeld hebben. De 
meeste CADASIL patiënten die tot nu toe zijn gediagnostiseerd krijgen een eerste 
beroerte rond de leeftijd van 50 jaar. De leeftijd waarop de eerste symptomen zich 
manifesteren varieert echter sterk. Hoofdstuk 6 laat zien dat er CADASIL patiënten 
zijn die tot de leeftijd van 70 jaar nauwelijks klachten hebben. Daarnaast toont 
hoofdstuk 6 aan dat de plek van de mutatie in het NOTCH3 gen waarschijnlijk 
één van de factoren is die een rol speelt bij de variatie in de ernst van de ziekte. 
Hoofdstuk 7 bevat een samenvatting van de verschillende studies beschreven in 
dit proefschrift, en bespreekt welk vervolgonderzoek nodig is om cysteine correctie 
verder te kunnen ontwikkelen als mogelijke toekomstige therapie voor CADASIL 
patiënten. Een belangrijke volgende stap die moet worden gezet is het aantonen 
dat cysteine correctie inderdaad NOTCH3 stapeling vermindert. Dit kan deels 
worden onderzocht in speciale celmodellen die momenteel worden gemaakt, maar 
zal uiteindelijk moeten worden bepaald door experimenten in muizen. Hiervoor is 
het van belang dat er voldoende AON terecht komt op de juiste plek: de gladde 
spiercellen in de hersenvaten. Vervolgonderzoek zal moeten aantonen wat de 
beste toedieningsmethode is om voldoende AON in de hersenvaten te krijgen. Een 
andere belangrijke stap is het verder ontwikkelen van uitleesmaten. De NOTCH3 
score zoals beschreven in hoofdstuk 5 van dit proefschrift is een uitleesmaat voor 
NOTCH3 stapeling in de muizen, maar kan potentieel ook worden gebruikt als 
uitleesmaat in mensen. Daarnaast zijn er mogelijk uitleesmaten in bloed. 
In de toekomst zal het steeds gangbaarder worden om bij mensen de gehele 
erfelijke code te analyseren. Hiermee zal duidelijk worden hoeveel personen in de 
populatie een NOTCH3 mutatie hebben die nu, deels vanwege een mild beeld, niet 
gediagnostiseerd worden. Het identificeren van meer personen met een NOTCH3 
mutatie is van belang om beter te begrijpen hoe variabel de ziekte CADASIL 
precies is, en welke factoren hierop van invloed zijn. Zo kunnen beschermende 
factoren worden geïdentificeerd, die als aangrijpingspunt kunnen dienen voor 
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Lieve broer en zus, geen idee waarom wij hier alle drie aan zijn begonnen… maar 
tot nu toe lijkt het toch steeds goed te komen  Lieve papa en mama, dankjewel 
voor jullie onvoorwaardelijke steun (zelfs bij onlogische school- en studiekeuzes). 
Jullie hebben mij het vertrouwen gegeven dat je alles aan kunt pakken wat je 
maar wilt.
 
En dan, lieve Wouter, ik heb jouw uithoudingsvermogen de afgelopen jaren op 
meerdere manieren op de proef gesteld…  ik ben dolblij en trots dat je nu naast me 
staat. Nog maar een paar weken te gaan tot ons zoontje erbij komt, ik kijk ernaar 
uit, hopelijk nog heel lang met jou samen! 
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